{
  "responseHeader":{
    "status":0,
    "QTime":3,
    "params":{
      "q":"(Background: colorectal cancer OR Doc_title:colorectal cancer) AND (Background: NRAS OR Doc_title: NRAS)"}},
  "response":{"numFound":445,"start":0,"docs":[
      {
        "Meeting_name":" Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer",
        "Background":"['Background', '  Colorectal cancer (CRC) is the third most common cancer worldwide, with metastatic disease accounting for 40 to 50% of newly diagnosed patients. EGFR monoclonal antibodies (Mab), cetuximab and panitumumab, are effective treatment for KRAS wild type CRC. Although mutations in KRAS predict resistance to EGFR Mab therapy, only 80% of CRC patients with KRAS wild-type (WT) status respond to treatment. This study is a retrospective evaluation of genomic alterations in the EGFR pathway such as  alterations in KRAS, BRAF, NRAS, PIK3CA and PTEN that may predict lack of response to EGFR Mab therapy in CRC patients.  Methods', '  A large database of 5,900 consecutive CRC patients was analyzed from 2011 onwards for demographics (sex, age, geography, site of tumor) and biomarkers that might correlate with response to EGFR Mab therapy. Comprehensive testing included gene sequencing for KRAS, BRAF, NRAS, PTEN, and PIK3CA (next-generation sequencing, Sanger, pyrosequencing) and immunohistochemistry for PTEN protein expression.  Results', '  Analysis revealed the incidence of KRAS mutation of 42% which is consistent with published literature. Analysis of the KRAS WT cohort revealed a mutation rate of 13.8 % for BRAF, 6.8% for NRAS, and 40% for patients with either PTEN loss of expression/mutation or a PIK3CA mutation. Earlier studies support that mutations in NRAS, BRAF and activation of the PI3K pathway by PTEN/PIK3CA analysis result in lower response rates to EGFR Mab therapy in CRC. Furthermore, multiplex biomarker testing revealed the rare occurrence of concurrent mutations', ' 1/5,900 subject harboring a BRAF and NRAS mutations, 7/5,900 others with BRAF and PIK3CA mutations, and 8/5,900 subjects with NRAS and PIK3CA mutations.  Conclusions', '  This is a comprehensive analysis of a large international cohort evaluating the prevalence of predictive molecular aberrations suspected of lack of response to EGFR Mab therapy in patients with WT KRAS. Prospective controlled studies are in progress to validate the role of BRAF, NRAS, PIK3CA, and PTEN in clinical management of CRC. It is imperative to further explore the molecular pathology of CRC beyond KRAS in patient selection for EGFR Mab therapy.']",
        "Doc_id":"ASCO_123000-143",
        "Doc_title":" Prevalence of KRAS, BRAF, NRAS, PIK3CA, and PTEN alterations in colorectal cancer",
        "_version_":1606189005042352128},
      {
        "Meeting_name":" Molecular analysis of Kras and Nras mutations in a series of 720 patients for guiding the treatment of metastatic colorectal cancer in Turkey.",
        "Background":"['Background', ' Mutations in Kras and Nras genes in primary colorectal tumors are the reasons for nonresponse to anti-epidermal growth factor receptor (EGFR) antibodies in patients with metastatic colorectal cancer (mCRC). Results of the molecular analysis guides the treatment decision-making in mCRC. The aim of this study was to evaluate the Kras and Nras mutation data from 720 patients with mCRC between 01 January 2015 and 31 January 2016 using minisequencing method. Methods', ' We performed a two round nested PCR for the amplification of Exons 1, 2, 3 of Kras and Nras genes harbouring codons 12, 13, 59, 61, 117, and 146 followed by a multiplex minisequencing reaction for the detection of potential mutations. Results', ' A total of 720 patients were analysed for the mutations in codons 12, 13, 59, 61, 117, and 146 of Kras and Nras genes. Results were obtained from 718 out of 720 (99,72%) patients and no results were obtained from 2 (0,28%) of the cases. 400/718 (55,71%) patients were wild-type for Kras mutations while 318 of them carried a Kras mutation (44,29%). 8 of 318 (2,52%) patients carried two mutations which made totally 326 Kras mutations. Kras mutation rates were 192/326 (58,90%), 98/326 (30,06%), 3/326 (0,92%), 8/326 (2,45%), 3/326 (0,92%), 22/326 (6,75%) in codons 12, 13, 59, 61, 117, 146 respectively. Additional Nras mutation testing was performed for 400 patients which were found to be wild-type for Kras mutations. 31/400 (7,75%) patients were found to carry Nras mutations while 369 (92,25%) of them were wild-type for Nras mutations. 1 of 31 (3,23%) patients carried two mutations which made totally 32 Nras mutations. Mutation distribution was 10/32 (31,25%), 4/32 (12,50%), 4/32 (12,50%), 11/32 (34,38%), 2/32 (6,25%), 1/32 (3,13%) in codons 12, 13, 59, 61, 117, 146 respectively. Conclusions', ' High rate (349/718, 48,61%) of mutation finding in Kras and Nras testing makes mutation profiling in Kras and Nras genes an effective approach to select patients who are more likely to respond to anti-EGFR immunotherapy or rule out this treatment for those who are not likely to respond, and predict patient outcomes using minisequencing reaction which is a highly sensitive and cost effective method.']",
        "Doc_id":"ASCO_169851-176",
        "Doc_title":" Molecular analysis of Kras and Nras mutations in a series of 720 patients for guiding the treatment of metastatic colorectal cancer in Turkey.",
        "_version_":1606189012618313728},
      {
        "Meeting_name":" The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer.",
        "Background":"['Background', ' KRAS mutations (MUT) negatively affect outcome after cetuximab (CTX) in metastatic colorectal cancer (mCRC). As only 40% of KRAS wild-type (WT) respond it is possible that other MUT, constitutively activating the Ras/Erk or PI3K/Akt pathways, are present in the non-responding KRAS WT. We analyzed the KRAS, BRAF, NRAS & PIK3CA MUT status in 276 chemorefractory CRC treated with CTX +- irinotecan and correlated the MUT status with outcome. Methods', \" KRAS codon 12,13, 61&146, BRAF V600E, NRAS codon 12&13, PIK3CA E542K, E545K, A, G, V (exon 9), H1047Y, R, L (exon 20), N345K, R88Q and Q546K MUT were evaluated on FFPE primary CRC using the Sequenom MALDI TOF MassArray system. A two- sided Fisher's exact test was used to evaluate the association between PIK3CA, KRAS, BRAF & NRAS MUT and objective response (OR). Progression-free (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Results\", ' 116/276 (42%) CRC had a KRAS MUT, 96% of which occurred in codon 12 or 13. KRAS WT was associated with OR (p<.0001), longer median PFS (p<.0001) and OS (p<.0001). 15/153 (9.8%) KRAS WT had a BRAF MUT. BRAF WT was associated with OR (p=.01), longer PFS (p<.0001) and OS (p=.007). 5/98 (5%) KRAS WT had an NRAS MUT and none of these showed OR. KRAS, BRAF and NRAS MUT were mutually exclusive. The combined KRAS/BRAF/NRAS WT state was associated with OR (p<.0001), longer PFS (p<.0001) and OS (p<.0001). 23/200 (12%) CRC carried a PIK3CA mutation', ' 5/39 (13%) of responders and 18/160 (11%) of non-responders (p=.781). Median PFS and OS were not associated with PIK3CA MUT state (p=.760 & p=.698) overall, nor in the KRAS/BRAF/NRAS WT subgroup (p=.946 & p=.509). 5/13 (38.5%) PIK3CA MUT KRAS/BRAF/NRAS WT CRC showed an OR. 13/107 (12%) of KRAS/BRAF/NRAS WT and 10/93 (11%) of KRAS/BRAF/NRAS MUT tumors harbored a PIK3CA MUT (p=.826). Conclusions', ' KRAS, BRAF & NRAS MUT are mutually exclusive and occur in at least 47% of CRC. Like KRAS WT, BRAF WT state of the primary is significantly associated with outcome in mCRC treated with CTX. The combined KRAS/BRAF/NRAS WT state is significantly associated with outcome. PIK3CA MUT occur independently of the KRAS/BRAF/NRAS MUT status. We cannot provide any evidence for a strong role of PIK3CA MUT as a marker in determining outcome to CTX.']",
        "Doc_id":"ASCO_34187-65",
        "Doc_title":" The role of KRAS, BRAF, NRAS, and PIK3CA mutations as markers of resistance to cetuximab in chemorefractory metastatic colorectal cancer.",
        "_version_":1606188976051322880},
      {
        "Meeting_name":" Characteristics of NSCLCs harboring NRAS mutations.",
        "Background":"['Background', '  We sought to determine the frequency and clinical characteristics of patients with non-small cell lung cancers (NSCLCs) harboring NRAS mutations.  We used preclinical models to identify targeted therapies likely to be of benefit against NRAS mutant lung cancer cells.  Methods', '  We reviewed data in the Catalogue of Somatic Mutations in Cancer (COSMIC) and clinical history from patients with NSCLC whose tumors underwent systematic screening for driver mutations including NRAS.  Patient characteristics examined included age, gender, race, smoking history, disease stage, treatment history, and overall survival (OS).  6 NSCLC cell lines with NRAS mutations were screened for sensitivity against multiple targeted agents.  Gene expression was profiled using Affymetrix U133A arrays in 5 NRAS mutant NSCLC cell lines, 8 with EGFR mutations and 17 with KRAS mutations.  Results', '  Among 4524 patients with NSCLC tested, NRAS mutations were present in 29 (0.64%).  The types of substitutions found were Q61H/K/L/R and G12A/C/D/R/S, with NRAS Q61L the most common (n=14; 48%). One tumor had a concurrent KRAS mutation.  83% had adenocarcinoma histology, with no significant differences in gender. While 90% of patients were former or current smokers, smoking-related G', 'C>T', 'A transversions were significantly less frequent in NRAS than in KRAS-mutant NSCLC (KRAS', ' 66%, NRAS', ' 13%, p<0.05).  Systemic chemotherapy showed limited efficacy in 7 patients with metastatic disease (median OS 7 mos). 5 of 6 NRAS mutant lung cancer cell lines were sensitive to the MEK inhibitors, AZD6244 and GSK1120212, while other targeted agents (against EGFR, ALK, MET, IGF-1R, PIK3CA, BRAF) were minimally effective.  Gene expression profiles of NRAS mutant cell lines were distinct from those with KRAS or EGFR mutations.  Conclusions', '  NRAS mutations define a distinct subset of NSCLCs (~1%) with potential sensitivity to MEK inhibitors. While NRAS gene mutations are more common in current/former smokers, the types of mutations are not those classically associated with smoking.']",
        "Doc_id":"ASCO_93761-114",
        "Doc_title":" Characteristics of NSCLCs harboring NRAS mutations.",
        "_version_":1606189000883699712},
      {
        "Meeting_name":" Detecting KRAS and NRAS resistance mutations in plasma of lung cancer patients.",
        "Background":"['Background', ' Mutations in KRAS and NRAS have been found in a number of malignancies, particularly metastatic colorectal cancer, lung adenocarcinoma, and thyroid cancer. Several studies have shown that specific mutations in KRAS and NRAS are less likely to respond to anti-EGFR therapies. Several diagnostics have been developed to identify such mutations. However, in a large number of cancer patients, tumor biopsy poses a significant health risk thereby limiting the tissue available for current molecular diagnostics. Non-invasive liquid biopsy diagnostics are revolutionizing cancer treatment selection, patient prognosis, and monitoring. Low abundance circulating tumor DNA (ctDNA) is purified from patient plasma and used as an alternative source of genomic material for detecting tumor mutations. Currently available qPCR kits for detecting RAS mutations have a limited sensitivity and coverage since they are not optimized for liquid biopsy purposes. Methods', ' We have developed a two-step PCR to qPCR method to identify down to single mutant copies of KRAS or NRAS in ctDNA isolated from plasma. The mutant copies are first enriched by a novel multiplexed formula of primers and wildtype (WT) allele blockers. The mutations are then identified by EntroGens RAS Mutation Screening Panel or next generation sequencing (NGS). Synthetic mutant DNA was spiked in a background of WT DNA purified from plasma to yield a range of mutant allelic burden over WT background. The dilutions were analyzed to determine the methods sensitivity. We subsequently used the method to screen 53 non-small cell lung cancer (NSCLC) patient samples. Results', ' Our two-step method detects single digit mutant copies of 35 clinically significant KRAS and NRAS mutations. Furthermore, NGS experiments demonstrated the two-step method can enrich mutations more than 52-fold. KRAS 12/13 mutations were identified in 6 out of 53 (11%) NSCLC patients. Conclusions', ' ctDNA-based liquid biopsy tests have been employed by few laboratories but are generally available only as a service. EntroGens platform agnostic liquid biopsy RAS assay provides clinicians the tools necessary to determine cancer treatment and monitor patients using most PCR and qPCR instruments.']",
        "Doc_id":"ASCO_187020-199",
        "Doc_title":" Detecting KRAS and NRAS resistance mutations in plasma of lung cancer patients.",
        "_version_":1606189037984415744},
      {
        "Meeting_name":" Frequent allelic imbalance in NRAS mutant melanomas.",
        "Background":"['Background', ' We recently showed that 19% of BRAF mutant melanomas have an increased mutant allele percentage ( > 60%) (BMC Cancer 2015). This allelic imbalance was mainly related to a polysomy of chromosome 7. We investigated the percentage of NRAS mutant allele in BRAFwild type (WT) melanomas. Methods', ' We searched for NRAS Q61 mutation by pyrosequencing method in 216 FFPE samples of cutaneous melanomas WT for BRAFV600. FISH was performed with probes specific for NRAS (RP11-245I3) and 1p34.1 (RP11-269F19) on 105 cases NRAS WT (n = 42), or NRAS mutant with equilibrate (E%, n = 43) and high (H%, n = 20) mutant allele percentage. Loss of Heterozygoty (LOH) was evaluated with 8 microsatellite (MS) markers (3 localized near NRAS, 3 at 1p and 2 at 1q) on 17 samples (E% n = 8 or H% n = 9). Pathological data of 73 NRASmutant melanomas, clinical characteristics and survival data of matching patients were analyzed. Results', 'NRAS mutation was detected in 109 (50.5%) of BRAF WT samples, of which 31 (34%) were H%. Allelic NRAS imbalance was observed in all mutation types', ' Q61R (n = 22), Q61K (n = 6), Q61L (n = 2) and Q61H (n = 1). Chromosome 1 disomy, disomy with rare polysomic cells and polysomy were observed in 24% (24% WT vs 24% mutant NRAS), in 24% (33% WT vs 18% mutant NRAS) and in 12% (3% WT vs 18% mutant NRAS) of samples, respectively. NRAS amplification and monosomy of chromosome 1 were rare aberrations in both groups (3.4% and 4.6%, respectively). Intra-tumor heterogeneity concerning chromosome 1 was defined as monosomic or polysomic cells (or both) accompanying disomic tumor cells. Heterogeneity was observed in 24% WT and 35% mutant NRAS samples (P < 0.01), and was more frequent in H% than E% mutant NRAS (47% vs 29.7%). MS analysis revealed no LOH in 8 E%, while LOH was present in 9 H% NRAS samples. No differences were observed between E% and H% NRAS mutant melanomas for clinic, histology and survival data. Conclusions', ' Allelic imbalance is more frequent in NRAS than in BRAF mutant melanomas (34% versus 19% of H%, P < 0.01). Amplification was rare in NRAS, as shown in BRAF mutant melanomas. NRAS mutant melanomas had high intra-tumor heterogeneity. Allelic imbalance of H% NRAS was closely related to LOH.']",
        "Doc_id":"ASCO_169489-176",
        "Doc_title":" Frequent allelic imbalance in NRAS mutant melanomas.",
        "_version_":1606188989590536192},
      {
        "Meeting_name":" Novel, sensitive simplex and multiplex assays for KRAS and NRAS mutation detection.",
        "Background":"['Background', ' Activating KRAS/NRAS mutations in colorectal cancer (CRC) predict resistance to anti Epidermal Growth Factor Receptor targeted therapies. To improve the molecular characterization of CRC, we developed novel simplex and multiplex real-time PCR based assays (SensiScreen) for KRAS/NRAS analysis, and compared them with Direct Sequencing (DS), Mutant-Enriched PCR (ME-PCR), TheraScreen and Cobas. Methods', ' SensiScreen assays (PentaBase) comprise SuPrimers (DNA primers with increased specificity), BaseBlockers (suppressing amplification of wild-type genes) and HydrolEasy probes (hydrolysis probe with increased S/N ratio and sensitivity). Sensitivity studies on plasmids and extracted cell line DNA were performed. Three cohorts were analyzed for KRAS exon 2 mutations', ' Cohort 1 (n = 100), SensiScreen was compared with DS and ME-PCR; Cohort 2 (n = 79), with DS and TheraScreen; and Cohort 3 (n = 307), with Cobas. KRAS exons 3/4 and NRAS exons 2/3/4 were tested by DS and SensiScreen on 156 patients. Results', ' Our sensitivity studies gave superimposable results for both simplex and multiplex assays. DS had a limit of detection of 10%, ME-PCR of 0.1% and SensiScreen of  0.1%. Patients with mutations found in KRAS exon 2 were', ' Cohort 1', ' 33 (33%) by DS, 43 (43%) by ME-PCR and 45 (45%) by SensiScreen. Cohort 2', ' 17 (21%) by DS, 19 (24%) by TheraScreen and 19 (24%) by SensiScreen. Cohort 3', ' 84 (27%) by Cobas and 88 (29%) by SensiScreen. In KRAS exons 3/4-NRAS exons 2/3, DS identified mutations in 6 (3.8%), 4 (2.6%), 1 (0.6%) and 2 (1.3%) cases respectively, whereas SensiScreen detected mutations in 8 (5.1%), 8 (5.1%), 4 (2.6) and 8 (5.1%) cases respectively. No NRAS exon 4 mutations were detected. Simplex and multiplex assays identified the same mutations. Conclusions', ' SensiScreen simplex and multiplex assays are novel, rapid, easy-to-use and highly sensitive methodologies enabling better identification of KRAS/NRAS mutations in CRC than currently used methodologies. The multiplex version analyzes 44 mutations of 6 exons with only 11 reactions.']",
        "Doc_id":"ASCO_166036-176",
        "Doc_title":" Novel, sensitive simplex and multiplex assays for KRAS and NRAS mutation detection.",
        "_version_":1606189002298228737},
      {
        "Meeting_name":" Patterns of KRAS, NRAS and BRAF testing among patients with metastatic colorectal cancer in the EU5.",
        "Background":"['Background', ' In mid-2013, the requirement for mCRC patients treated with panitumumab changed from wild-type KRAS to wild-type RAS (KRAS and NRAS). The objective of this study was to describe patterns of KRAS, NRAS, and BRAF testing among mCRC patients in the EU5 (United Kingdom (U.K.), Germany, France, Italy and Spain). Methods', ' This descriptive study utilized Oncology Analyzer data (IMS Health Oncology, Fairfield, CT, USA), which provides real-world quarterly cross-sectional, epidemiologic and clinical data for mCRC patients. Trends in biomarker testing during the study period were evaluated by calculating the frequencies and proportions of patients who were /were not tested for combinations of KRAS, NRAS, and BRAF within each of the five countries. KRAS and BRAF data were available in all countries from quarter three (Q3) 2012 to quarter two (Q2) 2015. NRAS was available in all countries from quarter 1 (Q1) 2014 to Q2 2015. Frequencies and proportions were also calculated to summarize patient demographic and clinical characteristics between groups with different testing choices. Results', ' A total of 32,961 patients with mCRC were included in the analyses. Prior to 2013, the majority of patients in each country were tested for only KRAS. The proportion of patients tested for both KRAS and NRAS increased substantially during the period of data availability for NRAS (Q1 2014 to Q2 2015), including <1% to 19.1% in the U.K., 8.8% to 31.9% in France, 13.1% to 43.2% in Germany, 5.9% to 24.6% in Italy, and 8.7% to 31.4% in Spain. The proportion of patients who were tested for all three biomarkers also increased during the period of data availability for all three biomarkers (Q1 2014 to Q2 2015), including 2.3% to 16.4% in the U.K., 4.8% to 26.6% in France, <1% to 2.4% in Germany, 4.2% to 22.3% in Italy, and 1.5% to 9.3% in Spain. There were few differences in patient demographic or clinical characteristics between those with different testing groups. Conclusions', ' This analysis provides a description of biomarker testing using read-world data and suggests an overall increase in testing among mCRC patients in the EU5. Although there was a trend towards increased testing, many mCRC patients are still not tested for these important biomarkers.']",
        "Doc_id":"ASCO_177093-195",
        "Doc_title":" Patterns of KRAS, NRAS and BRAF testing among patients with metastatic colorectal cancer in the EU5.",
        "_version_":1606188980229898240},
      {
        "Meeting_name":" Activated NRAS mediates self-renewal capacity in AML",
        "Background":"['NRAS mutations are found in 11-14% of AML (Schubbert et al. Nat Rev Cancer 2007, Bowen et al. Blood 2006), implicating NRAS signaling pathways as potential targets for clinical intervention. However, the specific effects of targeting these pathways on AML physiology are currently unclear. We employ a manipulatable murine model of AML to elucidate these phenomena for therapeutic applications. This model harbors a tetracycline repressible, activated NRAS (NRASG12V) transgene along with an Mll/AF9 transgene. Primary leukemia cells are then transplanted into SCID mice and, upon development of clinically evident leukemia, NRASG12V transgene expression is repressed with doxycycline. NRASG12V repression leads to apoptosis and disease remission (Kim et al. Blood 2009). To dissect the critical signaling networks directing remission, immunophenotypic markers, along with the phosphorylation status of critical signaling intermediates, were analyzed by flow cytometry after NRASG12V repression. This analysis revealed that NRAS withdrawal led to an enrichment of less differentiated Mac1/Gr1 negative cells indicating that, in addition to well-described effects on proliferation, NRAS affects leukemia differentiation status. Furthermore, we only found modifications in known NRAS signaling effectors in the less differentiated, Mac1 negative leukemia cells. Therefore, in addition to affecting the differentiation status of the leukemia, oncogene withdrawal leads to cell-type specific signaling alterations. We hypothesize that these signaling alterations mediate remission-induction by altering the self-renewal capacity of the leukemia at the gene expression level. Parallel RNA sequencing and gene expression microarrays were performed to address this hypothesis and revealed that the gene expression pattern of NRASG12V-expressing cells is enriched with hematopoietic self-renewal genes (Krivtsov et al. Nature 2006, Ivanova et al. Science 2002, Gene Set Enrichment Analysis per Subramanian et al. PNAS 2005). Withdrawal of the oncogene led to loss of this self-renewal gene expression program and an enrichment of genes expressed in terminally differentiated, mature cells. Furthermore, the NRASG12V-dependent gene expression program mimics the Mll/AF9-determined, Myb-mediated self-renewal program seen in a similar AML model (Zuber et al. Genes & Dev 2011). These data suggest that the Mll/AF9-mediated self-renewal program requires the continued expression of NRASG12Vand support a novel role for NRASG12V in maintaining the self-renewal capacity AML.']",
        "Doc_id":"AACR_2012-4176",
        "Doc_title":" Activated NRAS mediates self-renewal capacity in AML",
        "_version_":1606189001411133440},
      {
        "Meeting_name":" Differential roles of palmitoylation on oncogenic potential of NRAS and KRAS4A",
        "Background":"['The RAS family includes three RAS genes, which encode four highly homologous proteins', ' H-, N-, and KRAS4A and 4B, the latter two being alternatively spliced forms differing only at the carboxyl terminus. Hyperactivation of RAS is common in human cancer, including hematological malignancies. Since RAS proteins are difficult to target, identification of alternative means to block RAS oncogenic signaling is critical for developing therapies against RAS-driven cancers. The biological activity of RAS proteins relies upon post-translational modifications (PTMs) that anchor RAS to cellular membranes. Among RAS PTMs, palmitoylation is required for the high affinity plasma membrane binding of NRAS, HRAS and KRAS4A. We have previously shown that palmitoylation is essential for NRAS leukemogenesis, suggesting that targeting RAS palmitoylation may be an effective therapy for NRAS related cancers. In addition, it has been shown that KRAS4A plays an essential role in the development of KRAS-driven lung cancer, suggesting that targeting palmitoylation may impact on cancers with KRAS mutations as well. However, the exact role of palmitoylation in KRAS4A oncogenic activity is not known. In this study we compared the effect of palmitoylation on leukemogenic potential of oncogenic NRAS and KRAS4A whose high expression level is detected in some KRAS mutated leukemia cell lines. We found that palmitoylation of oncogenic NRAS and KRAS4A is both critical for their plasma membrane attachment and their activity to activate the MEK-ERK signaling pathway. Mutation at the palmitoylation site of the oncogenic KRAS4A significantly abrogates its leukemogenic potential. However, unlike NRAS, palmitoylation defective KRAS4A still induces leukemia in mice, albeit with a long latency. Using NRAS/KRAS4A chimeric constructs, we found that the KIKK (Lys-Ile-Lys-Lys) motif between amino acids 181 and 189 in the hypervariable region of KRAS4A effects on the oncogenic activity of KRAS4A, though its contribution is less than that of palmitoylation. After replacing the three lysine residues in the KIKK motif with glutamine residues, the leukemogenic potential of oncogenic KRAS4A is partially inhibited, while inactivating mutations of both palmitoylation site and KIKK motif completely suppress the ability of oncogenic KRAS4A to induce leukemia in mice. On the other hand, replacement of lysine residues in KIKK motif with arginine residues does not change the oncogenic activity of KRAS4A, indicating that the KIKK motif functions by providing positive charged residues. These studies demonstrate that KRAS4A contains an additional membrane association motif comparing to NRAS and suggest that though therapies targeting RAS palmitoylation would inhibit KRAS4A tumorigenesis, interfering the KIKK motif of KRAS4A would enhance the therapeutic effectiveness.']",
        "Doc_id":"AACR_2015-2167",
        "Doc_title":" Differential roles of palmitoylation on oncogenic potential of NRAS and KRAS4A",
        "_version_":1606188997729583104},
      {
        "Meeting_name":" Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.",
        "Background":"['Background', ' The requirement to establish RAS status prior to administration of an EGFR inhibitor has increased the need to understand which patients are tested for RAS and the length of time it takes for the treating oncologist to receive the RAS test result. Our objective was to evaluate factors that may influence RAS testing among metastatic colorectal cancer (mCRC) patients and the turn-around time for RAS testing among patients who are treated at community cancer centers in the United States (U.S.) Methods', ' The sample includes 1550 patients in the Oncology Services Comprehensive Electronic Records (OSCER) database who were diagnosed with mCRC between 1/1/2011 and 8/31/2015. Patient demographics and clinical characteristics were evaluated at the time of mCRC diagnosis. The median number of days and interquartile range (IQR) between the following dates was summarized', ' diagnosis for mCRC, tissue collection for biomarker testing, tissue was received by the lab for biomarker testing, and biomarker results returned to the oncologist. Results', ' The frequency of RAS testing was as follows', ' KRAS (n = 964; 62%), NRAS (n = 116; 7%), BRAF (n = 231; 15%), all three simultaneously (n = 94, 6%). There were significant differences in KRAS testing by age and type of insurance, with young (p < 0.001) and commercially-insured (p = 0.01) patients more likely to receive testing. The median number of days and IQR between specimen collection and diagnosis of mCRC was as follows', ' KRAS (0; 0 to 443), NRAS (0; -18.5 to 362), and BRAF (-3; -474 to 0). The median number of calendar days between the date the specimen was collected and the date it was received by the lab was as follows', ' KRAS (19; 1 to 303), NRAS (34.5, 8 to 518), and BRAF (29; 2 to 428). The median number of days between the date the specimen was received by the lab and the date the result was returned to the oncologist was as follows', ' KRAS (7; 5 to 13), NRAS (10; 7 to 15), and BRAF (8; 6 to 14). Conclusions', ' Many patients had a specimen collected for biomarker testing at the time of mCRC diagnosis and the results were generally returned to the treating oncologist within one week of it arriving at the lab.']",
        "Doc_id":"ASCO_170846-176",
        "Doc_title":" Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.",
        "_version_":1606188980977532928},
      {
        "Meeting_name":" Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.",
        "Background":"['Background', '    The requirement to establish RAS status prior to administration of an EGFR inhibitor has increased the need to understand which patients are tested for RAS and the length of time it takes for the treating oncologist to receive the RAS test result. Our objective was to evaluate factors that may influence RAS testing among patients with metastatic colorectal cancer (mCRC) and the turn-around time for RAS testing among patients who are treated at community cancer centers in the United States (U.S.). Methods', '    The sample includes 1550 patients in the Oncology Services Comprehensive Electronic Records (OSCER) database who were diagnosed with mCRC between 1/1/2011 and 8/31/2015. Patient demographics and clinical characteristics were evaluated at the time of mCRC diagnosis. The median number of days and interquartile range (IQR) between the following dates was summarized', ' diagnosis for mCRC, tissue collection for biomarker testing, tissue was received by the lab for biomarker testing, and biomarker results returned to the oncologist. Results', '    The frequency of RAS testing was as follows', ' KRAS (n = 964; 62%), NRAS (n = 116; 7%), BRAF (n = 231; 15%), all three simultaneously (n = 94, 6%). There were significant differences in KRAS testing by age and type of insurance, with young (p < 0.001) and commercially-insured (p = 0.01) patients more likely to receive testing. The median number of days and IQR between specimen collection and diagnosis of mCRC was as follows', ' KRAS (0; 0 to 443), NRAS (0; -18.5 to 362), and BRAF (-3; -474 to 0). The median number of calendar days between the date the specimen was collected and the date it was received by the lab was as follows', ' KRAS (19; 1 to 303), NRAS (34.5, 8 to 518), and BRAF (29; 2 to 428). The median number of days between the date the specimen was received by the lab and the date the result was returned to the oncologist was as follows', ' KRAS (7; 5 to 13), NRAS (10; 7 to 15), and BRAF (8; 6 to 14). Conclusions', '    Many patients had a specimen collected for biomarker testing at the time of mCRC diagnosis and the results were generally returned to the treating oncologist within one week of it arriving at the lab.']",
        "Doc_id":"ASCO_160157-173",
        "Doc_title":" Characterization of KRAS, NRAS, and BRAF testing and timing among mCRC patients treated at community cancer centers in the United States.",
        "_version_":1606189007768649728},
      {
        "Meeting_name":" Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts).",
        "Background":"['Background', '  NRAS belongs to RAS family. NRAS mutations are mutually exclusive with KRAS and BRAF mutations and contribute to the activation of Ras/Raf/MAPK pathway. Previous experiences evaluated the prognostic/predictive role of NRAS mutations suggesting a poorer prognosis and resistance to anti-EGFRs for NRASmutant (mut) mCRC pts. The aim of the present study was to confirm such preliminary findings in a large cohort of mCRC pts.  Methods', \"  Data on KRAS (codons 12, 13 and 61) and BRAF-V600E mutational status of mCRC pts referred to our pathology from '09 to '12 were collected. NRAS mutational status (codons 12, 13 and 61) was evaluated in KRAS and BRAF wt pts. OS was calculated from date of diagnosis of metastatic disease. Data on response and PFS according to RECIST were collected for NRASmut irinotecan-refractory pts treated with anti-EGFRs +/- irinotecan.  Results\", '    774 mCRC pts were included. KRAS/BRAF mutations were found in 384 (50%)/69 (9%) cases. NRAS was mut in 47 (15%) out of 318 KRAS and BRAF wt pts. NRAS mut pts had significantly shorter OS in comparison to KRAS-BRAF-NRAS wt pts (HR=0.60 [0.29-0.99] p=0.045). BRAF mut pts had significantly worse OS in comparison to NRAS mut pts (HR=1.75 [1.073-2.87] p=0.03). No difference was observed between NRAS mut and KRAS mut pts (HR=0.86 [0.51-1.43] p=0.61).  18 pts out of 47 NRAS mut pts received anti-EGFRs in advanced lines. 8 pts (7 cetuximab-based, 1 panitumumab monotherapy) were evaluable according to RECIST criteria and therefore eligible for the present analysis. None of them responded and only 1 SD was observed. Pooling our results with available data on anti-EGFRs activity in NRASmut pts in advanced lines of treatment (De Roock, 2010; Peeters, 2013; Andr, 2012), only 1 response is described out of 35 treated pts (2,9%).  Conclusions', '  Our data demonstrate that NRAS mutations have a relevant incidence in KRAS and BRAF wt mCRC pts. Present results are consistent with previous experiences and confirm that NRAS mutations affect prognosis of mCRC patients and predict lack of response to anti-EGFRs. Further insights into NRAS mut mCRC biology and prospective validation are warranted.']",
        "Doc_id":"ASCO_115168-132",
        "Doc_title":" Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts).",
        "_version_":1606189000245116928},
      {
        "Meeting_name":" Circulating tumor DNA(ctDNA) testing to detect identical gene mutation rates of KRAS, NRAS, PIK3CA and P53 compared to tissue-based testing and reflects treatment efficacy in patients with colorectal cancer.",
        "Background":"['Background', ' Molecular profiling for CRC commonly utilizes tissue, however, there are two major limitations. It is hard to overcome the complications of tumor heterogeneity and inconvenient to do multiple biopsies during the surveillance. While the alterations in KRAS have been shown to have a high degree of concordance between tissue and ctDNA testing, a detailed survey of other commonly mutated genes, and the influence of intervening treatment in CRC has not been conducted Methods', ' Tissue and blood samples underwent sequencing on a 50-gene hotspot AmpliSeq panel (IonTorrent) in a CLIA-compliant setting. The mutation rate and the concordance of gene mutations in tissue and in ctDNA were compared. Follow up blood draw was conducted in some patients Results', ' 161 patients with colorectal cancer underwent the test. 148 patients had tissue test, and 84 had ctDNA test, 63 had pairs of tissue and ctDNA. With the 50-gene hotspot tissue test, only 9.5% (14 in 148) of the patients did not have any mutation. The most common mutation gene was P53(72.3%, 107 in 148). The mutation rate of KRAS, NRAS, BRAF and PIK3CK in tissue was 45.1%, 4.6%, 5.1%, and 1.5% respectively. Whereas in blood, the mutation rate was 43.9%, 4.9%, 5.1% and 10.9% respectively. Both values are identical and in accord with the known prevalence of mutations observed in mCRC patient populations. In the paired 63 patients, the concordance for KRAS,NRAS, BRAF, PIK3CA and P53 was 96.6%, 100%, 96%, 97.9% and 90.9% respectively. In 25 patients who had more than twice ctDNA surveillance, the dynamic change of mutations in the blood was totally corresponding with the efficacy. 13 patients had no mutations detected after R0 resection, and 6 patients in 14 who received cetuximab treatment gain new mutations(RAS,EGFR,P53,SMARCB) before disease progression. 6 patients had dynamic gain and loss mutationS Conclusions', ' The common gene mutations rate in CRC detected in ctDNA is identical to that detected in tissue, is thus an appropriate surrogate testing in determining treatment options. And ctDNA reflects treatment efficacy, which warrants routine use in clinical practice']",
        "Doc_id":"ASCO_167419-176",
        "Doc_title":" Circulating tumor DNA(ctDNA) testing to detect identical gene mutation rates of KRAS, NRAS, PIK3CA and P53 compared to tissue-based testing and reflects treatment efficacy in patients with colorectal cancer.",
        "_version_":1606189039144140800},
      {
        "Meeting_name":" Modulating NRAS mRNA translation by nucleic acid clamp-mediated stabilization of the 5- UTR G-quadruplex",
        "Background":"['NRAS, a proto-oncogene belonging to the RAS oncogene superfamily, is a intracellular signal cascade mediator, with intrinsic GTPase activity, functioning to initiate the MAPK cell signaling pathway. Among the RAS oncogene superfamily that is mutated in approximately 30% of all cancers, the NRAS mutation accounts for about 15% of RAS related human malignancies, particularly myeloid leukemias and cutaneous melanomas. Recently, a stable G-quadruplex (G4) was previously identified in the 5-untranslated region (UTR) of NRAS mRNA. This G4 functioned as a translational silencer, downregulating NRAS protein and leading to the hypothesis that a small nucleic acid clamp could be optimized to facilitate the formation of specifically this G4, decrease NRAS expression, and facilitate cell death in melanoma cells. In the present study, a set of clamps were designed and examined for their ability to facilitate the formation of a G4 in the 5-UTR sequence of NRAS. These clamps are comprised of ribonucleotides complementary to the RNA 5- and 3-regions flanking the G4-forming sequence held together by a small linker element. Based on binding studies consisting of electromobility shift assays and circular dichroism, an optimal flank length and linker length was chosen for cellular studies. Effects on cellular viability and NRAS expression are being examined in leukemia and melanoma cells, and RNA ChIP-Seq is being used to localize the intracellular activity of the clamps to the 5-UTR. These nucleic acid clamps offer a high degree of selectivity for G4s over linear RNA facilitated by the small linker region; moreover, the approach of complementary nucleotides, versus small molecule-mediated G4 stabilization, allows for specificity for just one G4 out of all of the intracellular structures. This approach not only provides a solid base for developing the clamp into a non-small molecule cancer therapy, but also opens a new window for modulating oncogenic gene expression at the transcriptional or translational levels. The current study, in particular, offers a novel approach to anti-NRAS-mediated therapies for the treatment of myeloid leukemias and cutaneous melanomas.']",
        "Doc_id":"AACR_2015-2110",
        "Doc_title":" Modulating NRAS mRNA translation by nucleic acid clamp-mediated stabilization of the 5- UTR G-quadruplex",
        "_version_":1606188984666423297},
      {
        "Meeting_name":" Concordance of KRAS, NRAS, BRAF, PIK3CA mutation status in the primary tumor (PT) and metachronous metastases in patients (pts) with colorectal cancer (CRC).",
        "Background":"['Background', ' The concordance of KRAS mutation status between the PT of CRC and synchronous metastases is 95%. However, there were reports showing that KRAS mutation status in metastases may change during chemotherapy (CT). The aim of this study was to evaluate the concordance KRAS, NRAS, BRAF, PIK3CA mutation status between the PT and metachronous metastasesin pts with CRC. Methods', ' The inclusion criteria were', ' metachronous metastases (appearance  12 mo. from the date of surgery for the PT) and  2 metastasectomy. Only 19 from 1457 (1.3%) pts met the inclusion criteria. PT was located in the colon in 37% pts. The median time between the resection of the PT and metastasectomy was 19.7 mon. (12-63). Most of pts (74%) received CT before metastasectomy. None of the pts received anti-EGFR Mabs. We performed DNA melting analysis with TaqMan probes with following Sanger sequencing for detection of mutation hot-spots in exon 2 and 3 KRAS and NRAS, exon 15 BRAF, exon 9 and 20 PIK3CA. Statistical analyses were performed using SPSS v.22, Inc., Chicago, IL. Results', ' Mutations in KRAS, NRAS, PIK3CA and BRAF genes in PT were detected in 57.9%, 5.2%, 26.3% and 0%, respectively. Mutations in the tumor material obtained at the first metastasectomy were found in 68.4%, 0%, 21% and 0% pts, respectively. In tumor obtained in subsequent metastasectomy, mutations were detected in 52.6%, 5.2%, 10.5% and 0% pts, respectively. Discordance in any gene mutation status between PT and metastases were found in 42% pts', ' in KRAS status - 26.3%, NRAS - 5.2% and PIK3CA - 21% pts. The average time between the resection of the PT and metastasectomy did not differ between pts with or without changes in gene status', ' 18.2 mon. vs. 21.3 mon., p = 0.7. Nonsignificant prevalence in changes of mutation status revealed in pts with rectal cancer', ' 41.7% vs 14.2%, p = 0.3. CT between resection of the PT and metastasectomy was not associated with changes in gene mutation status (p = 1.0). Conclusions', ' We detected clinical significant differences in the mutational status of KRAS between the PT and metachronous metastases in pts with CRC. We recommend to re-test of KRAS mutation status in case of metachronous (  12 mon.) metastatic disease']",
        "Doc_id":"ASCO_166200-176",
        "Doc_title":" Concordance of KRAS, NRAS, BRAF, PIK3CA mutation status in the primary tumor (PT) and metachronous metastases in patients (pts) with colorectal cancer (CRC).",
        "_version_":1606189000386674688},
      {
        "Meeting_name":" RAF signaling and SHOC2 mediate mutant NRAS acquired resistance to RAF inhibitors in melanoma",
        "Background":"['RAS signaling through extracellular signal-regulated kinase 1/2 (ERK1/2)/mitogen-activated kinase (MAPK) pathway is critical for normal cellular homeostasis and is frequently aberrantly regulated in cancerous cells. Although often depicted as a linear sequence of RAS-RAF-MEK-ERK1/2, this pathway is also regulated by expression of multiple isoforms of proteins at each level, scaffold proteins that enhance pathway activation, and negative feedback mechanisms. Some of these factors may also impact on the response of the pathway to pharmacological inhibitors. To test this notion, we analyzed resistance to the RAF inhibitor, PLX4720, using mutant BRAF melanoma cell models. In a screen to isolate cells displaying resistance to the inhibitory effects of PLX4720, we observed a subset of cells harboring an acquired mutation in NRAS. In parental cells, expression of mutant NRAS was sufficient to prevent PLX4720-mediated inhibition of ERK1/2 signaling, entry into S phase and susceptibility to apoptosis in mutant BRAF cells. Effects of mutant NRAS were associated with the maintenance of RAF binding. Analysis of isolated clones of RAF inhibitor-resistant mutant BRAF cells demonstrated that re-activation of the ERK1/2 pathway in the presence of PLX4720 was dependent on NRAS, BRAF, CRAF, and the RAS-RAF scaffold protein, SHOC2/Sur-8. Depletion of SHOC2 also rendered resistant cells susceptible to PLX4720-mediated apoptosis in 3D collagen. Together, these data demonstrate the role of RAF isoforms and a RAS-RAF scaffold protein in the acquired resistance to RAF inhibitors induced by secondary mutations in NRAS.']",
        "Doc_id":"AACR_2012-2158",
        "Doc_title":" RAF signaling and SHOC2 mediate mutant NRAS acquired resistance to RAF inhibitors in melanoma",
        "_version_":1606189015921328128},
      {
        "Meeting_name":" Pharmacologic inhibition of EphA2 in NRAS and BRAF mutant melanomas.",
        "Background":"['The Eph receptors are the largest known family of receptor tyrosine kinases (RTKs). Research studies have shown that Eph receptors and ligands may be involved in many diseases including cancer. EphA2 is a member of the Eph family of receptor tyrosine kinases and is highly expressed in many aggressive cancer types, including melanoma. Our previous studies showed that EphA2 levels are elevated in melanoma cells and EphA2 plays critical roles in melanoma cell survival, proliferation, colony formation and migration in vitro and melanoma tumor growth in vivo. Together, these data suggest that EphA2 is a critical oncogene in melanoma and a potential pharmacologic target in the treatment of metastatic disease. Herein we present early evidence that EphA2 inhibitors (ALW-II-41-27 and HG-6-64-1) are effective in inhibiting proliferation of both NRAS and BRAF mutant melanoma cell lines in vitro through suppressing a series of EphA2 downstream signaling pathways. At the same time, EphA2 inhibitors are also effective at suppressing migration and invasion of melanoma cells with a reduction in actin cytoskeleton reorganization and lamellipodia formation. Animal studies are underway to determine the effectiveness of these agents in suppressing melanoma tumor growth in vivo. These results point to EphA2 inhibition as a promising therapeutic strategy for both NRAS and BRAF mutant melanomas either singly or in combination with BRAF or MEK inhibitors currently in trial.']",
        "Doc_id":"AACR_2013-5605",
        "Doc_title":" Pharmacologic inhibition of EphA2 in NRAS and BRAF mutant melanomas.",
        "_version_":1606189015588929536},
      {
        "Meeting_name":" Deciphering driver mechanisms for tumorigenesis in BRAF/NRAS double wild-type melanoma through integration of heterogeneous genome-wide datasets",
        "Background":"['In cutaneous melanoma, the most lethal form of skin cancer, BRAF is mutated in 45% of cases and NRAS in a further 20% of cases. The lack of known drivers in the remaining proportion of samples represents a challenge for personalized medicine. We hypothesize that the BRAF/NRAS double wild-type (WT) samples are a heterogeneous group driven by multiple events that arise independently. We performed whole exome sequencing (WES) and complimentary RNA-seq of 23 tumor tissue samples from 21 patients. Six of these tumors were WT for BRAF and NRAS, so we studied these cases further. The SNV load in the WT samples is more variable than the BRAF or NRAS driven melanomas. The median number of SNVs/Mb ( SD) for BRAF mutant (n = 9), NRAS mutant (n = 7) and BRAF WT/ NRAS WT (n = 6) samples were', ' 12.2  8.0, 42.2  82.7 and 12.6  90.2 respectively. Next we analyzed the TCGA cutaneous melanoma cohort where there are 154 BRAF and 92 NRAS mutated and 76 BRAF WT/NRAS WT samples. The median numbers of SNVs ( SD) were 374  638.3, 577  518.3 and 146.5  1221.6 respectively. The p-value for the comparisons BRAF vs. WT and NRAS vs. WT were 0.087 and 0.002 respectively (two-tailed Mann-Whitney test). We identified the somatic mutations that are specifically enriched for double wild-type samples and observed that the top two hits, NF1 (30.2% in double WT vs. 5.7% otherwise) and KIT (15.8% in double WT vs. 0.8% otherwise) are known driver gene candidates for wild-type melanomas, but we also find other novel candidate driver genes. Thus, we present a framework for identification of driver mutations and therapeutic targets in double wild-type melanomas and integration of these types of data with other large datasets such as those derived from RNA-seq and RPPA will assist in the development of approaches to stratify double wild-type patients for targeted or immune-therapies.']",
        "Doc_id":"AACR_2015-1094",
        "Doc_title":" Deciphering driver mechanisms for tumorigenesis in BRAF/NRAS double wild-type melanoma through integration of heterogeneous genome-wide datasets",
        "_version_":1606189026025406464},
      {
        "Meeting_name":" Analysis of KRAS/NRAS, PI3CA, and BRAF mutations in the phase II KSCC0901 study of cetuximab plus S-1 as third-line treatment for metastatic colorectal cancer in Japanese patients.",
        "Background":"['Background', '  Exploratory biomarker studies in the randomized phase III PRIME study suggested that patients with mCRC tumors harboring a mutation (MT) in KRAS or NRAS (beyond KRAS exon 2) do not respond to panitumumab-FOLFOX4 (2013 ASCO, JCO 31, #3511). We reported the efficacy and safety of S-1+. Cetuximab (Cmab) in wild-type (WT)-KRAS (exon 2) mCRC patients (pts) as third-line therapy (KSCC0901) (2012 ASCO, JCO 30, s3558). The full spectrum of characterized RAS (KRAS and NRAS), PI3CA, and BRAFMTs may affect efficacy in S-1+Cmab therapy in Japanese patients.  Methods', '  An analysis was conducted to assess the treatment effect of S-1+Cmab, according to RAS (KRAS and NRAS), PI3CA, and BRAF MTs. The treatment protocol of KSCC0901 was as follows', ' weekly intravenous Cmab administration of 400 mg/m2 (day 1), 250 mg/m2/week (following day 1) and oral administration of 80 mg/m2/day S-1 on days 128 of each 42-day cycle. MTs in KRAS codons 12 and 13 (exon 2) were detected using direct sequencing according to the manufacturers instructions. MTs in KRAS codons 61 and 146, NRAS codons 12, 13 and 61, BRAF codon 600 and PIK3CA codons 542, 545, 546, and 1047 were detected using the multiplex PCR-Luminex method-based MEBGEN MT Kit (Medical and Biological Laboratories, Nagoya, Japan).  Results', '  35 pts were eligible for the analysis. Number of MT cases of KRAS, NRAS, BRAF, and PIK3CA were 4, 2, 2, and 5, respectively. One case had MTs of NRAS and PIK3CA. In 37 cases with WT KRASexon2 pts, median progression-free survival (mPFS) was 5.6 [95% CI', ' 4.4  5.7] months; median overall survival (mOS), 13.5 [8.5-16.5] months; and best overall response (ORR), 37.8%. In the all-WT subgroup 23 cases, mPFS was 5.6 [5.1-7.1] months; mOS, 13.5 [9.3-21.2] months; and best ORR, 47.8%. In 12 patients with any MT, mPFS was 4.0 [2.7-7.5] months; mOS, 5.5[2.9- ] months; and  best ORR, 16.7%.  Conclusions', '  These results suggest that also in Japanese patients receiving a Cmab containing regimen, RAS, BRAF and PIK3CA MT status beyond KRAS exon2 might predict non-responders to treatment. Clinical trial information', ' UMIN000002475.']",
        "Doc_id":"ASCO_122070-143",
        "Doc_title":" Analysis of KRAS/NRAS, PI3CA, and BRAF mutations in the phase II KSCC0901 study of cetuximab plus S-1 as third-line treatment for metastatic colorectal cancer in Japanese patients.",
        "_version_":1606189023091490816},
      {
        "Meeting_name":" Gain of ALK gene copy number to predict lack of response to anti-EGFR treatment in advanced chemorefractory colorectal cancer (CRC) with KRAS/NRAS/BRAF/PI3KCA wild-type status.",
        "Background":"['Background', '  KRAS, BRAF, NRAS and exon 20 PIK3CA quadruple wild-type CRC is associated with 41.2% response rate to anti-EGFR treatments. Even in molecular characterized patients, there is still a subset of non responders. The identification of additional predictive biomarkers is an unmet clinical need for treatment personalization. Alterations of ALK oncoprotein may interfere with the biological activity of EGFR through cross-talk of downstream signalling pathways.  Methods', '  This retrospective analysis aimed to investigate the correlation between ALK gene copy number (GCN), assessed by fluorescence in situ hybridization (FISH), and clinical outcome in KRAS/NRAS/BRAF/PI3KCA wild-type chemorefractory advanced CRC patients receiving cetuximab or panitumumab. FISH was perfomed with break-apart ALK (2p23) probes and gain of ALK GCN was defined as a mean of 3 to 5 signals in 10% of cells and amplification as 6 signals. Association of ALK status with RECIST response was performed by Fishers exact test.  Results', '  Forty-one patients were identified, of whom 17 (41%) were ALK GCN positive, whereas the remaining 24 cases (59%) were ALK GCN negative. No ALK translocations were detected. Overall response rate was 19/41 (46%). We observed a partial response in 3/17 patients with ALK GCN positive versus 16/24 patients with ALK GCN negative (18% versus 67%, respectively; P=0.0036). Kaplan-meier curves for comparison of median progression-free and overall survival, as well as correlation with ALK expression by immunohistochemistry, will be presented at the Meeting exploring the whole National Cancer Institute data-set.  Conclusions', '  In this study population with KRAS/NRAS/BRAF/PI3KCA wild-type tumors, the response rate greater than 40% is in line with literature data. ALK GCN may be a biomarker for clinical outcome prediction in advanced chemorefractory CRC patients treated with cetuximab or panitumumab.']",
        "Doc_id":"ASCO_117318-132",
        "Doc_title":" Gain of ALK gene copy number to predict lack of response to anti-EGFR treatment in advanced chemorefractory colorectal cancer (CRC) with KRAS/NRAS/BRAF/PI3KCA wild-type status.",
        "_version_":1606189020752117760},
      {
        "Meeting_name":" Broad, hybrid capture-based next generation sequencing guided personalized therapy in metastatic colorectal cancer.",
        "Background":"['Background', ' Patients with metastatic colorectal cancer are now recommended to profile for RAS and BRAF mutations before receiving cetuximab or panitumumab. However, lots of patients with both RAS and BRAF wild-type tumors determined by non-NGS testing might still not respond due to the presence of additional gene mutation such as PIK3CA or PTEN. Therefore, its necessary to screen mutations in genes other than RAS and BRAF on the efficacy of anti-EGFR therapy. Besides, new available agents could potentially be used based on the other targetable alterations discovered. In this study, a broad, hybrid capture-based next generation sequencing (NGS) assay was used to identify RAS, BRAF and additionally targetable genetic alterations from colorectal cancer tissue. Methods', ' 72 cases of colorectal cancers were enrolled and all the patients signed the informed consent before assay. 7708 exons of 508 tumor related genes and 78 introns of 19 frequently rearranged genes were assessed for base substitutions, indels, copy number alterations, and gene fusions. The average median sequencing depth was 450. Results', ' 50.4% (37/72) of the tumors harbored a KRAS mutation, 4.2% (3/72) harbored a NRAS mutation and 4.2% (3/72) harbored a BRAF mutation. More specifically, 82.5% (33/40) of RAS mutation was located in exon 2. Except for RAS and RAF, 4.2% (3/72) anti-EGFR therapy response genetic mutations were found in PTEN (n = 3). Its also worth noting that actionable alterations were found in HER2 (n = 5, including 4 amplification and 1 activating mutation), FBXW7 (n = 3) and others (n = 5). Conclusions', ' Our results implied that 63.9% (46/72) metastatic colorectal cancers with genetic mutations including KRAS, NRAS, BRAF and PTEN might not benefit from anti-EGFR therapy. 26.4% (19/72) of samples harbored at least one actionable genetic alteration rather than RAS identified by NGS testing. Significantly, HER2 defined a unique subpopulation of 6.9% (5/72) of metastatic colorectal cancer and might be a promising driven-gene. These findings suggest that high throughput NGS testing in colorectal cancer tissue was a comprehensive and efficient genomic profiling assay to guide personalized therapy.']",
        "Doc_id":"ASCO_164103-176",
        "Doc_title":" Broad, hybrid capture-based next generation sequencing guided personalized therapy in metastatic colorectal cancer.",
        "_version_":1606189033249046528},
      {
        "Meeting_name":" Primary and acquired resistance to HERs inhibition in colorectal cancer cells",
        "Background":"[\"The monoclonal antibodies cetuximab and panitumumab are approved for the treatment of metastatic colorectal cancers (mCRC). When used as monotherapy, the anti-EGFR antibodies are effective in approximately 15% of patients. It is now well established that colorectal tumors carrying KRAS and BRAF mutations (40%) are refractory to EGFR targeted therapies (primary resistance). Virtually all-responsive patients eventually become insensitive to anti-EGFR antibodies (secondary resistance) within 3 to 12 months of initiating therapy. Primary and acquired resistance therefore limits the clinical benefit of EGFR blockade in CRC patients.We postulated that concomitant inhibition of multiple members of the HER (ErbB) receptors family might suppress the growth of CRC cells more effectively than selectively targeting only the EGFR with cetuximab or panitumumab.Accordingly, we assessed the pharmacological activity of momelotinib and afatinib- two pan-HER tyrosine kinase inhibitors- in a collection of 40 CRC cell lines, which recapitulate the genetic profiles commonly detected in CRC patients. We report that primary resistance to pan-HER inhibition is associated with KRAS and BRAF mutations thus suggesting that this patients' population will unlikely benefit from momelotinib and afatinib treatments. Notably, however, pan-HER blockade was effective in a subset of KRAS/BRAF wild type CRC cell lines refractory to cetuximab and panitumumab indicating that a subgroup of patients, which do not benefit from EGFR blockade, may profit from pan-HER inhibition.To define the molecular mechanisms of acquired resistance to ErbB inhibitors, three KRAS/BRAF/NRAS wild type CRC cell models were continuously treated with cetuximab, momelotinib and afatinib, until resistant derivatives emerged. Genetic characterization of such derivatives unveiled that, regardless of the drug used, the resistant populations were a mixture of clones carrying distinctive mutations in KRAS or NRAS. Detailed biochemical analyses of the ErbB signalling pathway revealed that resistant variants displayed high levels of MEK and ERK activation, which persisted upon ErbBs inhibition.Collectively, these results identify KRAS, BRAF and NRAS mutations as major drivers of primary and/or acquired resistance to HERs inhibition in colorectal cancer cells and suggest that a molecularly defined subset of CRC patients might benefit from pan-HER blockade.\"]",
        "Doc_id":"AACR_2014-1843",
        "Doc_title":" Primary and acquired resistance to HERs inhibition in colorectal cancer cells",
        "_version_":1606189036357025793},
      {
        "Meeting_name":" Evaluation of a fully automated extended RAS-BRAF test on prospectively collected plasma samples from patients with metastatic colorectal cancer.",
        "Background":"['Background', ' Extended analysis of RAS genes in metastatic colorectal cancer (mCRC) is not available in many settings and the need for an easy plasma test is high. Methods', ' Pre-treatment plasma samples from 198 mCRC patients enrolled in the prospective multicenter RASANC study (NCT02502656) were retrospectively assessed for the presence of ctDNA mutations in KRAS, NRAS and BRAF by the fully automated Idylla platform.Proper informed consent and statistical analysis were included. The study is ongoing. We used Idylla platform which allows analysis of 21 KRAS, 18 NRAS and 4 BRAF ctDNA mutations from mCRC using 2 ml of plasma. The tests were performed using prototype versions of the Idylla ctKRAS and ctNRAS-BRAF-EGFR S492R Mutation Assays (RUO), which contain all reagents for integrated sample preparation and multiplex real time PCR detection. The tests each require 1 ml of plasma, less than 1 minute hands-on time, and have a turnaround time of less than 130 minutes.As a comparator test, NGS analysis with a sensitivity of 0.2% was performed on extracted plasma ctDNA according to Pcuchet et al. (2016). Results', ' The Idylla ctDNA assays identified 84 KRAS mutated (42.4%), 6 NRAS mutated (3%) and 13 BRAF mutated (6.6%) cases. The Idylla assays detected 62 KRAS codon 12 (31%), 16 codon 13 (6.5%), 3 codon 61 (1.5%), and 8 codon 146 (4%), and 1 NRAS codon 13 (0.5%) and 5 (2.5%) codon 61 mutated samples. All BRAF mutations detected were V600E. Overall agreement between Idylla and NGS for KRAS, NRAS, and BRAF was 96%, 100%, and 99.5% respectively. Overall RASconcordance with the NGS reference method was 96.5% with a positive agreement of 98% and a negative agreement of 95% (Table 1). Discordancy analysis by means of ddPCR on plasma and/or tissue will be presented. Conclusions', ' Plasma-based analysis of 41 extended RAS and BRAF mutations in ctDNA on the Idylla platform enables rapid and reliable genotyping in patients with advanced colorectal cancers. Clinical trial information', ' NCT02502656Agreement between Idylla and NGS plasma analysis.NGS Plasma RAS StatusWildtypeMutantTotalIdylla Plasma RAS StatusWildtype1012103Mutant59095Total10692198Overall agreement96.5%Negative agreement95%Positive agreement98%']",
        "Doc_id":"ASCO_191667-199",
        "Doc_title":" Evaluation of a fully automated extended RAS-BRAF test on prospectively collected plasma samples from patients with metastatic colorectal cancer.",
        "_version_":1606189016378507264},
      {
        "Meeting_name":" Clinical support with integrated multimodality molecular profiling for colorectal tumors.",
        "Background":"['Background', ' Current recommendations for colorectal cancer testing include KRAS and NRAS for anti-EGFR therapy, and BRAF mutational analysis with microsatellite instability (MSI) testing for prognostic stratification and Lynch syndrome. We developed a multi-modality colorectal cancer profile useful for clinical management. Methods', ' 133 Colorectal cancer samples were profiled with our platform, which includes 1) 21 gene mutation analysis using deep sequencing (ca. 15K reads), 2) MSI status, 3) MLH1 Promoter Methylation, 4) MET amplification and PTEN deletion by FISH, and 5) PD-L1 expression (30% of samples) by IHC. Results', ' 99% of tumors contained at least 1 mutation found by NGS. The most commonly observed mutations were TP53(85%), KRAS (49%), PIK3CA(26%), BRAF(19%), EGFR(16.5%), NRAS(8%), FGFR3(6%), HRAS(5%), KIT (5%), SMO(5%), JAK3(5%), and ERBB2(5%). 39 patients had a TP53 mutation allele frequency consistent with germline mutations, raising the possibility of a LiFraumeni syndrome. Most tumors (51%) also had at least 1 abnormal non-sequencing result. The most common findings were PTEN deletion (25%), MLH1(17%) methylation, MSI(11%), PDL1 (17.5%) overexpression. PTEN/MET/PDL1 was anticorrelated to MSH/MLH status. (p < 0.05). Our integrated profile (NGS, FISH, MSI, MLH) robustly recapitulated hypermutation profiles that were associated with BRAF+/MLH+/MSH+ profiles using comprehensive WGS in a recent TCGA study. In addition, 25%(10) were KRAS-/MLH-/MSH-/BRAF- of unknown prognosis without PTEN deletion status. The integrated profile also identified ~2 percent (3/131) of patients as candidates for Lynch Syndrome testing (MSH+/MLH-/BRAF- and < 50 years). Conclusions', ' Multimodality Colorectal Cancer profiling identified patients with potential new targeted therapy. Specifically, we identified a significant number of cases that were PTEN, PI3KCA, HRAS, FGFR3, MET, KIT, ERBB2, and PDL1 positive that change treatment options. In addition, to identifying patients with prognostic status (e.g.BRAF+, MSI+/MLH+), we identified important candidates for Lynch syndrome testing or possibly Li-Fraumeni Syndrome who would benefit from alternative treatments and different management.']",
        "Doc_id":"ASCO_168194-176",
        "Doc_title":" Clinical support with integrated multimodality molecular profiling for colorectal tumors.",
        "_version_":1606189016103780352},
      {
        "Meeting_name":" Phase I study of trametinib and neoadjuvant chemoradiation (CRT) in patients with locally advanced rectal cancers (LARC) that harbor KRAS, BRAF, or NRAS mutations.",
        "Background":"['Background', ' KRAS, NRAS, and BRAF mutations constitutively activate and dysregulate the MAPK pathway in colorectal cancer. Pre-clinical data suggest that MEK 1/2 inhibition radiosensitizes RAS mutant cancers. Thus, we conducted a phase I study with trametinib, a MEK1/2 inhibitor, in combination with 5-FU CRT in patients with LARC. Methods', ' A phase I study for patients with stage II or III rectal cancer that harbor KRAS, NRAS, or BRAF mutations. It is a standard 3+3 design with 3 dose levels of trametinib', ' 0.5mg, 1mg, and 2mg daily, given in combination with 5-FU 225mg/m2/day (5 days week) and a total of 50.4 Gy radiation (1.8 Gy daily fractions). Trametinib is administered with a 5-day lead-in, and for the duration of CRT. Patients then undergo surgery 6-10 weeks later. There is an expansion cohort planned for a total of 12 patients at the maximum tolerated dose (MTD). The primary endpoint is to determine the MTD of trametinib with CRT. Results', ' Thirty-five patients have been screened and 10 patients (8 male, 2 female) enrolled. Median age is 54 years (range 38-64). Nine patients are evaluable for toxicities thus far. Patients have been enrolled to all 3 dose levels without dose-limiting toxicities, and the 10th patient is receiving trametinib 2mg. There are no grade 4 toxicities, and the most common toxicities observed are shown (Table). Skin rash due to trametinib (2mg) led to dose-reduction in 1 patient and holding trametinib in another, both for the last 3 days of CRT. There were no interruptions in radiation therapy; 5FU was held for 3 days in 1 patient due to mucositis. Conclusions', ' Trametinib in combination with CRT has been well-tolerated. Additional patient enrollment and longer follow-up time are needed to detect activity of MTD on rates of pathologic response, local control, distant relapse, and survival. Clinical trial information', ' NCT01740648Grade 1 N (%)Grade 2 N (%)Grade 3 N (%)HematologicalLeukopenia1 (11)1(11)0Lymphopenia4 (44)02 (22)Anemia2 (22)2 (22)0Thrombocytopenia3(33)00Non-HematologicalDiarrhea7 (78)1 (11)0Generalized skin rash3 (33)00Nausea3 (33)00Dyspepsia2 (22)00Oral mucositis1 (11)1 (11)0Fatigue2 (22)00Hyperglycemia2 (22)00Rectal pain1 (11)2 (22)0']",
        "Doc_id":"ASCO_164209-176",
        "Doc_title":" Phase I study of trametinib and neoadjuvant chemoradiation (CRT) in patients with locally advanced rectal cancers (LARC) that harbor KRAS, BRAF, or NRAS mutations.",
        "_version_":1606189008441835520},
      {
        "Meeting_name":" Mutational analysis of clinically relevant cancer related genes in colorectal cancer.",
        "Background":"['Background', '    Whole genome sequencing of colorectal cancer (CRC) has identified common mutations that have been implicated in tumorigenesis. We investigated the association between genetic mutations in known cancer related signaling pathways, and clinicopathological variables in patients with CRC.  Methods', '    DNA samples of patients with CRC were genotyped for Single Nucleotide Polymorphisms (SNPs) including potentially clinically relevant mutations using the Sequenom platform.  Results', '    Tissue from 68 patients was genotyped. 163 mutations were identified in 21 cancer related genes. 45% of patients had stage III CRC & 10% had stage IV CRC at diagnosis. 17 patients developed metastatic CRC.  59 patients had at least 1 mutation. Mutations occurring in at least 5% of patients included KRAS(35%), PIK3R1(34%), TP53(32%), PHLPP2(32%), BRAF(16%), PIK3CA(13%), APC(13%), IDH1(12%), FBXW(7%) & MET(6%). Less frequent mutations (<5%) included GNAS, PTPN, NRAS, STK11, TBX3, and EGFR.  KRAS mutations were associated with mucinous histology (P=0.04). TP53 mutations were associated with nodal disease at diagnosis (p=0.03).  There was no statistically significant difference in overall survival in patients with KRAS, PIK3, TP53 or BRAF mutations as compared to their wild type (WT) counterparts.  No mutation was predictive of disease progression. In patients with mCRC and TP53 mutations, DFS was significantly shorter when mutations in APC, FBXW7, IDH1, MET and NRAS were present (10 months verses 15.5 months p=0.01). Mutations in APC, FBXW7, IDH1, MET and NRAS only occurred in the presence of other mutations. A trend towards reduced DFS was seen in KRAS WT patients with mCRC when mutations in APC, FBXW7, IDH1, MET and NRAS were present (9 months vs. 22 months, p=0.2). A trend towards reduced DFS was seen in patients with mCRC & 3 or more distinct mutations (10 months vs. 18 months p=0.2).  Conclusions', '  These results suggest that mutations in known cancer related signaling pathways occur frequently in patients with CRC. Mutations in APC, FBXW7, IDH1, MET and NRAS conferred a shorter DFS in patients with mCRC &, TP53 mutations, KRAS wild type patients and patients with multiple distinct mutations']",
        "Doc_id":"ASCO_140610-158",
        "Doc_title":" Mutational analysis of clinically relevant cancer related genes in colorectal cancer.",
        "_version_":1606189005572931584},
      {
        "Meeting_name":" PIK3CA mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome.",
        "Background":"['Background', '  Double somatic mutations in mismatch repair (MMR) genes have recently been described in a high proportion of colorectal and endometrial cancers with microsatellite instability (MSI) not attributable to MLH1 hypermethylation or germline mutation. We sought to define the molecular phenotype of this new tumor subtype.  Methods', '  We identified patients with double somatic colorectal and endometrial tumors from two Ohio-based prospective Lynch syndrome screening studies who had abnormal tumor testing (MSI and/or by immunohistochemistry (IHC) without coexistent MLH1 methylation), but normal germline MMR testing. We determined the frequency of PIK3CA, BRAF, KRAS, NRAS, and PTEN mutations in double somatic tumors by targeted next-generation sequencing and compared the mutation frequencies to tumors of other MSI sub-groups', ' Lynch syndrome, MLH1 hypermethylation, and microsatellite stable (MSS) tumors. The frequencies were compared among groups with a logistic regression model.  Results', '  We found that 28/35 (80%) of double somatic tumors had PIK3CA mutations compared to 6/21 (29%) in Lynch syndrome tumors, 4/13 (31%) in MLH1 hypermethylated tumors, and 17/90 (19%) in MSS tumors, p < 0.0001. Among double somatic cases, a PIK3CA mutation was observed in 100% (13/13) of endometrial tumors and 68% (15/22) of colorectal tumors. These frequencies were significantly higher than all other case groups when analyzing by tumor type (colorectal p < 0.0001, endometrial p = 0.02). As expected, BRAF V600 mutations were frequent in MLH1 hypermethylated tumors (8/13) and not detected in any double somatic or Lynch tumors (p < 0.0001). No substantive differences were observed for KRAS, NRAS, or PTEN.  Conclusions', ' PIK3CA mutations are present in the majority of double somatic colorectal and endometrial cancers at frequencies significantly higher than those observed in other MSI sub-groups. PIK3CA mutation status may improve identification of Lynch syndrome by tumor-based screening and better define an emerging molecular entity in colorectal and endometrial cancers.']",
        "Doc_id":"ASCO_146200-156",
        "Doc_title":" PIK3CA mutations in colorectal and endometrial cancer with double somatic mismatch repair mutations compared to Lynch syndrome.",
        "_version_":1606189027810082816},
      {
        "Meeting_name":" Trends in biomarker testing among metastatic colorectal cancer patients",
        "Background":"['Background', ' The European Medicines Agency (EMA) changed its indication language from wild-type KRAS to wild-type RAS (KRAS and NRAS) for metastatic colorectal cancer (mCRC) patients treated with panitumumab in July 2013. The objective of this study was to describe patterns of KRAS, NRAS, and BRAF testing among mCRC patients in the EU5 (United Kingdom (U.K.), Germany, France, Italy and Spain) and to evaluate if there were demographic or clinical differences in the patients who were/were not tested. Methods', ' This descriptive study utilized a serial physician survey from Oncology Analyzer data (IMS Health Oncology, Fairfield, CT, USA), which provides real-world epidemiologic and clinical data. Trends in biomarker testing were evaluated by calculating the proportion of patients who were /were not tested for combinations of KRAS, NRAS, and BRAF within each of the five countries. KRAS and BRAF data were available in all countries from quarter three (Q3) 2012 to quarter two (Q2) 2015. NRAS was available in all countries from quarter 1 (Q1) 2014 to Q2 2015. Frequencies and proportions were also calculated to summarize patient demographic and clinical characteristics between groups with different testing choices. Results', ' The study included 32,961 mCRC patients. Prior to July 2013, most patients were tested for only KRAS. The proportions of patients tested for both KRAS and NRAS increased substantially during the period of data availability for NRAS, including < 1% to 19.1% in the U.K., 8.8% to 31.9% in France, 13.1% to 43.2% in Germany, 5.9% to 24.6% in Italy, and 8.7% to 31.4% in Spain. The proportions of patients tested for all three biomarkers also increased during the period of data availability for all three biomarkers (Q1 2014 to Q2 2015), including 2.3% to 16.4% in the U.K., 4.8% to 26.6% in France, < 1% to 2.4% in Germany, 4.2% to 22.3% in Italy, and 1.5% to 9.3% in Spain. There were few differences in patient demographic or clinical characteristics between those with different testing choices. Conclusions', ' This analysis provides a description of the patterns of biomarker testing using read-world data and suggests a consistent increase in testing among mCRC patients in the EU5.']",
        "Doc_id":"ASCO_193404-199",
        "Doc_title":" Trends in biomarker testing among metastatic colorectal cancer patients",
        "_version_":1606188976442441728},
      {
        "Meeting_name":" MEK162 (ARRY 438162), a MEK1/2 inhibitor, has activity in melanoma cells independent of BRAF and NRAS mutation status.",
        "Background":"['Background. Activation of the Ras/Raf/MEK/MAP kinase pathway is implicated in uncontrolled cell proliferation and tumor growth. Mutated, oncogenic forms of Ras are found in colon, pancreatic, and lung cancers; BRAF mutations have been identified in more than 60% of malignant melanomas and from 40-60% of papillary thyroid cancers. MEK, a dual specific kinase, is a key player in this pathway; it is downstream of both Ras and Raf and activates ERK1/2 through phosphorylation of key tyrosine and threonine residues. MEK162 (ARRY 438162) is a novel small molecule ATP-uncompetitive inhibitor of the kinases MEK1 and MEK2. MEK162 showed promising data in an ongoing Phase 2 Clinical Trial in patients with BRAF and NRAS mutated advanced melanoma. This is the first targeted therapy to show activity in patients with NRAS mutated melanoma. Methods and Results. The melanoma cell line panel was the most sensitive after investigating the growth inhibitory effect of MEK162 on 328 cancer cell lines from diverse histologies including melanoma, head and neck, colon, pancreas, lung, ovarian, liver, kidney, breast and endometrial. When a cutoff of IC50 <500nM or >70% Inhibition at 1uM after 6 days of culture was used 83% out of 47 melanoma cell lines were sensitive to the treatment with the MEK inhibitor. Sensitivity to MEK162 was independent of BRAFV600E andNRASQ61mutation status in this cell line panel. Cell cycle arrest and apoptosis was assessed upon exposure to MEK162 using flow cytometry. MEK162 led to a G1 arrest and marked increase in apoptotic cells in the majority of the sensitive melanoma cell lines regardless of their origin and oncogenic driver mutations. Western blots were used to characterize the changes induced by exposure to MEK162 in the MAPK and PI3K/mTOR pathways. MEK1/2 inhibition resulted in a decrease in pERK in all the cell lines tested regardless of their mutational status and the in vitro sensitivity. We observed an increase in pMEK more prominently in NRASQ61L mutant and wild type for NRAS and BRAF mutations cell lines than in BRAFV600Emutant cell lines. We found pAKT and pS6 decreased in the NRAS and BRAF mutant cell lines after treatment, suggesting that the inhibition of the mTOR pathway by MEK162 may be crucial for the sensitivity to the drug. Conclusion. These data provide evidence for supporting the use of MEK162 in the treatment of patients with melanoma.']",
        "Doc_id":"AACR_2013-2437",
        "Doc_title":" MEK162 (ARRY 438162), a MEK1/2 inhibitor, has activity in melanoma cells independent of BRAF and NRAS mutation status.",
        "_version_":1606189039669477376},
      {
        "Meeting_name":" Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.",
        "Background":"['Background', ' To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients (pts.) with mCRC receiving first-line combination chemotherapy with or without bevacizumab. Methods', ' 1239 pts. from 5 randomized trials (FIRE-1, FIRE-3, AIOKRK0207, AIOKRK0604, RO91) were included into the analysis. Outcome was retrospectively evaluated by Kaplan-Meier method, log rank tests and cox regression. Results', ' In 664 tumors no mutation was detected, 462 tumors were diagnosed with KRAS mutation, 39 tumors with NRAS mutation and 74 tumors with BRAF mutation. This categorization was associated with significant differences in progression-free (PFS) (P<0.01) and overall survival (OS) (P<0.01). Furthermore, KRAS exon 2 mutation variants were associated with heterogeneous OS (p=0.01). In particular G12D and G12V subtypes that occur with high frequency among KRAS exon 2 variants were associated with rather favourable OS, whereas other less frequent subtypes (G12C, G13D, G12S) correlated with less favourable outcome. Outcome data are summarized in table 1. Multivariate analyses will be presented at the meeting. Conclusions', ' In this retrospective evaluation, KRAS exon 2 mutation variants G12D and G12V were associated with rather favourable OS while KRAS G12C, G12S and G13D mutant tumors were associated with less favourable OS. Expectedly, any mutations in KRAS and NRAS were associated with inferior OS of mCRC patients compared to patients with tumors not being mutated in any of these genes. SubgroupsProgression-free survivalmonths (95% CI)Overall survivalmonths (95% CI)No mutation (n=664)10.3 (9.7-10.8)26.9 (25.2-28.5)KRAS mutation (n=462)9.5 (8.9-10.1)21.0 (18.5-23.5)G12D (n=152)10.5 (9.0-11.9)25.2 (22.2-28.2)G12V (n=92)9.5 (8.2-10.8)23.5 (16.7-30.3)G13D (n=71)8.8 (7.6-10.0)17.6 (13.3-21.9)G12S (n=34)9.3 (7.1-11.4)19.1 (15.2-23.0)G12C (n=28)10.1 (6.4-13.8)16.8 (15.6-18.0)G12A (n=22)9.8 (7.7-11.8)24.0 (16.4-31.5)NRAS mutation (n=39)9.5 (8.3-10.7)21.3 (14.9-27.8)BRAF mutation (n=74)7.4 (6.2-8.5)11.7 (9.7-13.6)']",
        "Doc_id":"ASCO_167141-176",
        "Doc_title":" Influence of KRAS exon 2 mutation variants as well as NRAS- and BRAF-mutations on outcome of patients with metastatic colorectal cancer (mCRC) receiving combination chemotherapy with or without bevacizumab.",
        "_version_":1606189022962515968},
      {
        "Meeting_name":" Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).",
        "Background":"['Background', '  Analysis of a phase III pmab monotherapy study indicated that KRAS and NRAS mutations beyond KRAS exon 2 may be predictive of pmab efficacy (Peeters et al, 2013).  Methods', '  The primary objective of this prospectively defined retrospective analysis of PRIME was to assess the effect of pmab + FOLFOX vs FOLFOX on overall survival (OS) in pts with mCRC based on RAS (KRAS or NRAS) or BRAF mutation status. \"Gold standard\" bidirectional Sanger sequencing and WAVE-based SURVEYOR Scan Kits from Transgenomic (conducted independently) were used to detect mutations in KRAS exon 3, exon 4; NRAS exon 2, exon 3, exon 4; and BRAF exon 15. Results', '  RAS ascertainment rate was 90%. Tx HRs for pts with WT RAS were 0.78 (95% CI, 0.62 - 0.99; p = 0.04) for OS (median gain of 5.8 months in the pmab arm) and 0.72 (95% CI, 0.58 - 0.90; p = < 0.01) for PFS. Tx HRs for WT KRAS exon 2/mutant (MT) other RAS were 1.29 (95% CI, 0.79 - 2.10; p = 0.31) for OS and 1.28 (95% CI, 0.79 - 2.07; p = 0.32) for PFS. Tx HRs for pts with WT or MT BRAF were inconsistent with a predictive biomarker (Table). Prognostic effects of the tested biomarkers will be presented.  Conclusions', '  A statistically significant OS benefit was observed in pts with WT RAS mCRC treated with pmab + FOLFOX vs FOLFOX. Pmab is unlikely to benefit pts with any RAS mutations. In this analysis, BRAF mutation had no predictive value.  Clinical trial information', ' NCT00364013.']",
        "Doc_id":"ASCO_115136-132",
        "Doc_title":" Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).",
        "_version_":1606189015346708480},
      {
        "Meeting_name":" Relationship between oncogenic mutations (RAS, BRAF and PIK3CA) and tumor location and prognosis in colorectal cancer.",
        "Background":"['Background', ' Several studies have reported that right-sided colon cancers (RCC) and left-sided colorectal cancers (LCRC) differ in several factors including genetic features. We investigated the difference in clinicopathological characteristics and oncogenic mutation status between patients with RCC and LCRC in all stages and assessed outcome. Methods', ' This study was a prospective, observational study. Patients were recruited from November 2014 to February 2016. Formalin-fixed paraffin-embedded tissue blocks were collected and DNA wes extracted from tissue sections from 227 cases. There was no double cancer. Mutations in KRAS, NRAS, HRAS, BRAF and PIK3CA were detected by next-generation DNA sequencer. Tumors from cecum to transverse colon were defined as RCC, and tumors from descending colon to rectum were defined as LCRC. The median follow-up period was 521 days. Results', 'KRAS, NRAS, BRAF and PIK3CA mutations were present in 95 patient (41.9%), 7 patients (3.1%), 10 patients (4.4%) and 23 patients (10.1%) respectively, and there was no HRAS mutation in all patients. RCC was 68 patients and LCRC was 159 patients. Poorly differentiated adenocarcinoma and mutinous adenocarcinoma were significantly more frequent in RCC compared to LCRC (P = 0.031). KRAS mutations were detected in 37 patients with RCC (54.4%) and in 58 patients with LCRC (36.5%). BRAF mutations were detected in 7 patient with RCC (10.3%) and in 3 patients with LCRC (1.9%). KRAS and BRAF mutation in RCC were significantly more frequent than in LCRC (P = 0.012 and P = 0.005, respectively). The incidence of NRAS and PIK3CA mutation was no difference between two groups. In all patients, overall survival was evaluated. On univariate Cox regression analysis, BRAF mutation was associated with significantly poorer overall survival than BRAF wild type (HR = 4.831, P = 0.013). Other oncogenic mutation status and tumor location werent associated with overall survival. Conclusions', 'KRAS and BRAF mutation were more frequent in the patients with RCC compared to those with LCRC in all stages. This study suggested BRAF mutation correlated with poor outcomes in patients with colorectal cancer.']",
        "Doc_id":"ASCO_189036-199",
        "Doc_title":" Relationship between oncogenic mutations (RAS, BRAF and PIK3CA) and tumor location and prognosis in colorectal cancer.",
        "_version_":1606188996262625280},
      {
        "Meeting_name":" Liquid biopsies to prospectively select patients with KRAS or NRAS mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib",
        "Background":"['Background', ' In a retrospective analysis performed in a phase II study evaluating efficacy and safety of the MEK-inhibitor refametinib plus sorafenib in Asian patients with HCC (Lim et al., Clin Cancer Res, in press), patients with mutant RAS appeared to exhibit a particularly robust clinical response to refametinib plus sorafenib compared to patients with wild-type RAS. To further investigate clinical activity of refametinib as monotherapy or in combination with sorafenib in HCC patients with mutant RAS, two Ph II studies for patients with unresectable HCC have been initiated; refametinib monotherapy (NCT01915589) and refametinib plus sorafenib combination therapy (NCT01915602). Since RAS mutations are very rare events in HCC and biopsies are not routinely taken in patients with underlying liver cirrhosis, only liquid biopsies seemed feasible for prospective patient selection. Therefore, Sysmex Inostics BEAMing (Beads, Emulsions, Amplification, and Magnetics) technology based on cell-free circulating DNA in plasma is used to select patients for KRAS/NRAS Mutation status prior to enrollment. Patients are eligible if they exhibit any one or multiple of 13 KRAS/NRAS mutations.Results', ' Between Sep 2013 and Nov 2014 more than 1000 plasma samples from patients with unresectable HCC enrolled in the refametinib monotherapy study or the refametinib plus sorafenib combination study, have been tested at a CLIA certified laboratory in Baltimore, MD. The turnaround time from shipping the plasma sample from the clinical trial site to the results reporting was 6-10 days. Out of 1004 samples from 116 trial sites in 18 countries, 47 (4.7%) have been reported to harbor a KRAS and / or a NRAS mut. The following mutations have been reported', ' KRAS_G12A, KRAS_G12C, KRAS_G12D, KRAS_G12R, KRAS_ G12S, KRAS_G12V, KRAS_G13D, NRAS_Q61K, NRAS_Q61L, NRAS_Q61H, NRAS_Q61R. The frequency of the mutant allele ranged from 0.02% to 9.75%. No obvious differences in the incidence of any of the mutations with regards to geography, demographic factors are other baseline characteristics have been observed.Conclusion', ' To our knowledge this is the largest dataset of KRAS and NRAS mutations in HCC. The observed prevalence of RAS mutations of approximately 5% across both trials is well in line with published data including the COSMIC database. Our data support that prospective selection of patients with HCC for KRAS or NRAS mutation is feasible with a turn-around time of 1-2 weeks depending on geographical region. These data further support the broad utility of such approaches for large randomized prospective studies in patients with specific tumor genetic profiles. The clinical outcome of the 2 clinical studies will help understand whether KRAS or NRAS can potentially be a predictive marker for response to refametinib in patients with HCC.']",
        "Doc_id":"AACR_2015-5252",
        "Doc_title":" Liquid biopsies to prospectively select patients with KRAS or NRAS mutant hepatocellular carcinoma (HCC) in two phase II studies with Refametinib",
        "_version_":1606188979958317056},
      {
        "Meeting_name":" Anti-EGFR-based conversion chemotherapy in RAS wildtype colorectal cancer patients",
        "Background":"['Background', ' Initially unresectable colorectal liver metastases can become resectable after chemotherapy. Chemotherapy combined with EGF-receptor antibodies has shown consistent high response rates in patients with RAS wildtype tumors. However, the influence of RAS mutations other than exon 2 mutations in the context of a conversion strategy has not been systematically studied yet. Methods', ' Out of a cohort of 424 patients with mCRC, we identified 30 patients with initially unresectable KRAS exon 2 wildtype colorectal liver metastases who received neoadjuvant chemotherapy including cetuximab or panitumumab between January 2008 and February 2014. In all patients extended RAS analysis (KRAS and NRAS exon 3 codon 59 and 61 and exon 4 codon 117 and 146) was carried out. Resection status (R0, R1 or R2), PFS and OS were recorded in all patients and maximum tumor shrinkage was calculated. Results', ' RAS mutation analysis identified further KRAS mutations in 4/30 patients (13.3%). No NRAS mutations were found. In none of these four patients a R0 resection could be achieved. In contrast, 15/26 (57.7%) RAS wildtype patients could be R0 resected. Median survival of patients with a RAS wildtype tumor was 64.0 [range', ' 7.4-98.6] months vs. 28.0 [range', ' 16.4- 40.6] months in those with a RAS mutation (hazard ratio, HR, 0.53; 95% confidence interval, CI', ' 0.15-1.81, p = 0.3). Median PFS in patients with a RAS mutation was 8 [range', ' 6-28.8] months compared to 10.4 [range, 1.7-15.2] months in patients with a RAS wildtype cancer. Median overall survival was > 63.3 months in R0-resected patients vs. 30.0 months in those with a R1 or R2 resection (HR 0.23; [95% CI 0.10- 0.75; p = 0.008). Conclusions', ' Our data suggest that a RAS wildtype status and a R0 resection are the strongest predictors for overall survival. The extended RAS analysis allows a better patient selection for anti-EGFRbased conversion chemotherapy before secondary resection of colorectal liver metastases.']",
        "Doc_id":"ASCO_188077-199",
        "Doc_title":" Anti-EGFR-based conversion chemotherapy in RAS wildtype colorectal cancer patients",
        "_version_":1606189008476438528},
      {
        "Meeting_name":" Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).",
        "Background":"['Background', '   Patients with refractory KRAS WT mCRC benefit from EGFR-inhibiting antibodies (EGFR-I). Retrospective analyses suggest tumours bearing KRAS exon 2 G13D mutations may also derive benefit. Recent data restricts the profile of responders to tumours which are WT for KRAS exons 2, 3 & 4 and NRAS. Retrospective data indicates WT PIK3CA gene may also be needed for response, whilst the predictive value of BRAFmutations is more uncertain.  ICECREAM is a currently recruiting international randomised phase II trial of cetuximab +/- irinotecan in 100 patients with quadruple WT tumours (KRAS, NRAS, PIK3CA, BRAF) or with KRAS G13D mutation.   Methods', '  Tumour samples were screened at any stage following mCRC diagnosis. Sanger sequencing and SNaPshot analysis (limit of sensitivity 15%, 3%) was performed for KRAS exons 2, 3 & 4, NRAS, BRAF exon 15 and PIK3CA exons 9 & 20.  Results', '  Samples from 149 patients were screened for KRAS and 131 of those for the additional genes. Six samples failed technically. 59 of 125 (47%) were WT for all 4 genes. Mutation frequencies were', ' KRAS exon 2  45; exon 3  3; exon 4 - 1 (49/143 (34%)), NRAS 7/125 (6%), BRAF 13/125 (10%) and PIK3CA exon 9  11; exon 20  5; (16/125 (13%)).  KRAS G13D was identified in 7 cases (5%).  KRAS, NRAS & BRAF mutations were mutually exclusive whereas PIK3CA mutation frequently co-existed with KRAS mutations.  Of 59 quadruple WT patients, 13 are enrolled on trial, with 27 G13D mutation patients.  Sanger sequencing identified rare or unusual mutations (KRAS Q22K, KRAS V14I, KRAS T74P, BRAF D584G(2), BRAF D584N and PIK3CA M1943I) of uncertain significance in 7 cases (5%); these would be missed by allele-specific methods directed towards common hotspot mutations.  Conclusions', '  The mutation frequencies in genes predicting sensitivity to EGFR-I in a trial- eligible community population are similar to those reported in retrospective analyses from large Phase III trials.  Screening for exons rather than hotspot mutations identified rare or unusual mutations of uncertain clinical significance in 5% of patients. Clinical trial information', ' ACTRN12612000901808.']",
        "Doc_id":"ASCO_132217-144",
        "Doc_title":" Prospective evaluation of KRAS, NRAS, BRAF, and PI3KCA mutation screening for patient enrolment in AGITG ICECREAM (Irinotecan Cetuximab Evaluation and the Cetuximab Response Evaluation among Patients with G13D Mutation) trial in metastatic colorectal cancer (mCRC).",
        "_version_":1606189031583907840},
      {
        "Meeting_name":" A zebrafish model of NF1-mutant melanomas that lack activating mutations of BRAF or NRAS.",
        "Background":"['Cutaneous melanoma is the most lethal type of skin cancer, with ~76,380 newly diagnosed melanoma and ~10,130 melanoma-associated deaths per year in the US. Thus, there is a need for improved understanding of the molecular pathogenesis and more effective targeted therapies for this devastating disease. The recent work of The Cancer Genome Atlas Network has defined melanoma as an RTK/RAS-driven solid tumor that can be classified into four genomic subtypes', ' BRAF-mutant, RAS-mutant, NF1-mutant, and triple-wild-type. This landmark study highlighted the important role of the previously understudied NF1 tumor suppressor in melanoma pathogenesis, especially for the 9% of melanoma patients who have acquired inactivating NF1-mutations, but lack hotspot mutations that activate BRAF or RAS. To date, animal models have not been developed for the NF1-mutant subtype of melanoma, which has significantly impaired the development of novel therapeutic strategies for this subtype. Here we report the first zebrafish model for NF1-mutant melanoma, which we generated by combining the loss of nf1 with loss of both pten and p53. The resultant compound mutant zebrafish develop aggressive melanomas from the age of 7 weeks and the tumor penetrance is 80% by the age of 18 weeks. We demonstrate further that these high-risk zebrafish melanomas were exclusive of hotspot mutations of braf and nras. Sustained inhibition of both MEK and PI3K suppressed tumor progression in vivo, whereas inhibition of MEK or PI3K alone was insufficient to suppress the growth of these tumors. Surprisingly, single agent therapy with rapamycin, an MTOR inhibitor, proved even better for short- and long-term suppression of tumor cell growth in nf1/pten-mutant melanomas. Thus our model appears ideal for the testing of drugs that will prove uniquely active for the significant subset of NF1-mutant, BRAF/NRAS-wildtype human melanomas.']",
        "Doc_id":"AACR_2017-801",
        "Doc_title":" A zebrafish model of NF1-mutant melanomas that lack activating mutations of BRAF or NRAS.",
        "_version_":1606188990091755520},
      {
        "Meeting_name":" Routine multiplexed mutational analysis of colorectal cancers (CRCs)",
        "Background":"['Background', '  Colorectal tumors harbor mutations in genes that play key roles in CRC carcinogenesis and that may enable prioritization of appropriate anti-cancer therapy.  KRAS testing is part of standard of care testing prior to initiation of anti-epidermal growth factor receptor antibodies.  Other mutations are emerging as significant drivers, but they are not yet part of routine screening.  Methods', '  As part of Vanderbilt-Ingram Cancer Centers Personalized Cancer Medicine Initiative, we developed a  clinical algorithm to genotype patients colorectal tumors using a SNaPshot-based assay (multiplexed PCR, primer extension, and capillary electrophoresis) designed to detect 65 somatic mutations in 7 genes (KRAS, BRAF, AKT1, PIK3CA, SMAD4, PTEN, and NRAS) important in CRC carcinogenesis.  Adult patients with metastatic CRC were consented for genotyping of tumor tissue.  Mutational profiling was performed in Vanderbilts CLIA-certified Molecular Diagnostics Laboratory.  Results were reported in the electronic medical record for clinical use.  Results', '  Study enrolled from May 2012 to February 2014.  SNaPshot results were available from 126 patients.  49 tumors (38.9%) were wildtype for all mutations tested.  58 (46.0%) tumors had a KRAS mutation, including one with two KRAS mutations; the most common was G12D (n=23), but two had a Q61H mutation and two had a K117N mutation, which are not included in some commercial KRAS tests.  Ten (8.9%) tumors carried the V600E BRAF mutation.  Nine (7.1%) tumors harbored a PIK3CA mutation.  Three (2.4%) tumors had mutations in SMAD4.  Four (3.2%) tumors had a NRAS mutation.  One (0.8%) tumor had a PTEN mutation.  Nine (7.1%) tumors harbored double mutations, the most common being KRAS and PIK3CA double mutations (N=6).  24 (19%) subjects subsequently were treated on clinical trial therapy, including 6 subjects on therapy based on the SNaPshot results.  Not surprisingly, RAS results impacted use of anti-EGFR therapy.  Conclusions', '  61% of the tumors carried at least one mutation in the seven genes tested, suggesting that trials of tumor genotyping-based treatment assignment are feasible.   Study was supported by Vanderbilt University Medical Center.']",
        "Doc_id":"ASCO_140647-158",
        "Doc_title":" Routine multiplexed mutational analysis of colorectal cancers (CRCs)",
        "_version_":1606189035847417856},
      {
        "Meeting_name":" High intra- and inter-tumoral heterogeneity of RAS mutations in colorectal cancer.",
        "Background":"['Background', ' Anti-epidermal growth factor receptor monoclonal antibodies (anti-EGFR mAbs) are a standard treatment in metastatic colorectal cancer (mCRC) with wild-type (WT) RAS status. However, approximately 30% of patients with RAS WT mCRC are non-responders to anti-EGFR mAbs, possibly due to undetected tumoral subclones harboring RAS mutations. The aim of this study was to analyze the distribution of RAS mutations in different areas of the primary tumor, metastatic lymph nodes and distant metastasis. Methods', ' A retrospective cohort of 18 patients with a CRC was included in the study. All tumors were tested for KRAS, NRAS (codon 12, 13, 59, 61, 117 and 146) and BRAFV600E mutations using transparietal sections. Six were KRAS mutant, one NRAS mutant and one BRAF mutant. Multiregion analysis was performed in 60 spatially separated tumor areas according to the pTNM staging, including 49 in primary tumors (submucosa (pT1), musculosa (pT2) and/or subserosa (pT3)), 10 in metastatic lymph nodes and 1 in metastasis. KRAS, NRAS and BRAF mutations were tested using pyrosequencing. Intra-tumoral heterogeneity is defined by the presence of different tumoral subclones within the same tumor mass. Inter-tumoral heterogeneity consists in the presence of different tumor subclones in various tumor sites (i.e. primary tumor, metastatic lymph nodes or metastases). Results', ' Among the 60 tumor areas, 35 were KRAS mutated (in 11 tumors), 8 NRAS mutated (in 3 tumors) and one BRAF mutated(in 1 tumor). In primary tumors (n = 18), intra-tumoral heterogeneity for RAS mutation was found in 8 patients (44%). Inter-tumoral heterogeneity for RAS mutation between primary tumors and metastatic lymph nodes or distant metastasis (n = 11) was found in 6 patients (54%). Moreover, 5 tumors had multiple RAS mutated subclones in the same tumor (28%). Indeed, we observed the coexistence of different KRAS mutations (n = 3) as well as KRAS and NRAS mutations (n = 4). Conclusions', ' A high proportion of CRC presented intra- and/or inter-tumoral heterogeneity, which has relevant clinical implications for anti-EGFR mAbs prescription. These results suggest the need for multiple RAS testing in different part of the same tumor and/or more sensitive techniques.']",
        "Doc_id":"ASCO_164964-176",
        "Doc_title":" High intra- and inter-tumoral heterogeneity of RAS mutations in colorectal cancer.",
        "_version_":1606189013178253312},
      {
        "Meeting_name":" Molecular and clinical prognostic factors in metastatic colorectal cancer (CRC) patients (pts)",
        "Background":"['Background', '  Strong evidence is emerging about the usefulness of mutational profiling for CRC pts. This study aimed to evaluate the overall survival in three molecular groups, taking as reference the all-wild type category', ' (1) BRAF mutated; (2) KRAS mutated codons 12-13 only; (3) any of KRAS codons 61-146, PIK3CA exon 9-20 or NRAS cod 12-13-61 mutations. Also clinical variables were investigated as potential prognostic factors.  Methods', '  Data of 194 consecutive pts treated for metastatic colorectal cancer (mCRC) at our University Hospital in Udine, Italy, between Jan 2004 and Jan 2013 were reviewed. Point mutations were detected by pyrosequencing platform PyroMark Q96 ID instrument for KRAS/NRAS codons 12, 13, 61, and 146, BRAF exon 15, and PIK3CA exons 9 and 20.  Clinical and molecular prognostic factors were identified using the Cox proportional hazards model.  Results', '  The all wild-type population consisted of 76 pts (39%). 62 cases (32%) harboured mutations in KRAS codons 12-13. BRAF V600E mutation was found in 10 (5.2%) samples. Mutations in KRAS 61-146, PIK3CA and NRAS codons were detected in 9 (4.6%), 32 (16.5%) and 6 (3.1%) pts, respectively. All factors significant in univariate analysis were subjected to multivariate analysis (see Table). The all-wild type category had the longest survival (27.7 months). Patients carrying BRAF mutations reported an overall survival of 7.6 months and those with KRAS 12-13 mutation 16.7 months.  Conclusions', '  This study reinforces the prognostic value of a full mutational molecular profile and points out some prognostic clinical factors in CRC. The influence of clinical variables such as right colon cancer, primary tumour not resected, exposure to bevacizumab and lines of chemotherapy need further investigation.']",
        "Doc_id":"ASCO_123338-143",
        "Doc_title":" Molecular and clinical prognostic factors in metastatic colorectal cancer (CRC) patients (pts)",
        "_version_":1606189031161331712},
      {
        "Meeting_name":" Efficacy of photoactivated generation of a meditope-enabled anti-EGFR antibody drug conjugate in RAS/RAF mutant colorectal carcinoma.",
        "Background":"['Background', ' EGFR is a clinically validated target for advanced colorectal carcinoma, but EGFR targeted therapies are useless against EGFR expressing tumors with K/NRAS mutations. We hypothesized that an anti-EGFR antibody drug conjugate (ADC) that used EGFR to target the tumor and deliver a cytotoxic payload rather than blocking EGFR pathways may be useful for K/NRAS mutant EGFR expressing cancers. To this end, an anti-EGFR ADC was designed using a meditope-directed site-specific conjugation strategy. This strategy uses proprietary peptides that bind an antibody Fab fragment noncovalently in a unique site outside the paratope. This novel binding is exploited for site-specific covalent conjugation of cytotoxic payloads to any meditope-enabled antibody. The meditope peptide can be designed with a photoactivatable side chain, allowing the peptide-antibody interaction to be covalent. Herein, we report the development of an anti-EGFR ADC, utilizing a technology which we call SnAP (site-specific novel antibody platform) which may be effective against KRAS/NRAS mutant forms of colorectal carcinoma. Methods', ' An ADC was designed and tested for cytotoxicity in wild type and KRAS mutant cancer cell lines. Highly efficient site-directed covalent attachment of a toxin to the antibody was facilitated by a novel photoactivatable meditope peptide. Non-GLP safety studies were performed, and conjugation stability was assessed. Efficacy studies were performed in KRAS wildtype as well as KRAS mutant EGFR expressing xenografts. Results', ' A stable ADC with precisely controlled drug-antibody ratio (DAR) and unaltered affinity for EGFR was created using a novel photoactivation strategy. The meditope-directed ADC showed selective cytotoxic activity in EGFR+ cell lines, irrespective of KRAS mutation status. The potency of the ADC against EGFR dependent tumors was demonstrated in an EGFR expressing colon carcinoma xenograft study. Conclusions', ' Meditope-directed photoactivation is a novel way to generate site-directed ADCs. Anti-EGFR ADCs created in this fashion may permit patients with KRAS mutated EGFR expressing tumors to receive EGFR targeted therapies.']",
        "Doc_id":"ASCO_171398-176",
        "Doc_title":" Efficacy of photoactivated generation of a meditope-enabled anti-EGFR antibody drug conjugate in RAS/RAF mutant colorectal carcinoma.",
        "_version_":1606189000560738305},
      {
        "Meeting_name":" Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients",
        "Background":"['The molecular landscape of colorectal cancers (CRC) is presently assessed by genotyping neoplastic tissue obtained through surgical or bioptic procedures. We evaluated whether blood-based molecular profiles could be used to perform diagnostic determinations and monitor resistance to therapy in colorectal cancer patients. We find that RAS pathway mutations, which are commonly evaluated prior to administration of anti-EGFR antibodies, can be ascertained directly in the blood. Sequencing of circulating DNA identified genomic alterations in KRAS, NRAS, MET, ERBB2, FLT3, and MEK1 in patients with primary or acquired resistance to cetuximab or panitumumab. Secondary resistance to EGFR blockade is frequently accompanied by emergence of mutant RAS clones, which can be tracked in blood. We find that upon withdrawal of anti-EGFR antibodies, KRAS alleles decline in circulating DNA indicating that clonal evolution continues beyond clinical progression. Functional analysis of CRC cell populations, which had acquired resistance to cetuximab, revealed that KRAS mutant clones can decay when EGFR blockade is suspended. These results establish proof of principle that genotyping colorectal cancers using circulating DNA can inform therapeutic decisions, identify mechanisms of drug resistance and provide insights for further lines of therapy.']",
        "Doc_id":"AACR_2015-616",
        "Doc_title":" Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients",
        "_version_":1606189018776600576},
      {
        "Meeting_name":" Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma.",
        "Background":"['Our pre-clinical in vitro data suggested that all BRAF-mutated cell lines, and some NRAS-mutated melanoma are sensitive to MEK inhibition. BRAFwt/NRASwt were uniformly resistant. Among the sensitive cell lines, those with enhanced activation of the PI3K/AKT pathway did not undergo apoptosis. This is consistent with a recent phase II trial with Selumetinib, an allosteric MEK inhibitor, which showed a 6% response rate in unselected melanoma patients. Retrospectively, 5 of 6 of the responders were found to harbor BRAFV600E mutations. We hypothesized that treatment of BRAF-mutated or NRAS-mutated melanomas with Selumetinib will induce clinical responses only in the subset of tumors in which the PI3K/AKT pathway is not activated. In this phase II trial, melanoma patients with either BRAF or NRAS mutation were stratified based on phospho-AKT (pAKT) expression (high vs. low), as measured by immunohistochemistry staining of pre-treatment tumor specimens. Patients were treated with Selumetinib 75 mg p.o. daily in 28-day cycles. We found that the incidence of high pAKT melanoma tumors was about 4 times higher than low pAKT tumors. None of the 10 patients in the high pAKT cohort responded, although 4 patients showed stable disease for 4 months. This cohort was closed to further accrual. In contrast, in the low pAKT group, 1 patient had a true partial response (PR) and 2 others had near PRs. One of these patients had to discontinue treatment due to toxicity; the other had his remaining tumor resected. This cohort was closed due to slow patient accrual. We used an exon capture, next-generation sequencing assay to define the mutational status of 230 cancer associated genes in pre-treatment tumors, derived from patients belonging to both cohorts. The assay detects point mutations, small indels and copy number alterations. Among the two low pAKT patients who were resistant to MEK inhibition, one had a mutation in MAP2K1 that encodes for a K57N mutation in helix A of MEK1. We speculate that this is an activating mutation, since a missense mutation in the amino acid just proximal (Q56P) was previously shown to be highly activating. The other non-responding patient in the low pAKT cohort had an activating mutation in EGFR. Both of these could drive increased activation of the MAPK pathway, thus explaining the resistance to the drug. We conclude that future trials with MEK inhibitors in melanoma should exclude patients with high pAKT tumors. The occurrence of complex genetic changes in melanoma requires studies to better stratify the patients according the prediction of response to MEK inhibitors.']",
        "Doc_id":"AACR_2013-2284",
        "Doc_title":" Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- or NRAS-mutated melanoma.",
        "_version_":1606188984564711425},
      {
        "Meeting_name":" Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).",
        "Background":"['Background', '  Previously, this study showed significant improvement in progression-free survival (PFS) in pmab + FOLFIRI vs FOLFIRI (HR=0.73; 95% CI', ' 0.59-0.90; p=0.004) and a trend toward improved overall survival (OS; HR=0.85; 95% CI', ' 0.70-1.04; P=0.12; Peeters et al. JCO 2010).  Recently, analysis from 1st-line mCRC PRIME study showed that mutations in RAS genes (KRAS/NRAS exons 2/3/4) predicted a lack of response to pmab (Douillard et al. NEJM 2013).   Methods', '  The primary objective was to assess the tx effect of pmab + FOLFIRI vs FOLFIRI on OS and PFS based on RAS mutation status in the primary analysis population.  Bidirectional Sanger sequencing was used to detect mutations in KRAS exons 3, 4 and NRAS exons 2, 3, 4 in patients (pts) with known WT KRAS exon 2 mCRC.  Results', '  In this prospective retrospective analysis, overall RAS ascertainment rate was 85% (n=1008/1186).  18% of the WT KRAS exon 2 pts harbored additional RAS mutations (n=107/597).  Efficacy is shown (Table).  Tx HR for pts with WT RAS was 0.803 (95% CI', ' 0.629-1.024; P=0.077) for OS and 0.695 (95% CI', ' 0.536-0.903; P=0.006) for PFS.   Conclusions', '  Improvements were observed in the tx effect of pmab + FOLFIRI vs FOLFIRI on OS and PFS in the WT RAS group vs the WT KRAS exon 2 group.  Pts with MT RAS mCRC are unlikely to benefit by the addition of pmab to FOLFIRI, similar to pts with MT KRAS exon 2 mCRC in this study.  These findings are consistent with previously reported outcomes by RAS status and support RAS testing to determine potentially appropriate pts for pmab tx.     Clinical trial information', ' NCT00339183.']",
        "Doc_id":"ASCO_122548-143",
        "Doc_title":" Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).",
        "_version_":1606189042071764992},
      {
        "Meeting_name":" The prevalence RAS and BRAF mutations among patients in the Middle East and Northern Africa with metastatic colorectal cancer.",
        "Background":"['Background', '  Anti-EGFR therapies are recommended for metastatic colorectal cancer (mCRC) patients with confirmed wild-type RAS (exons 2, 3, 4 of KRAS and NRAS) status. There is limited published information on the prevalence of RAS mutations using real world data. The objective of this study was estimate the prevalence of RAS and BRAF mutations among patients with mCRC in the Middle East and Northern Africa (MENA) in an effort to inform the rationale for biomarker testing and treatment choice.  Methods', '  The study included 1,669 patients from August 2013 to July 2015 with mCRC from Algeria, Bahrain, Egypt, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, and the United Arab Emeritus. Information on RAS mutation status was obtained from one pathology lab using High Resolution Melting Analysis. Extended RAS analysis was conducted in a subset of patients, including', ' overall RAS (exon 2, 3, 4 of KRAS and NRAS; n = 750), KRAS exon 2 (n = 750), KRAS exon 3 and 4 (n = 507), NRAS exon 2, 3, and 4 (n = 507), and BRAF exon 15 (n = 78). The proportion of patients with each mutation was summarized.  Results', '  The overall RAS mutation in the full sample was 35.3% (n = 589/1669). The observed mutation for KRAS exon 2 in a subset of patients with extended RAS analysis (n = 750) was 32.4% (243/750). Out of the subjects with wild-type exon 2 (n = 507), the observed mutations rates were as follows', ' KRAS exon 4 (20/507 = 3.9%), KRAS exon 3 (13/507 = 2.6%), NRAS exon 2 (7/507 = 1.4%), NRAS exon 3 (6/507 = 1.2%), and NRAS exon 4 (0%). The prevalence of BRAF exon 15 was 3.8% (3/78). The most robust data on specific RAS mutations was obtained from Algeria, Egypt, and Saudi Arabia. The prevalence of KRAS exon 2 mutations in these countries was as follows', ' Algeria (n = 33/86 = 38.4%), Egypt (n = 83/303 = 27.4%), Saudi Arabia (n = 85/245 = 34.7%).  Conclusions', '  To our knowledge, this is the first study to evaluate the prevalence of RAS and BRAF mutations in the Middle East using real world data. The results of this descriptive study illustrate that there is variation in the prevalence of RAS and BRAF mutations in MENA.']",
        "Doc_id":"ASCO_160187-173",
        "Doc_title":" The prevalence RAS and BRAF mutations among patients in the Middle East and Northern Africa with metastatic colorectal cancer.",
        "_version_":1606189022159306752},
      {
        "Meeting_name":" The prevalence RAS and BRAF mutations among patients in the Middle East and Northern Africa with metastatic colorectal cancer.",
        "Background":"['Background', ' Anti-EGFR therapies are recommended for metastatic colorectal cancer (mCRC) patients with confirmed wild-type RAS (exons 2, 3, 4 of KRAS and NRAS) status. There is limited published information on the prevalence of RAS mutations using real world data. The objective of this study was estimate the prevalence of RAS and BRAF mutations among patients with mCRC in the Middle East and Northern Africa (MENA) in an effort to inform the rationale for biomarker testing and treatment choice. Methods', ' The study included 1,669 patients from August 2013 to July 2015 with mCRC from Algeria, Bahrain, Egypt, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, Saudi Arabia, and the United Arab Emeritus. Information on RAS mutation status was obtained from one pathology lab using High Resolution Melting Analysis. Extended RAS analysis was conducted in a subset of patients, including', ' overall RAS (exon 2, 3, 4 of KRAS and NRAS; n = 750), KRAS exon 2 (n = 750), KRAS exon 3 and 4 (n = 507), NRAS exon 2, 3, and 4 (n = 507), and BRAF exon 15 (n = 78). The proportion of patients with each mutation was summarized. Results', ' The overall RAS mutation in the full sample was 35.3% (n = 589/1669). The observed mutation for KRAS exon 2 in a subset of patients with extended RAS analysis (n = 750) was 32.4% (243/750). Out of the subjects with wild-type exon 2 (n = 507), the observed mutations rates were as follows', ' KRAS exon 4 (20/507 = 3.9%), KRAS exon 3 (13/507 = 2.6%), NRAS exon 2 (7/507 = 1.4%), NRAS exon 3 (6/507 = 1.2%), and NRAS exon 4 (0%). The prevalence of BRAF exon 15 was 3.8% (3/78). The most robust data on specific RAS mutations was obtained from Algeria, Egypt, and Saudi Arabia. The prevalence of KRAS exon 2 mutations in these countries was as follows', ' Algeria (n = 33/86 = 38.4%), Egypt (n = 83/303 = 27.4%), Saudi Arabia (n = 85/245 = 34.7%). Conclusions', ' To our knowledge, this is the first study to evaluate the prevalence of RAS and BRAF mutations in the Middle East using real world data. The results of this descriptive study illustrate that there is variation in the prevalence of RAS and BRAF mutations in MENA.']",
        "Doc_id":"ASCO_170726-176",
        "Doc_title":" The prevalence RAS and BRAF mutations among patients in the Middle East and Northern Africa with metastatic colorectal cancer.",
        "_version_":1606189023093587968},
      {
        "Meeting_name":" Mapping the metastatic colorectal cancer phospho-proteome for predicting response to cetuximab",
        "Background":"['Introduction', ' The discovery of the key role of the epidermal growth factor receptor (EGFR) and its downstream signaling effectors in the pathophysiology of colorectal cancer (CRC) has resulted in the clinical use of targeted therapies in the treatment of metastatic CRC (mCRC). However, clinical benefit to EGFR blockade is observed in only a subgroup of CRC patients wild type for KRAS andNRAS. Genomic characterization of patient derived xenograft (PDX) models of mCRC have revealed additional resistance mechanisms to the EGFR MAb cetuximab including amplification of MET, HER2 and mutations in ERBB2, EGFR, FGFR1, PDGFRA, and MAP2K1 (Bertotti et al. 2011, 2015). However, not all resistance is understood and the biochemical signaling correlates of sensitivity and resistance remain incompletely understood. Phosphoproteomics allows for comprehensive protein phosphorylation profiling, and thereby may shed new insights into the biology of CRC and the molecular basis of cetuximab response.Aim', ' To identify aberrant signaling pathways, predictive biomarkers, and alternative drug targets in genomically-annotated CRC PDX models by mass spectrometry-based phosphoproteomics.Methods', ' We performed LC-MS/MS based phosphoproteome profiling (van der Mijn et al. 2015; Piersma et al. 2015) on untreated CRC PDX models lacking KRAS, NRAS or BRAF mutation (n = 20). For comparison, KRAS, BRAF or NRAS-mutant and MET or HER2 amplified models (n = 21) were analyzed. Phosphopeptides were captured by phosphotyrosine antibodies and titanium dioxide. MS/MS data was searched using MaxQuant. Phosphoproteome data (ion intensities and spectral counts) were correlated with drug sensitivity. Dedicated bioinformatics was used to identify hyperactive kinases and signaling pathways in individual tumors.Results', ' The dataset contained 13.418 tyrosine-, serine- and threonine-phosphorylated peptides derived from 4588 proteins, including 237 phosphorylated kinases. Unsupervised hierarchical clustering of phosphopeptide intensities revealed subclusters enriched for sensitive and resistant models. Among cetuximab-resistant models, HER2 and MET were identified as hyperphosphorylated and hyperactive driver kinases, confirming the genomic annotation. Sensitivity to combination treatment of both EGFR and driver kinases was observed previously, providing proof-of-principle of the use of phosphoproteomics for the identification of driver kinases.Conclusion/Future', ' This project is uncovering the phosphoproteomic landscape of colorectal tumors and will yield a better understanding of signaling pathways involved, with an emphasis on identifying activated drug targets and predictive biomarkers in this disease, in relation to KRAS/NRAS/BRAF status and response to anti-EGFR therapy.']",
        "Doc_id":"AACR_2016-880",
        "Doc_title":" Mapping the metastatic colorectal cancer phospho-proteome for predicting response to cetuximab",
        "_version_":1606189005409353728},
      {
        "Meeting_name":" CNV patterns in 822 routine diagnostic cases of NSCLC, melanoma, and colorectal cancer",
        "Background":"['Targeted deep massive parallel sequencing (MPS) has been implemented in routine molecular diagnostics for high-throughput genetic profiling of formalin-fixed paraffin-embedded cancer samples. This approach is now widely used to interrogate simple somatic mutations but experience with the analysis of copy number variations (CNV) is still limited. Here, we retrospectively analyzed CNVs in 822 cancer cases (n = 135 melanoma, n = 468 non-small cell lung cancers (NSCLC), n = 219 colorectal cancers (CRC)) that were sent to our institution for routine molecular profiling using a semiconductor based sequencing platform. Amplifications and deletions inferred by MPS coverage data were independently validated by a qPCR assay. We observed a decreasing frequency of CNV in clinically actionable genes from melanoma to NSCLC to colorectal cancer.Of 56 melanomas with genetic aberrations in BRAF, 31 showed co-occurring CNV in other genes, mainly affecting CDKN2A. Some tumors (5 cases each) revealed clustered deletions affecting either ABL1, NOTCH1, and RET or STK11, GNA11, and JAK3. 8.1% of the cases had amplifications in clinically actionable genes. In the group of NRAS mutant tumors (n = 39), 26 showed co-occurring CNVs in other genes, such as CDKN2A and FGFR3, and 9 NRAS mutant cases were additionally mutated in BRAF. 19.1% had amplifications in clinically actionable genes. In contrast to BRAF mutant tumors, we did not see any specific CNV clusters. In the group of BRAF/NRASwt tumors (n = 11), we observed 5 cases with co-amplification of KDR, KIT, PDGFRA and another 6 cases with KIT mutations. While co-amplified cases had many gene deletions, KIT mutated tumors harbored only very few genetic aberrations in other genes.Across both NSCLC data sets, we identified 14 cases with amplified EGFR (10 of them harboring co-occurring EGFR mutations) and detected 8 NSCLC with KRAS amplifications (of which 7 had co-occurring mutations of KRAS). KRAS mutated tumors displayed frequent amplifications in MYC (n = 10) and MDM2 (n = 5). Of the 22 BRAF mutant tumors, two harbored mutated KRAS. In contrast to melanoma, we observed no clustering of CNVs in BRAFmut NSCLCs. Within the group of KRAS/EGFR/BRAFwt tumors, we identified 15 cases harboring genetic aberrations in MET (n = 8 mutations, n = 7 amplifications).Compared to melanoma and NSCLC, the number of CNV in CRC was rather low. IGF2 amplifications were most prevalent (n = 13) followed by MYC (n = 9). Two cases showed amplified wild-type alleles of KRAS. Two KRAS mutant tumors showed concomitant amplification of NRAS and three cases harbored amplified EGFR.In conclusion we demonstrate that i) detection of CNVs by targeted MPS data obtained from FFPE material is feasible and ii) could be validated independently, iii) this approach enables detection of known CNV patterns, and iv) uncovers new CNV patterns in clinically actionable targets across cancers.']",
        "Doc_id":"AACR_2016-3167",
        "Doc_title":" CNV patterns in 822 routine diagnostic cases of NSCLC, melanoma, and colorectal cancer",
        "_version_":1606188994698149888},
      {
        "Meeting_name":" Genomic profiling of young adults with colorectal cancer",
        "Background":"['Background', ' 2-8% of all colorectal cancer (CRC) cases are in younger adults (YAs), patients (pts) less than age 50. However, current understanding of CRC in YAs is inadequate, especially that of sporadic onset. We conducted a study to describe the landscape of genomic alterations in YA CRC pts presenting to a large academic practice. Methods', ' Adult pts with CRC presenting to The Ohio State University Comprehensive Cancer Center oncology clinics were offered next generation sequencing (NGS) through a customized 22-gene Ion AmpliSeq Mutation Panel as part of clinical care. Commonly mutated areas of select genes (including AKT1, ALK, BRAF, EGFR, ERBB2/4, FBXW7, FGFR1/2/3, KRAS/NRAS, MET, NOTCH1, PIK3CA, PTEN, TP53) were sequenced from tumor sections. Institutional review board approval was obtained to retrospectively analyze this NGS testing between 1/2013-3/2016. Results', ' 258 CRC pts underwent genomic profiling. 57 pts (22.1%) were YAs at diagnosis (range 22-49 years); 20 pts (7.8%) were 40 years old or younger. 31 YA pts (54.4%) had metastatic disease. Of the YAs with CRC, 18 pts (31.6%) were diagnosed with R-sided colon, 16 pts (28.1%) with L-sided colon, and 22 pts (38.6%) with rectal cancer. 110 genomic alterations were found in YA pts, with a mean of 1.9 mutations per tumor (range 0-6); 35 (31.8%) of these in 32 (56.1%) YA pts were actionable. Of these 110 alterations, 41.8% were in TP53, 28.2% in KRAS/NRAS, 10.0% in PIK3CA, 3.6% in BRAF, 3.6% in FBXW7, and 2.73% in PTEN. 6 YA pts (10.5%) had microsatellite instability (MSI-H). Only 1 pt had concomitant MSI-H and a BRAF mutation; 4 pts with BRAF mutations were microsatellite stable. Comparing our YA pts to a separate cohort of pts age > 50 who had testing done, no significant difference was seen in mutation incidence in KRAS/NRAS (p = 1.0), TP53 (p = 0.3), PIK3CA (p = 0.128), or BRAF (p = 1.0). Conclusions', ' Genomic profiling through a targeted NGS panel is feasible as part of routine clinical practice. There is disagreement in the literature on genetic mutations in YA compared to older age CRC pts. Knowledge of the genomic landscape in YAs with CRC will lead to improved understanding of the underlying biology of CRC in YAs as it differs from CRC in older pts, and could impact future care of this cohort.']",
        "Doc_id":"ASCO_190873-199",
        "Doc_title":" Genomic profiling of young adults with colorectal cancer",
        "_version_":1606189023443812352},
      {
        "Meeting_name":" Comparative genomic analysis of primary versus metastasis in colorectal carcinomas.",
        "Background":"['Background', '  Activating mutations in exon 2 of KRAS are routinely used to exclude colorectal cancer (CRC) patients from treatment with  EGFR inhibitors. Retrospective studies have also shown a lack of response among patients with BRAF and NRAS mutations, whereas preliminary studies of PIK3CA have been conflicting. As most testing is done on primary tumor tissue, while metastatic disease is what is treated with anti-EGFR agents, we compared the mutational and copy number profiles of primary and metastatic CRCs.  Methods', '  736 fresh frozen tumors from 613 patients were analyzed for mutations in KRAS, NRAS, BRAF, PIK3CA and TP53 using a Sequenom MALDI-TOF mass spectrometry-based genotyping assay and Sanger sequencing.  The cohort included 84 matched primary and metastases and 30 matched metastases.  Formalin-fixed paraffin embedded tissue was also subjected to Sanger sequencing in cases showing discrepant results in their mutational profile. All tumors were checked for misidentification using a multiplexed PCR/MS-based genetic fingerprinting assay and a subset of matched pairs was analyzed by comparative genomic hybridization (Agilent, 1M array). Results', '  We identified 259 (42%) KRAS (219 in exon 2, 12 in exon 3 and 28 in exon 4), 18 (3%) NRAS, 40 (6%) BRAF, 72 (12 %) PIK3CA and 247 (40%) TP53 mutations in the 613 cases. BRAF mutations were significantly less frequent in metastatic CRC tumors, compared to primary tumors (3.8% vs. 7.3%, p=0.01), while TP53 mutations were significantly more frequent (55.6% vs. 30.2%, p<0.001). Mutational analysis of 84 matched pairs of primary and metastatic CRC revealed a concordance rate of 98%, 98% and 95% for RAS/BRAF, PIK3CA and TP53 mutations, respectively. Unsuperivised clustering of array CGH data from 22 matched pairs of primary and metastatic CRC showed that all pairs clustered together. Conclusions', '  In regards to RAS/BRAF/PIK3CA and TP53 mutational status, primary and metastatic CRC tumors show an extremely high degree of concordance. The results suggest that genomic characterization of the primary tumor for RAS/BRAF/PIK3CA and TP53 mutations can correctly characterize the mutational status of these genes in the patients with metastatic disease.']",
        "Doc_id":"ASCO_80181-102",
        "Doc_title":" Comparative genomic analysis of primary versus metastasis in colorectal carcinomas.",
        "_version_":1606189041499242496},
      {
        "Meeting_name":" DUSPs as markers of MEK/Erk activation in primary colorectal cancer.",
        "Background":"['Background', ' DUSPs dephosphorylate P-MAPK and are activated as a negative feedback loop upon RTK signaling. Higher expression of DUSP 4 & 6 is also found in cells with constitutive Erk activation like KRAS mutant (MUT) cells (Bild et al. Nature 2005). We correlated DUSP1, 4, 6 (isoforms a & b) & 8 mRNA expression level in FFPE primary colorectal cancer (CRC) of 186 chemorefractory patients treated with cetuximab (CTX) with KRAS MUT state and progression-free survival (PFS) and overall survival (OS). Methods', ' KRAS codon 12,13, 61&146, BRAF V600E and NRAS codon 12&13 MUT were analyzed with the Sequenom MALDI TOF MassArray system. The DUSPs and 3 housekeeping genes were quantified by qRT-PCR. TwoStep cluster analysis was performed. PFS and OS were estimated by the Kaplan-Meier method. Results', ' KRAS MUT was associated with increased DUSP4 (MWU;p=.0006) & 6a (p=.0067). DUSP6a dephosphorylates P-Erk, DUSP4 also dephosphorylates P-JNK & P-p38. DUSP1 & 8 primarily dephosphorylate P-JNK & P-p38 and were not associated with KRAS MUT. KRAS MUT clustered into 3 groups according to DUSP4 expression', ' 32 high, 38 median & 13 low (t- test;p<.0001). The low MUT expression was comparable to wild-type (WT) expression. KRAS WT clustered into 2 groups', ' 69 low & 24 high DUSP4 (ANOVA;p<.0001). 7/24 of high expressors were found to have a BRAF or NRAS MUT. The 32 MUT high expressors had a longer median PFS (log-rank;p=.015) and OS (p=.065) after CTX. The 17 KRAS/BRAF/NRAS WT high expressors had a shorter median OS (p=.026), but not PFS (p=.745). Conclusions', ' There is a significantly higher DUSP4 & 6a mRNA expression in the KRAS MUT compared to WT primary CRC. However, this is not a black and white observation. In the KRAS MUT there are 3 distinct clusters of DUSP4 expression. The high expressors (= supposed attenuated Erk signaling) have a longer PFS and OS after CTX. Adaptation to constitutive KRAS signaling with differential levels of MEK/Erk activation needs to be further investigated and will be of help in selecting patients for therapy with MEK inhibitors. It suggests not all KRAS MUT will be good candidates for MEK inhibitors. In the cluster of high DUSP4 expressing KRAS WT 30% are BRAF or NRAS MUT. This suggests DUSP expression of FFPE samples could be a more sensitive marker of MEK/Erk activation and resistance to EGFR inhibitors than KRAS MUT analysis alone.']",
        "Doc_id":"ASCO_33836-65",
        "Doc_title":" DUSPs as markers of MEK/Erk activation in primary colorectal cancer.",
        "_version_":1606188999358021632},
      {
        "Meeting_name":" Survival in glioblastoma cancer patients is predicted by miR-340, that regulates key cancer hallmarks by inhibiting NRAS",
        "Background":"['Glioblastoma is the most frequent brain tumor in adults and is the most lethal form of human cancer. Despite the improvements in treatments, patients survival remains poor. Nevertheless, a subset of patients survives longer than 3 years and they are classified as long-term survivors (LTS). The molecular and cellular mechanisms underlying the rare phenomenon of LTS are not well known. MicroRNAs (miRNAs or miRs) are a class of endogenous non-coding RNA of 19-24 nucleotides in length that have an important role in the negative regulation of gene expression. Deregulation of miRNAs is linked to the pathogenesis of many types of cancer. We performed a nanostring miRNA analysis on long and short glioblastoma survivors patients to individuate miRs potentially involved in LTS phenotype. Using this approach, we identified miR-340 as a novel tumor-suppressor-miR in glioblastoma. miR-340 expression was increased in LTS compared to short term survivors. Moreover, a log-rank test analysis on both the data collected from TCGA database and from a cohort of glioblastoma patients present in our lab revealed that low levels of miR-340 were a risk indicator for glioblastoma patients survival. miR-340 overexpression decreased cell proliferation, anchorage independent cell growth, cell cycle and response to temozolomide in different glioblastoma cell lines. We identified NRAS as a direct target of miR-340. Rescue experiments showed its essential role in mediating the onco-suppressive activity of miR-340. The overexpression of miR-340 decreased the activation of ERKs and AKT, the main pathways downstream NRAS. Furthermore, glioblastoma cells stably infected with a lentivirus encoding miR-340 exhibited a drastic reduction of tumor growth in nude mice. In conclusion, our findings reveal miR-340 as a new tumor-suppressor miRNA up-regulated in LTS in glioblastoma. Its expression inversely correlates with survival of glioblastoma patients. miR-340 is able to regulate multiple tumorigenic features of glioblastoma cells, offering a novel potential prognostic and therapeutical target for glioblastoma.']",
        "Doc_id":"AACR_2015-3126",
        "Doc_title":" Survival in glioblastoma cancer patients is predicted by miR-340, that regulates key cancer hallmarks by inhibiting NRAS",
        "_version_":1606189017606389760},
      {
        "Meeting_name":" Occurrence of PIK3CA mutations simultaneously with RAS and RAF mutations in patients with advanced cancers.",
        "Background":"['Background', ' Oncogenic mutations in PIK3CA, RAS, and RAF have been indentified in various malignancies. Preclinical data suggest that PIK3CA mutations may predict for response to PI3K/AKT/mTOR inhibitors, but that concomitant RAS or RAF mutations may mediate resistance. Methods', ' Tumor tissues from patients with diverse cancers referred to the Phase I Program for targeted therapy from 10/08 to 05/10 were analyzed for PIK3CA, RAS (KRAS, NRAS), and RAF (BRAF) mutations using PCR-based DNA sequencing. Results', ' Overall, tumor tissues from 504 patients were analyzed', ' colorectal, n=103; ovarian, n=60; melanoma, n=55; head and neck, n=48; breast, n=29; endometrial, n=29; cervical, n=22; lung, n=22, soft-tissue sarcoma, n=17; thyroid, n=16; pancreatic cancer, n=11; and others, n=92. PIK3CA mutations were found in 54 (11%) of 504 patients tested. KRAS mutations were identified in 71 (19%) of 368 patients tested, NRAS mutations in 19 (9%) of 220 patients tested, and BRAF mutations in 32 (9%) of 362 patients tested. PIK3CA mutations were most frequent in squamous cells cervical (5/14, 36%), endometrial (7/29, 24%), breast (6/29, 21%), and colorectal cancers (17/103, 17%). KRAS mutations were most frequent in pancreatic (5/9, 56%), colorectal (47/95, 49%), and endometrial cancers (4/21, 19%). NRAS mutations were most frequent in melanomas (12/40, 30%), and endometrial cancers (2/8, 25%). BRAF mutations were most frequent in melanomas (23/52, 44%), and colorectal cancers (5/88, 6%). Irrespective of histology, PIK3CA mutations in comparison to wild-type PIK3CA were more frequently associated with simultaneous KRAS mutations (38% vs. 16% respectively; p=0.001) and simultaneous RAS/RAF (KRAS, NRAS, BRAF) mutations (49% vs. 27% respectively; p=0.002). RAS and RAF mutations were usually mutually exclusive; however, there was an endometrial cancer patient with simultaneous KRAS and BRAF mutations and a patient with melanoma with simultaneous NRAS and BRAF mutations. Conclusions', ' PIK3CA, RAS, and RAF mutations are frequent in diverse tumors. PIK3CA mutations often coexist with RAS and RAF mutations.']",
        "Doc_id":"ASCO_61025-101",
        "Doc_title":" Occurrence of PIK3CA mutations simultaneously with RAS and RAF mutations in patients with advanced cancers.",
        "_version_":1606189039741829120},
      {
        "Meeting_name":" HER2 activating mutations are potential targets for colorectal cancer treatment",
        "Background":"['Background', 'Cancer genome sequencing is identifying new genetic alterations and new driver events in human cancers. The Cancer Genome Atlas (TCGA) colorectal cancer project found that 7% of colorectal cancer (CRC) patients have HER2 somatic mutations or HER2 gene amplification. HER2 gene amplification in CRC is known to produce resistance to the EGFR monoclonal antibodies, cetuximab and panitumumab. However, the impact of HER2 somatic mutations in CRC has not been studied and it is open question as to whether HER2 mutations are clinically important in CRC.Results', \"Introduction of the HER2 mutations, S310F, L755S, V777L, and V842I, into immortalized colon epithelial cells increased cell signaling pathways and anchorage-independent cell growth, indicating that they are activating mutations. Introduction of HER2 V842I mutation into colorectal cancer cell lines produced resistance to the EGFR antibodies, cetuximab and panitumumab. HER2 mutations are potently inhibited by low nanomolar doses of the second generation, irreversible tyrosine kinase inhibitors neratinib and afatinib. HER2 gene sequencing of 48 cetuximab resistant, quadruple WT (KRAS, NRAS, BRAF, and PIK3CA WT) colorectal cancer patient derived xenografts (PDXs) identified 4 PDX's with HER2 mutations (4/48 = 8.3%). Treatment of these PDX's with a single HER2 targeted drug (trastuzumab, neratinib, or lapatinib) delayed tumor growth, but dual HER2 targeted therapy with trastuzumab plus a tyrosine kinase inhibitor produced durable shrinkage of the tumors in mice. After the final timepoint in each PDX experiment, the mice were sacrificed and the tumors excised. The tumor histology demonstrated that dual HER2 targeted therapy caused reduction in tumor cellularity and acquisition of more differentiated features.Conclusions\", 'These data demonstrate that HER2 activating mutations are a new drug resistance mechanism to EGFR monoclonal antibodies. More importantly, these data suggest that HER2 activating mutations may themselves be a drug target for the treatment of colorectal cancer. These data form a strong pre-clinical rationale for clinical trials targeting HER2 activating mutations in metastatic CRC patients. The NSABP Foundation is in the design stage for such a clinical trial and will use its living patient biorepository (MPR-1 trial) that contains 1350 colorectal cancer patients to identify subjects for this trial.']",
        "Doc_id":"AACR_2015-132",
        "Doc_title":" HER2 activating mutations are potential targets for colorectal cancer treatment",
        "_version_":1606189037871169536},
      {
        "Meeting_name":" Comparison of three molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer (mCRC).",
        "Background":"['Background', ' Mutational analysis of RAS in mCRC has showed an improvement in patient (pts) selection for anti-EGFR drugs. The standard techniques (Techs) have an analytical sensitivity (Sns) of 1-5%. Digital PCR (dPCR) can detect mutated alleles at .05-.1% Sns, but it is unclear if this offers a clinical advantage. Objective', 'To compare the Sns and feasibility to detect point mutations in KRAS, NRAS, BRAF and PIK3CAby Cobas, Therascreen assays and quantitative dPCR (Fluidigm), and correlate them with progression-free survival (PFS) when treated with anti-EGFR- or bevacizumab (bev)-based therapies (Tx). Methods', ' 585 pts datasets treated with anti-EGFR- or bev-based Tx were pooled from several mCRC trials and retrospective series from the TTD/RTICC Spanish network. Concordance and predictability were evaluated using kappa and Harrels C index. Results', ' Out of the 585 pts, 385 were male (65.8%), median age 65, 192 pts (32.8%) included in trials (122 anti-EGFR (20.8%) and 70 bev (12%)), 393 pts (67.2%) treated as per label indication [143 anti-EGFR (24.4%) and 250 bev (42.7%)]. There were 4 invalid results for Therascreen and 6 for Cobas and dPCR, respectively (Table). No differences in PFS or OS in bev group were observed by molecular profiling with any platform. Globally, in pts who received anti-EGFR Tx, PFS was significantly better in RAS/BRAF wt groups (HR = 1.45, p = .016 for Cobas; HR = 1.78, p < .001 for Therascreen; and HR = 1.45, p = .005 for dPCR. Differences in OS in anti-EGFR group were detected for sensitive (HR = 2.041, p = .011) and chemorefractary (HR = 2.72, p = .001) pts by dPCR and considering all mutations. dPCR only outperformed the other Techs when predicting OS. Fine tunning of the optimal Sns threshold of quantitative Techs will be presented. Conclusions', ' Although the rate of mutations between Techs is different, the predictability of PFS to anti-EGFR Tx is similar in the first-line setting, but higher sensitivity methods tend to perform better in chemorefractory patients MutationsCobasN %KappaTherascreenN %KappadPCRN %Kappa dPCR/CobasKRAS (exon2/3)209 36.87208 36.71262 45.77RAS extended (exon2/3/4)273 47.73276 47.63333 57.64Any mutation333 57.67326 56.58361 62.60']",
        "Doc_id":"ASCO_169647-176",
        "Doc_title":" Comparison of three molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer (mCRC).",
        "_version_":1606189009652940801},
      {
        "Meeting_name":" Inactivation/loss of PTPRS promotes ERK activation that sensitizes colorectal cancer cells to ERK inhibitors.",
        "Background":"['The RAS pathway is a driver of many cancers, and has been targeted for the development of a variety of therapeutic inhibitors of BRAF, MEK, and more recently ERK. One of challenging issues is to predict response to targeted therapies. Here we report identification of PTPRS, a receptor-type protein tyrosine phosphatase, as a regulator/biomarker of ERK activation and inhibitor response in colorectal cancer. To identify the genes with high frequency mutations that might be predictive of RAS pathway dependence (addiction), we used a gene expression signature score to stratify 468 colorectal cancer tumors that also underwent targeted exome sequencing for 1321 cancer-associated genes. We found that, when the masking effects caused by mutant KRAS, BRAF and NRAS was iteratively removed, mutant PTPRS was strongly correlated with RAS pathway activation, with a mutation rate of 10.4% (22 out of 211 remaining tumors). This led us to inactivate PTPRS in vitro using a specific peptide inhibitor, siRNA or CRISPR approaches in various colorectal cancer cell lines. Inhibition/loss of PTPRS significantly elevated phosphorylation of ERK and AKT and substantially sensitized cancer cells to the treatment of ERK inhibitors, which was enhanced by an AKT inhibitor. Surprisingly, PTPRS did not modulate the activity of EGFR and the ERK kinase, MEK. Our data indicate that PTPRS negatively regulates ERK signaling downstream of the EGFR/RAS/RAF/MEK pathway in a mechanism independent of AKT and DUSP6. As a result, inactivation/loss of PTPRS promotes ERK activation and addiction, thereby contributing to increased sensitivity to ERK inhibitors.']",
        "Doc_id":"AACR_2017-4135",
        "Doc_title":" Inactivation/loss of PTPRS promotes ERK activation that sensitizes colorectal cancer cells to ERK inhibitors.",
        "_version_":1606189031651016704},
      {
        "Meeting_name":" Molecular analysis of KRAS exon 2 wild type colorectal cancer patients enrolled in the CAPRI clinical trial reveals high degree of tumor heterogeneity",
        "Background":"['The CAPRI clinical trial (Optimal strategy in KRAS wild type metastatic colorectal cancer patients', ' cetuximab plus FOLFIRI followed by FOLFOX +/- cetuximab) enrolls metastatic colorectal carcinoma (mCRC) patients with no codon 12/13 (exon 2) KRAS mutations. Recent data showed that exon 3 and 4 KRAS mutations as well as NRAS exon 2, 3 and 4 mutations might confer resistance to EGFR monoclonal antibodies. In addition, somatic mutations in other genes such as BRAF, PIK3CA, PTEN, have been hypothesized to be prognostic and/or predictive in CRC. Therefore, molecular sub-classification of KRAS exon 2 wild type CRC might allow to identify subgroups of patients highly sensitive or resistant to anti-EGFR agents within the CAPRI trial. We analyzed 182 FFPE samples from mCRC patients enrolled in the CAPRI clinical trial by using a next generation sequencing (NGS) approach based on the Ion AmpliSeq technology. In particular, 10 ng of genomic DNA were analyzed with the Ion Ampliseq Colon and Lung cancer panel that targets over 500 hotspot mutations in 22 genes implicated in colon and lung cancers. Data analysis was performed using Ion Reporter Software. The analysis with the IonAmpliseq panel was successful in all the tested samples. Among the 182 analyzed cases, 58 (31.9%) showed no mutations in the investigated genes, whereas a total of 206 mutations in 14 genes were detected in 124 cases (68.1%). Surprisingly, 30 exon 2 KRAS mutations were identified in 29 patients (15.9%). Mutations at a frequency >4% were also found in', ' TP53 (39.5% of the cases mutant), KRAS exon 3 and 4 (7.5%), PIK3CA (13.2), BRAF (8.2%), NRAS (7.1%), FBXW7 (4.9%). A significant degree of tumor heterogeneity was observed', ' several tumors had multiple mutations in different genes, with some cases showing up to 5 mutations. In particular, 30/45 KRAS, 5/13 NRAS, 12/15 BRAF and 19/24 PIK3CA mutant cases showed variants in additional genes. The frequency of mutant alleles also differed significantly among tumors. For example, among the KRAS exon 2 mutant cases, the frequency of KRAS mutant alleles, after normalization for the neoplastic cell content, ranged between 6% and 130%, suggesting that some KRAS mutant cases were polyclonal and that in some other cases gain of mutant or loss of wild type KRAS alleles might have occurred. These data suggest that molecular classification of KRAS exon 2 wild type CRC with the Ion Ampliseq Colon and Lung cancer panel is feasible. This approach reveals mutations in several key genes involved in CRC tumor progression. The relatively high incidence of codon 12/13 KRAS mutations also suggests that an high rate of false negative results in KRAS testing occurs in clinical practice. Finally, the huge degree of tumor heterogeneity might have important implications for prognosis and response to therapy.']",
        "Doc_id":"AACR_2014-937",
        "Doc_title":" Molecular analysis of KRAS exon 2 wild type colorectal cancer patients enrolled in the CAPRI clinical trial reveals high degree of tumor heterogeneity",
        "_version_":1606189020275015680},
      {
        "Meeting_name":" Detection of tumor progression via cell-free DNA (cfDNA) in patients with colorectal cancer.",
        "Background":"['Background', \"  Individualized therapy based on molecular stratification has become an integrative part in modern targeted treatment approaches. Here, we aimed to assess whether repeated measurements of cfDNA in patients' plasma could indicate tumor progression.  Methods\", '  We prospectively collected and stored serum from patients with colorectal cancer presenting for treatment or follow-up. KRAS and NRAS mutations were determined in the formalin fixed, paraffin embedded initial tumor material. A group of patients with confirmed KRAS or NRAS mutation, radiologically proven tumor progression and subsequent change of therapy was selected. cfDNA was extracted from samples taken at time of progression, as well as day -30 and day -60. Mutations were analyzed using a highly sensitive method based on ultradeep Next Generation Sequencing on a semiconductor-based NGS system (IonTorrent PGM), with a lower limit of detection down to 0.01% for selected mutations.  Results', '  Twenty patients were identified to meet the inclusion criteria; 17 were KRAS mutated, three were NRAS mutated within the initial tumor material. In three patients (15%), RAS-mutation was not detectable at time of progression. While in two of them RAS-mutation had been measurable in prior samples, in one case the mutation was not detectable in cfDNA at any time. In 11 (65%) of the remaining 17 patients, RAS variant allele frequency (VAF) in the cfDNA was increased at time of progression compared to measurements at days -30 and/or -60. The median slope of increase was 3.5 (range 0.12 to 15.13). In six patients, there was no correlation between tumor progression and cfDNA; The amount of cfDNA decreased in comparison to prior measurements, either at 30 days prior to or at progression.  Conclusions', '  In almost all cases cfDNA could be detected in the blood of patients with RAS-mutated tumors which demonstrates the high sensitivity of the method. Data suggest a trend toward an increase of cfDNA during tumor progression. However, it is not clear why deviations, especially a decrease of VAF in cfDNA occurred in some patients prior to or at tumor progression. Currently unknown tumor-biological or therapy-associated factors might contribute to this finding. Further investigation is planned.']",
        "Doc_id":"ASCO_140210-158",
        "Doc_title":" Detection of tumor progression via cell-free DNA (cfDNA) in patients with colorectal cancer.",
        "_version_":1606188975076147201},
      {
        "Meeting_name":" Colorectal cancer cell lines recapitulate molecular and pharmacological features of clinical samples",
        "Background":"['Colorectal Cancer (CRC) is characterized by wide genetic, biological and clinical heterogeneity. Oncogenic events, such as KRAS, NRAS and BRAF mutations, are known negative biomarker of response to EGFR targeted therapies. In addition to mutational analysis, transcriptional profiling has been recently exploited to identify distinct CRC molecular subtypes, associated with biological and clinical features such as cell of origin, microsatellite instability, prognosis and response to treatments. Detailed analysis of the relationships between the subtypes and clinical/biological features requires a large panel of preclinical models closely recapitulating the molecular heterogeneity of CRC. To this aim, we assembled a large collection of 151 CRC cell lines. For each line, we', ' (i) verified genetic identity by short tandem repeat (STR) analysis; (ii) assessed microsatellite instability (MSI) status; (iii) sequenced mutational hotspots in the KRAS, BRAF, NRAS and PIK3CA genes; (iv) performed microarray-based global mRNA expression profiling; (v) evaluated sensitivity to the EGFR-targeting drug cetuximab. STR analysis revealed that some cell lines previously thought to be unrelated are indeed derived from the same individual. This result was confirmed by cell line hierarchical clustering based on mRNA expression profiles. Overall, the mutational landscape of the compendium was concordant with what observed in patients (mutation rates', ' KRAS = 47%; BRAF = 17%; NRAS = 0.7%; PIK3CA = 18%). Similarly, sensitivity to cetuximab was confined to lines without RAS or BRAF mutations. Gene expression profiling was exploited to assign cell lines to molecular subtypes, according to five different published transcriptional classifiers. We found that all molecular subtypes previously identified in CRC patients were robustly maintained in the lines. Moreover, significant overlaps were detected between individual subtypes across distinct classifiers. Subtype-specific molecular and pharmacological associations previously defined in CRC samples were largely recapitulated in the compendium. In particular, MSI+ cells were significantly enriched in inflammatory and goblet subtypes and less prevalent in the Transit Amplifying (TA) and Stem groups. Cell lines carrying BRAF mutations clustered in the inflammatory subtype, while RAS mutations were equally distributed among all subtypes. Notably, in TA lines without RAS or BRAF mutations, the fraction of cetuximab-sensitive cells was strongly enriched (56%), confirming clinical data and indicating that addiction to the EGFR pathway is an intrinsic feature of this CRC subtype. In conclusion, our results describe a powerful preclinical resource reflecting the molecular and functional heterogeneity of CRC, which can be used to explore multidimensional information of potential clinical relevance.']",
        "Doc_id":"AACR_2015-583",
        "Doc_title":" Colorectal cancer cell lines recapitulate molecular and pharmacological features of clinical samples",
        "_version_":1606188977204756481},
      {
        "Meeting_name":" Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC)",
        "Background":"['Background', ' Mutational analysis of RAS in mCRC has demonstrated an improvement in patient selection for anti-EGFR drugs. The techniques for the detection of point mutations have an analytical sensitivity of 1-5%. Even more sensitive techniques can detect 0.05-0.1% mutated alleles, although it is not clear the impact on anti-EGFR treatment benefit.  Objective', ' The aim of our study was to compare the sensitivity to detect point mutations in KRAS, NRAS, BRAF and PIK3CAby cobas, therascreen assays and Digital PCR (Fluidigm), and their predictive value to anti-EGFR and bevacizumab (bev) treatments in terms of progression free survival. 600 patient level datasets treated with chemotherapy and anti-EGFR or bev were pooled from several mCRC trials and retrospective series from the TTD/RTICC Spanish network.  Methods', '  Interim analysis of mutational studies of tumor samples from 249 (out of 600) mCRC mostly treated in clinical trials with bev (37.4%), cetuximab (12.6%) or panitumumab (49.9%) is reported. Invalid rates and turnaround time (TAT) were assessed for each platform. Concordance and predictive capability were evaluated using kappa and Harrels C index.  Results', '  There were no invalid results for Digital PCR and only one for cobas and therascreen each. The average time for DNA extraction per 24 samples was 21.5 hrs for cobas Kit and 23 hrs for QIAamp DNA mini Kit. The average time for testing all genes per 24 samples was 14 hrs for cobas, 35 hrs for therascreen and 65 hrs for Digital PCR. There was a very good concordance between cobas and therascreen in the KRAS mutation analysis (kappa index', ' 0.87 (95% CI, 0.8-0.94)). The best platforms in terms of Harrels C index for all patients were KRAScriteria by cobas and Digital PCR (both with 0.53).  Conclusions', ' Concordance in the KRAS mutation analysis between platforms is good with a TAT favoring cobas assay. Mutations (n,% & kappa)CobasKappaTherascreenKappaDigital PCRKappa Digital PCR/CobasKRAS (exon2/3)64(25.70%)0.8760(24.1%)0.688(35.34%)0.7RAS extended (exon2/3/4)90(36.14%)0.7881(32.53%)0.58111(44.58%)0.64Any mutation120(48.2%)0.70106(46.57%)0.52124(49.8 %)0.60']",
        "Doc_id":"ASCO_149563-156",
        "Doc_title":" Comparison of three different molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer samples (mCRC)",
        "_version_":1606188974129283072},
      {
        "Meeting_name":" PTEN null expression is concordant in colorectal cancer primaries and metastases and associates with poor survival.",
        "Background":"['Background', ' Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a negative regulator of the phosphoinositide-3-kinase (PI3K) survival pathway. In colorectal cancer, the method of detection is relevant in determining the frequency of loss of PTEN and the association of PTEN status with outcome. Earlier studies reported discordant PTEN expression in an average of 1 in 3 matched colorectal primaries and metastases. Ours is the first investigation of PTEN concordance using a standardized immunohistochemistry assay.Objectives', ' Our primary aim was to determine the level of concordant PTEN expression in matched human colorectal primaries and liver metastases using a robust assay. Secondary aims were to relate PTEN status to oncogenic mutations in the RAS and PI3K pathways, and to overall survival.Experimental Design', ' We used a standardized immunohistochemistry assay and a reproducible method of interpretation to characterize PTEN expression in paired colorectal primaries and liver metastases collected from 70 patients. Mutational hotspots in KRAS, NRAS, BRAF and PIK3CA were sequenced.Results', ' 7 patients were excluded due to insufficient primary tumor. PTEN null expression was found in 7 of 62 assessable colorectal primaries (12.3%) and 6 of 58 assessable liver metastases (10.3%). PTEN expression (positive or null) was concordant in 98% of matched primaries and liver metastases. There was no significant association between PTEN status and RAS family or PIK3CA mutations. The median overall survival of patients with PTEN null tumors was 9 months, compared to 49 months with PTEN expressing tumors (HR=6.25, 95% CI (1.98, 15.42), p = 0.0017). The association of increased risk of death with PTEN null expression remained significant in multivariate analysis (HR=6.31, 95% CI (2.03, 17.93), p = 0.0023).Conclusion', ' PTEN status was highly concordant in matched colorectal primaries and liver metastases. Loss of PTEN expression predicted poor overall survival.']",
        "Doc_id":"AACR_2013-1201",
        "Doc_title":" PTEN null expression is concordant in colorectal cancer primaries and metastases and associates with poor survival.",
        "_version_":1606188972479873024},
      {
        "Meeting_name":" Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer",
        "Background":"['Colorectal cancer (CRC) patients who respond to the anti-EGFR antibody cetuximab often develop resistance within several months of initiating therapy. To design new lines of treatment the molecular landscape of resistant tumors must be ascertained. We investigated the role of mutations in the EGFR signalling axis on the acquisition of resistance to cetuximab in patients and cellular models.Mutational profiling was performed on both biopsies collected from 37 CRC patients who became refractory to cetuximab and on a collection of cetuximab-resistant derivatives obtained from CRC cells sensitive to EGFR blockade.The genetic profile of tumor specimens obtained after cetuximab treatment revealed the emergence of a complex pattern of mutations in EGFR, KRAS, NRAS, BRAF and PIK3CA genes, including two novel EGFR ectodomain mutations. Mutational profiling of cetuximab resistant cells recapitulated the molecular landscape observed in clinical samples and revealed three additional EGFR ectodomain alleles.Structural modelling showed that these mutations are located in the cetuximab-binding region, except for one mutant. Functionally, EGFR ectodomain mutations prevent binding to cetuximab but a subset is permissive for interaction with panitumumab.In conclusion, we reported that colorectal tumors evade EGFR blockade by constitutive activation of downstream signalling effectors and through mutations affecting receptor-antibody binding. Both mechanisms of resistance may occur concomitantly. Our data have implications for designing additional lines of therapy for CRC patients who relapse upon treatment with anti-EGFR antibodies.']",
        "Doc_id":"AACR_2015-3588",
        "Doc_title":" Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer",
        "_version_":1606189028811472896},
      {
        "Meeting_name":" Genomic overview of right-sided and left-sided colorectal cancer using comprehensive genomic sequencing.",
        "Background":"['Background', ' Although the difference in right vs. left sidedness of colorectal cancer (CRC) in response to targeted therapy has been reported, we hypothesized that right-sided colorectal cancer (RCC) is more likely to have genetic alterations associated with resistance of anti-EGFR therapy. We tested this hypothesis using comprehensive genomic sequencing (CGS) on a set of samples from well-characterized CRC patients. Methods', ' Two-hundred-one primary colon cancer patients with either RCC or left-sided colorectal cancer (LCC) were analyzed. We investigated gene alterations using 415 gene panel, which includes the gene alterations associated with resistance of anti-EGFR therapy', ' TK receptors (ERBB2, MET, EGFR, FGFR1, and PDGFRA), RAS pathway (KRAS, NRAS, HRAS, BRAF, and MAPK2K1), and PI3K pathway (PTEN and PIK3CA). We defined the patients who had no alterations in any of the genes as all wild-type, who are theoretically considered as responders of anti-EGFR therapy. Other patients with genetic alterations in resistance pathways were defined as mutant-type. Results', ' Fifty-six patients (28%) and 145 patients (72%) had RCC and LCC, respectively. Mutation of PIK3CA, BRAF, ACVR2A, MSH6, and CTNNB1 were significantly associated with RCC. Conversely, mutation of APC and TP53 were significantly associated with LCC. Regarding the gene alterations associated with anti-EGFR therapy, only 6 of 56 patients (11%) of RCC were all wild-type; in contrast to 41 of 145 patients (28%) of LCC that were all wild-type (P = 0.009). In 45 Stage IV patients treated with anti-EGFR therapy, RCC showed significantly worse progression-free survival (PFS) than LCC (P = 0.019), and mutant-type RCC showed worse PFS compared to the others (P = 0.018). Conclusions', ' RCC is more likely to have the genetic alterations associated with resistance of anti-EGFR therapy compared to LCC. Primary tumor sidedness is a surrogate for the non-random distribution of molecular subtypes in CRC.']",
        "Doc_id":"ASCO_187862-199",
        "Doc_title":" Genomic overview of right-sided and left-sided colorectal cancer using comprehensive genomic sequencing.",
        "_version_":1606189002048667648},
      {
        "Meeting_name":" Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases",
        "Background":"['Background', ' Tumour heterogeneity may limit the efficacy of targeted therapies. Pulmonary metastases (PM) occur in 10-20% of patients (pts) with colorectal cancer, but little is currently known about the genetic characteristics of colorectal PM and whether they differ from the primary tumour. Methods', ' Clinical data and archival formalin fixed paraffin embedded tissue samples were retrospectively collected from pts who underwent  1 pulmonary metastastectomies for colorectal cancer between 1997  2012. Primary tumour and metastatic samples were analysed using a targeted capture sequencing panel of 45 cancer-associated genes (median depth 806x, median coverage 96.6%). Results', ' Clinical data were collected from 81 pts. The median progression-free survival (PFS) and overall survival (OS) were 24 months (95% CI 19  38) and 91 months (95% CI 72  130) respectively, and the 5-year PFS and OS rates were 32% and 77%. No clinicopathological factors were prognostic for PFS or OS by multivariate analysis. Fifty-four pts had samples available from  1 PM, and sequencing data was successfully obtained from 33 PM samples from 24 pts. The most frequently altered genes were APC (76%), KRAS (67%) and TP53 (48%). Mutations were also detected in a number of other genes ( < 20% frequency), including FBXW7, PIK3CA and ATM. Results were available from matched primary and PM samples for 15 pts, and 11 of these pts (73%) had concordant genetic profiles. The allele frequencies of key cancer mutations were slightly lower in the first PM in contrast to the primary tumour. Six of the 7 pts with results from  2 PM (86%) had concordant results. The overall concordance for all matched samples was 95% and 100% for KRAS and NRAS. Conclusions', ' Pts treated at our institutions for resectable colorectal PM had a favourable prognosis. In keeping with previously published data, KRAS mutations occurred at a higher frequency in pts with colorectal PM. Mutation status, and RAS status in particular, was highly concordant between the primary cancer and PM from the same individual. When PM develop, it may not be necessary to undertake repeat biopsies to determine pts suitability for anti-EGFR therapy.']",
        "Doc_id":"ASCO_169784-176",
        "Doc_title":" Comparison of the genetic profiles of primary colorectal cancers and their subsequent pulmonary metastases",
        "_version_":1606189002121019392},
      {
        "Meeting_name":" Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes.",
        "Background":"['Background', ' PD-L1 expression as detected by immunohistochemistry (IHC) is significantly lower in colorectal cancers (CRC) when compared with lung cancer or other types of cancer. We explored if mutations in the RAS/RAF gene family, TP53 or PIK3CA can define a subgroup of CRC that express PD-L1. Methods', ' Tissue samples collected from 107 patients with CRC were studied for the expression of PD-L1 using clone SP142. The same samples were also tested for mutations in NRAS, KRAS, HRAS, BRAF, TP53, and PIK3CA using Next Generation Sequencing (NGS). Results', ' Of the 107 CRC samples only 15 (14%) showed PD-L1 positive tumor cells (1%) and 8 of the 15 (7.5% of total) had PD-L1 in 5% of tumor cells. Detected mutations in these samples were as follows', ' TP53 65%, KRAS 49.5%, PI3KCA 22.5%, NRAS 5%, HRAS 1%, and BRAF 17%. There was no correlation between PD-L1 expression and mutation status in any of the RAS/RAF genes. There was also no correlation between TP53 mutation and PD-L1 expression. This was true irrespective if PD-L1 expression is considered as a continuous variable or when cut-off points of 5%, 20%, or 50% were used. However, patients without any mutation in RAS or TP53 had significantly (P = 0.005) more expression of PD-L1 when cut-off point of 5% is used. This remained true if PD-L1 expression is considered as a continuous variable (P = 0.04). There was no correlation between PIK3CA and PD-L1 expression. Conclusions', ' PD-L1 expression is significantly more common in CRC that lack mutations in RAS or TP53. PD-L1 expression is detected in 31% of patients with wild-type RAS/TP53 as compared with 12% in patients with RAS/TP53 mutations (P = 0.04). If a cut-off point of 5% is used, 31% of RAS/TP53-wild-type CRC were positive for PD-L1, while only 6% of RAS/TP53- mutant CRC were positive for PD-L1 (P = 0.005). This suggests that in CRC without RAS/TP53 mutation, the PD-L1 may play a more important role in oncogenesis. Exploring immunotherapy in this group of CRC patients might be justified.']",
        "Doc_id":"ASCO_180398-199",
        "Doc_title":" Expression of PD-L1 in colorectal cancer that lack mutations in RAS or TP53 genes.",
        "_version_":1606188990330830848},
      {
        "Meeting_name":" Impact of patient age on molecular alterations in left-sided colorectal tumors.",
        "Background":"['Background', ' The incidence of colorectal cancer (CRC) in younger patients (pts) is rising. This increase is most pronounced in tumors arising from the distal colon and rectum. Since tumor sidedness has emerged as an important prognostic and predictive biomarker in CRC, we aim to explore the impact of age on the tumor biology of left-sided colon cancer (LCC). Herein, we compare profiles of LCC from younger ( 45 years) and older pts ( 65 years). Methods', ' LCCs (splenic flexure to rectum; n = 1,602) were examined by NextGen sequencing, protein expression, gene amplification, and microsatellite instability fragment analyses. Tumor mutational load (TML) was calculated using only somatic nonsynonymous missense mutations. Chi-square tests were used for comparisons. Results', ' LCCs from younger (median age 40, range 22-45 years, n = 229) and older (median age 71, range 65-89, n = 503) pts were studied. The most frequently mutated genes included APC, TP53, KRAS, PIK3CA, ARID1A, FBXW7, SMAD4, ATM, BRAF, and NRAS. Comparing younger v. older pts, there were no significant differences in the rates of APC (75.3% v. 82.9%, P = 0.139), TP53 (79.5% v. 73.1%, P = 0.261), KRAS (37.6% v. 43.0%, P = 0.403), PIK3CA (9.4% v. 14.6%, P = 0.234), ARID1A (14.3% v. 13.2%, P = 0.884), FBXW7 (11.4% v. 10.5%, P = 0.830), SMAD4 (13.1% v. 7.4%, P = 0.129), BRAF (4.8% v. 5.7%, P = 0.762), or NRAS (3.5% v. 2.6%, P = 0.680) mutations. Additionally there were no significant differences in protein overexpression. However, there was a trend towards increased HER2 amplification in younger pts (5.7% v. 2.1%, P = 0.05). MSH6 (4.8% v. 0.5%, P = 0.015), MSH2 (2.4% v. 0%, P = 0.032), POLE (2.4% v. 0%, P = 0.032), and NF1 (7.9% v. 0%, P < 0.001) mutations were observed at higher rates in younger pts. High TML ( 17 mutations per megabase) was seen more frequently in younger pts (8.2% v. 2.6%, P = 0.02). Conclusions', ' The molecular differences between LCC in younger and older pts are mostly due to mutations in mismatch repair genes. Higher TML may predict a higher response rate to checkpoint inhibitors in younger pts with LCC. The differences in tumor biology observed here warrant further study and may eventually be used to tailor therapy.']",
        "Doc_id":"ASCO_192404-199",
        "Doc_title":" Impact of patient age on molecular alterations in left-sided colorectal tumors.",
        "_version_":1606189042113708032},
      {
        "Meeting_name":" Large panel genomic profiling using CancerPlex to reveal candidates for HER2 targeted therapies in colorectal cancer.",
        "Background":"['Background', ' Human epidermal growth receptor type 2 (HER2) overexpression/amplification is associated with the efficacy of HER2 targeted therapies in breast and gastric cancers, where candidates for its targeted therapies are selected by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH) testing. However, the HER2 status in colorectal cancer (CRC) has not been fully investigated to date. CancerPlex is a comprehensive next-generation sequencing-based test that evaluates 400-plus genes for mutations and copy number changes, including HER2. In the present study, we aimed to clarify the association between HER2 status and HER2 gene alteration detected with CancerPlex in CRC. Methods', ' This retrospective study included 100 patients with Stage I-IV CRC, who were evaluated HER2 status and HER2 gene alteration. IHC for HER2 was classified as 4 grades according to the immunoreactivity. The patients with IHC2+ were further tested with FISH. IHC3+/IHC2+ and FISH positive patients were defined as HER2 positive. HER2 gene alteration was tested with CancerPlex, and the associations between HER2 status and HER2 gene alteration were analyzed using Fishers exact test. Results', ' HER2 positive cases were observed in 8% patients (IHC3+ in 6% and IHC2+ and FISH positive in 2% patients). CancerPlex results demonstrated that 6% had HER2 amplification, 15% had HER2 mutations, and 1% had both HER2 amplification and mutation. Additionally, CancerPlex detected the other mutations of MAPK pathway (KRAS, NRAS, HRAS, and BRAF). The Fishers exact test revealed a significant association between HER2 status and HER2 amplification detected with CancerPlex (P< 0.001), however, there was no significant association between HER2 status and HER2 mutation. Conclusions', ' We found 8 of 100 (8%) Japanese CRC cases are HER2 positive. There is a significant association between HER2 status and HER2 amplification detected with CancerPlex. CancerPlex is a comprehensive testing tool for detecting gene alterations including not only mutations of MAPK pathway (KRAS, NRAS, HRAS, and BRAF), but also HER2 amplification, which is a possible useful predictor of the candidates for HER2 targeted therapies in CRC.']",
        "Doc_id":"ASCO_163212-176",
        "Doc_title":" Large panel genomic profiling using CancerPlex to reveal candidates for HER2 targeted therapies in colorectal cancer.",
        "_version_":1606189041737269248},
      {
        "Meeting_name":" Improving access to molecularly defined clinical trials for patients with colorectal cancer",
        "Background":"['Background', '  Molecular diagnostics can identify subgroups of colorectal and other cancers that are relevant for the mode of action of new anti-cancer agents. The efficient, GCP-conform and quality assured molecular screening to identify potential study patients is one of the major challenges for targeted drug development. The EORTC has implemented a new collaborative molecular screening platform in order to facilitate these next generation trials.  Methods', '  SPECTAcolor (Screening Patients for Efficient Clinical Trial Access in advanced colorectal cancer) is a pan European network of institutions collaborating in centralized, high-throughput screening of tumor material from patients with colorectal cancer. After informed written consent, patients are screened for molecular alterations. Molecularly annotated patients can be offered so called downstream clinical trials.  Results', '  Launched in September 2013, SPECTAcolor is now initiated in 19 clinical centers in 9 countries. As of 12 September 2014, 406 patients were enrolled exceeding the expected accrual target of 300 patients in the first year. Of these 406 patients, 293 patients had their tumor block shipped to the central biobank at the Dresden University Hospital for central quality and pathological review, and core analyses. Tumor samples are being additionally analyzed using next generation sequencing for 360 key cancer alterations in cooperation with the Sanger Institute (Cambridge, UK).  In the first year, the blocks were analyzed for 5 baseline biomarkers. KRAS was wild type for exon 2, 3 and 4 in 151/284 pts (53%) and mutated 133 pts (47%; 114 pts in exon 2 (40%), 8 pts in exon 3, and 11 pts in exon 4). NRAS was tested in KRAS wild type pts only; mutations were found in 14 pts (4.9%; 6 pts in exon 2 and 8 pts in exon 3). BRAF mutations, all in exon 15, were found in 18 pts (7%). PI3K mutations occurred in 41 pts (15%; 13 in exon 20 and 28 in exon 9). IHC staining was showing deficient mismatch repair in 16 patients.  Conclusions', '  SPECTAcolor is the first pan-European and EORTC screening platform. Its successful implementation proves that a logistically complex infrastructure to run next generation trials in a multinational setting is feasible.']",
        "Doc_id":"ASCO_140182-158",
        "Doc_title":" Improving access to molecularly defined clinical trials for patients with colorectal cancer",
        "_version_":1606189024608780288},
      {
        "Meeting_name":" Intrinsic and acquired resistance to cetuximab in colorectal cancer patients.",
        "Background":"['Anti-EGFR antibodies, such as cetuximab, are effective therapies for many late-stage colorectal cancer (CRC) patients; unfortunately, many tumors are initially unresponsive while others show initial efficacy but eventually develop acquired resistance. Genomic studies of patient tumors, cell lines, and xenograft models have identified putative anti-EGFR resistance markers, including mutations in KRAS, NRAS, BRAF, PIK3CA, and the EGFR extracellular domain, as well as amplifications in ERBB2 and MET. In order to further confirm and identify new resistance mechanisms to anti-EGFR treatment in CRC, we performed retrospective genomic profiling of 25 CRC patients treated at Samsung Medical Center from 2006-2015. Patients received cetuximab containing chemo regimens with varying duration of responses, including acquired resistance cases. Our analysis identifies mutations in receptor tyrosine kinases, such as EGFR, NTRK1, and PDGFRA, as well as RAS/MAPK pathway genes that affect cetuximab response. We also uncover genomic alterations in ERBB2 and c-KIT as potential novel mechanisms regulating sensitivity to anti-EGFR antibodies. Additional genomic analyses of acquired resistance tumors and in vitro studies of a patient-derived cell line provide added insights into clonal selection and signaling pathways that bypass the EGFR blockade. Overall, our study elucidates important new facets in the landscape of anti-EGFR resistance mechanisms.']",
        "Doc_id":"AACR_2017-4104",
        "Doc_title":" Intrinsic and acquired resistance to cetuximab in colorectal cancer patients.",
        "_version_":1606189031797817344},
      {
        "Meeting_name":" Linking tumor evolution and therapy response using diagnostic targeted next generation sequencing in colorectal cancer",
        "Background":"['Complex sets of driver mutations critically control clinical course and treatment response in colorectal cancer (CRC). It is expected that multiple mutations in different signaling pathways interact to establish an individual cancer cell phenotype. Furthermore, mutational patterns can evolve under selective pressure, for instance during tumor metastasis or targeted therapy. Yet only few mutations, such as these in KRAS, NRAS and BRAF, are routinely assessed in the clinic today. With the introduction of next generation sequencing (NGS) many more genes can be simultaneously sequenced, allowing detailed analyses of mutational patterns.We have assembled the CRC5.2 NGS panel for application with Ion Torrent PGM covering 100 frequently mutated genes with 784 amplicons (covering 21,000 COSMIC mutations), going well beyond the scope of commercially available cancer panels. In particular, exon coverage was optimized to embrace all genomic information related to drug sensitivity, using several drug and signaling network databases.The German Consortium for Translational Cancer Research (DKTK) comprises the top cancer centers in Germany. As a part of this group, we employ our custom CRC5.2 panel for the analysis of mutational patterns in CRC. We address several key questions relevant for current diagnostics and treatment in colorectal cancer. In retrospective and prospective clinical studies, we assess mutational heterogeneity in primary tumors, synchronous and metachronous metastases of individual patients. In-depth NGS mutational analyses, transcriptome analysis and methylation studies will identify (epi-)genetic alterations occurring as a consequence of selective pressure during tumor evolution e.g. during metastasis, chemotherapy or targeted tumor therapy. Thus, we will uncover new links between cancer-specific mutations, clinical course and treatment response as well as novel mechanisms of secondary resistance. In addition we aim to identify novel predictive and prognostic mutational markers for the benefit of future CRC patients']",
        "Doc_id":"AACR_2014-5170",
        "Doc_title":" Linking tumor evolution and therapy response using diagnostic targeted next generation sequencing in colorectal cancer",
        "_version_":1606188970829414400},
      {
        "Meeting_name":" Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).",
        "Background":"['Background', '  Previously, extended RAS analysis from this study showed a trend toward improvements in HR on OS and PFS with pmab + FOLFIRI vs FOLFIRI in WT RAS group vs WT KRAS exon 2 group. Here we report updated RAS data and new analysis by BRAF status.   Methods', '   The primary objective was to assess the tx effect of pmab + FOLFIRI vs FOLFIRI on OS and PFS based on RAS/BRAF mutation status in the primary analysis population.  Bidirectional Sanger sequencing was used to detect mutations in KRAS exons 3, 4 and NRAS exons 2, 3, 4, and BRAF exon 15 in patients (pts) with known WT KRAS exon 2 mCRC.  Results', '   Overall RAS/BRAF ascertainment rate was 85% (n=1014/1186).  18% of WT KRAS exon 2 pts harbored additional RAS mutations (n=107/597).  The incidence of BRAF mutations was 8.3% (45/541). Efficacy is shown (table).  Tx HR for pts with WT RAS was 0.81 (95% CI', ' 0.63, 1.03; P=0.08) for OS and 0.70 (95% CI', ' 0.54, 0.91; P=0.007) for PFS.  Conclusions', '   Improvements continued to be observed in the tx effect of pmab + FOLFIRI vs FOLFIRI on OS and PFS in WT RAS group vs WT KRAS exon 2 group in this update.  Pts with MT RAS mCRC are unlikely to benefit by the addition of pmab to FOLFIRI, similar to pts with MT KRAS exon 2 mCRC.  BRAF mutations appear to be associated with reduced OS among pts without RAS mutations regardless of tx arm.  These findings support RAS testing to determine potentially appropriate pts with mCRC for pmab tx.    Clinical trial information', ' NCT00339183.']",
        "Doc_id":"ASCO_129544-144",
        "Doc_title":" Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).",
        "_version_":1606188988941467648},
      {
        "Meeting_name":" Clinical correlation with codon-specific mutations in metastatic colorectal cancer.",
        "Background":"['Background', ' Mutational status in colorectal cancer (CRC) impacts response to EGFR inhibition, prognosis, and may affect response to chemoradiation. It is unclear if obesity or other clinical characteristics, including smoking and diabetes, increases the predilection for certain genotypes. The purpose of the following study was to explore the relationship between clinical factors, codon-specific mutations and overall survival (OS). Methods', ' Metastatic colorectal cancer patients were retrospectively analyzed; clinical characteristics including smoking, diabetes, and body mass index (BMI) were extracted from medical records. Genotyping was performed for > 150 mutations across 15 commonly mutated cancer genes including NRAS, KRAS, PIK3CA, BRAF, and PTEN as part of their clinical management and recorded. Logistic regression was used to establish associations between clinical characteristics and genotypes. Results', ' 394 metastatic CRC patients were identified. Median age was 58 (range 25-89). 219 (56%) were male. 202 (51%) were non-smokers. 61 had diabetes. 272 patients had a BMI  25. 136 patients had KRAS mutations, the most common of which was G12D (37%). Diabetes was associated with a higher incidence of KRAS (odds ratio [OR] 1.9 95% CI 1.1-1.3; p = 0.02) and PIK3CA mutations (OR 2.4 95% CI 1.1-5.0; p = 0.02), but not OS. KRAS mutations were not significantly associated with BMI  25 nor OS. BRAF mutations were significantly associated with poorer OS (hazard ratio [HR] 1.9 95% CI 1.3-2.7; p < 0.001). Current smokers were more likely to have CTNNB1 mutations (OR 11.3 95% CI 1.5-83.2; p = 0.02) and G12D KRAS mutations (OR 5.6 95% CI 1.0-30.3). Current smokers were less likely to have BMI  25 (OR 0.44; p = 0.02). Patients with BMI  18.5 have an association with poor OS (HR 2.6 95% CI 1.1-6.4; p = 0.03), although this needs to be corroborated with a larger sample size. Conclusions', ' A statistically significant association was found between diabetes and KRAS and PIK3CA mutations. The association of BRAF mutations and decreased overall survival was significant, concordant with previous reports. Smokers were more likely to harbor G12D KRAS mutations, and low BMI ( 18.5) trended toward poorer overall survival.']",
        "Doc_id":"ASCO_169054-176",
        "Doc_title":" Clinical correlation with codon-specific mutations in metastatic colorectal cancer.",
        "_version_":1606188981260648449},
      {
        "Meeting_name":" Efficiency of biomarker screening for enriched metastatic colorectal cancer trials",
        "Background":"['Background', '  Incorporation of multiple enrichment biomarkers into prospective clinical trials for metastatic colorectal cancer (mCRC) has been proposed or initiated by NSABP, EORTC, NCI Colon Task Force, and UK MRC. The feasibility of large scale screening efforts in mCRC has not been previously assessed.  Methods', '  Patients (pts) with 5-FU refractory mCRC at MD Anderson Cancer Center were offered screening in the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) program to identify eligibility for companion clinical trials with a therapy targeted to an aberration detected in the patient.  Results', '  Between 8/2010 and 8/2013, 400 heavily pretreated mCRC pts were enrolled onto ATTACC for screening and allocation onto 10 separate Phase I or II companion trials based on banked FFPE tumor testing by IHC, gene sequencing, and CpG island methylation phenotype (CIMP) assay.  Outside tissue was obtained with a median of 6 calendar days (8% had insufficient tumor).  IHC, sequencing, and CIMP results required a median of 11, 12, and 20 days, respectively.  In this population, 53% tumors had KRAS mutations, with BRAF, NRAS, and PI3KCA mutations, and complete PTEN loss present in 8.1%, 8.6%, 21%, and 12%, respectively. CIMP-high status (2 markers) was noted in 38% of pts.  Given molecular results, trial-specific eligibility, and intermittent study openings, fewer than 25% of screened pts were eligible for enrollment onto a companion protocol. Of these eligible patients, approximately half (13%) enrolled onto a companion trial. Within the entire cohort, 19% enrolled in unenriched trials, and 51% received standard-of-care therapies. ATTACC screening, with an expanding biomarker panel, remains ongoing at a rate of 25-30 patients per month.  Conclusions', '  Universal screening programs such as ATTACC represent an optimal strategy for enrolling patients in multiple biomarker enrichment studies.   Even in the setting of multiple companion treatment studies, motivated patients/physicians, and a dedicated screening infrastructure, a majority of patients did not ultimately participate on a companion trial, emphasizing the lack of drugs targeting a number of common aberrations.']",
        "Doc_id":"ASCO_123359-143",
        "Doc_title":" Efficiency of biomarker screening for enriched metastatic colorectal cancer trials",
        "_version_":1606188993142063104},
      {
        "Meeting_name":" The treatment continuum of panitumumab, cetuximab, and bevacizumab in 1st through 3rd line by KRAS, NRAS, and BRAF mutation status among mCRC patients treated at community cancer centers in the United States.",
        "Background":"['Background', ' Our objective was to use real world data to evaluate of the treatment continuum of bevacizumab (Bmab), cetuximab (Cmab), panitumumab (Pmab) or no biologics across 1st, 2nd, and 3rd lines among metastatic colorectal cancer (mCRC) patients who were treated at community cancer centers in the United States. This objective was applied separately to patients with confirmed KRAS, NRAS, or BRAF wild-type (WT) or mutation (MUT) status, as well as patient who did not receive biomarker testing (UNK). Methods', ' This descriptive study utilized data from the Oncology Services Comprehensive Electronic Records (OSCER) database. It included 5,446 (2,064 WT, 1,807 MUT, and 1,575 UNK) patients diagnosed with mCRC between 1/1/2011 and 8/31/2015. Patients were stratified into the following mutually-exclusive categories in 1st, 2nd line, and 3rd line', ' Pmab only, Cmab only, Bmab only, or no biologic. Patients who survived and continued therapy were followed through the lines of therapy. Results', ' 23.8% of WT, 36.3% of MUT and 49.5% of UNK patients did not receive a biologic in 1st line. There were 1,003 WT patients who were treated with Bmab in 1st. Of those, n=587 (58.5%) survived and elected to continue treatment in 2nd line as follows', ' n=221 (37.6%) continued with Bmab, n=216 (36.8%) initiated Cmab, n=65 (11.1%) initiated Pmab, and n=85 (14.5%) received no biologic in 2nd line. Of the 221 WT patients who received Bmab in 1st and 2nd line, n=129 (58.4%) survived and initiated 3rd line treatment, of which n=20 (15.5%) received Bmab in 3rd line. There were 127/2,604 (4.9%) WT patients who were treated with Pmab in 1st line. Of those 127 patients, n=46 (36.2%) survived and elected to continue treatment in 2nd line as follows', ' n=11 (29.3%) continued treatment with Pmab in 2nd line, while n=14 (30.4%) initiated treatment with Bmab, n=4 (8.7%) initiated treatment with Cmab, and n=16 (36.4%) did not receive a biologic in 2nd line. Conclusions', ' A small proportion of patients continued treatment with the same biologic throughout subsequent lines of therapy. Many patients were not treated with a biologic in any line, even if they were confirmed WT.']",
        "Doc_id":"ASCO_177030-195",
        "Doc_title":" The treatment continuum of panitumumab, cetuximab, and bevacizumab in 1st through 3rd line by KRAS, NRAS, and BRAF mutation status among mCRC patients treated at community cancer centers in the United States.",
        "_version_":1606189011318079488},
      {
        "Meeting_name":" Correlation of CpG island methylation with clinical and pathologic characteristics in metastatic colorectal cancer patients",
        "Background":"['Background', ' Colorectal cancer morbidity and mortality rates vary by race and ethnicity. The combined contribution of genetics and environment to response to chemotherapy, progression-free and overall survival in colorectal cancer patients is unclear, but CpG island hypermethylation (CIMP), a discrete molecular subtype of colorectal cancer, is associated with inflammation and environmental exposures. Hence our main objective is to assess correlation between various modifiable risk factors and CIMP status among metastatic colorectal cancer patients.Methods', ' We characterized CIMP methylation (MINT1, MINT2, MINT31, p14, p16, and MLH1) in 229 metastatic colorectal cancer patients using PCR amplification of bisulfite treated DNA followed by pyrosequencing. The number of methylated probes were averaged to obtain the% methylation with CIMP-High (CIMP-H) being defined as 40% of probes methylated. Associations of demographic and clinical characteristics, including BMI, diabetes, obesity, physical activity, smoking and drinking status, as well as presence or absence of other molecular alterations (BRAF, KRAS, NRAS, PIK3CA and PTEN loss) with overall survival were assessed in multivariable-adjusted Cox proportional hazards models.Results', 'When treating methylation as a continuous variable, patients with BRAF mutation had higher methylation as compared to participants with BRAF wildtype (40.6% vs 20.5%, p = 0.001). White, non-Hispanic (WNH) patients had greater degree of tumor methylation (24.8%) as compared to other racial categories (p = 0.02). When classified as a categorical variable, moderate to vigorous physical activity was associated with higher rate of having any methylated probes, as compared to sedentary patients (p = 0.02). CIMP status was not associated with OS in these patients in multivariable-adjusted Cox models. However when stratified by CIMP status. When stratified by CIMP status; among patients with 0-40% methylation, KRAS mutation was associated with poor OS(HR = 3.19, p = 0.006) and diabetes was protective (HR = .14, p = 0.025). Among patients with high methylation(41-100%) methylation, obesity was associated with poor OS (HR = 5.20, p = 0.038) and former smoking was associated with poor OS(HR = 2.92, p = 0.05). When stratified by KRAS mutation status, among patients with KRAS wildtype, obesity was associated with poor OS(HR = 2.86, p = 0.019) and among patients with KRAS mutation, diabetes was protective (HR = 0.18, p = 0.033)Conclusion and Impact', 'CpG island methylator phenotype was associated with unique clinicopathologic characteristics. Methylation, as assessed by the 6-gene CIMP panel, was not associated with worse outcomes after correcting for the KRAS mutations, a well-established genetic marker of poor prognosis. Hypermethylation did appear to modulate outcomes in obese patients with hypermethylated tumors.']",
        "Doc_id":"AACR_2015-4763",
        "Doc_title":" Correlation of CpG island methylation with clinical and pathologic characteristics in metastatic colorectal cancer patients",
        "_version_":1606189028970856448},
      {
        "Meeting_name":" Association of right-sided colon cancer with poor efficacy of cetuximab in patients with RAS wild-type metastatic colorectal cancer.",
        "Background":"['Background', ' Right-sided colon cancer (RC) is distinct from left-sided colorectal cancer (LC) in terms of embryology, pathology and genetics. Previous reports have shown that RC have more KRAS and BRAF mutations and poorer clinical outcomes than LC. We investigated whether primary tumor location affects cetuximab efficacy in patients with RAS wild-type (WT) metastatic colon cancer determined by extended RAS genotyping. Methods', ' Extended RAS analysis by SequenomMassARRAY technology platform (OncoMap) targeting KRAS (exon 2, 3, 4), NRAS (exon 2, 3, 4), PIK3CA and BRAF (exon 15) was performed in tumors from 307 patients treated with cetuximab as salvage treatment. Tumors with mutated RAS (n = 127) and synchronous primary tumors (n = 10) were excluded. The border of right-sided colon and left-sided colon was defined as splenic flexure. Results', ' A total of 170 patients were included (RC versus LC, 23 and 147). More mutant BRAF (39.1% vs. 5.4%), poorly differentiated (17.4% vs. 3.4%) and mutant PIK3CA (13% vs. 1.4%) tumor and peritoneal involvement (26.1% vs. 8.8%) were observed in RC. Progression-free survival (PFS) was significantly shorter in RC (2.0 vs 4.9 months, P = 0.004). Overall survival (OS) was 4.1 months in RC and 13.0 months in LC (P = 0.002). In multivariate analysis, BRAF mutations, RC, poorly differentiated histology and peritoneal involvement were associated with shorter overall survival (adjusted hazard ratios, 2.96, 1.63, 2.97 and 2.12, respectively). Conclusions', ' In RAS WT colon cancer treated with cetuximab as salvage treatment, right-sided colon cancer had a poor survival. Further investigation is required to verify the difference in cetuximab efficacy according to primary site of metastatic colorectal cancer.']",
        "Doc_id":"ASCO_170068-176",
        "Doc_title":" Association of right-sided colon cancer with poor efficacy of cetuximab in patients with RAS wild-type metastatic colorectal cancer.",
        "_version_":1606188994192736256},
      {
        "Meeting_name":" Correlation between comprehensive molecular profiling and clinical outcomes in patients with colorectal liver metastases.",
        "Background":"['Background', ' Genomic alterations in KRAS, NRAS, and BRAF have been associated with recurrence and survival for patients (pts) with liver metastatic colorectal cancer (mCRC). We used a multi-gene next generation sequencing (NGS) assay to evaluate the effect of genomic alterations on outcomes. Methods', ' A total of 253 pts with mCRC were identified from a prospectively maintained database of pts receiving hepatic arterial infusion (HAI) therapy and who had MSK-IMPACT analysis  a targeted exome capture NGS assay that includes 410 genes. Pts were separated into two groups', ' those who had complete resection of liver mCRC and were treated with adjuvant (ADJ) HAI (n = 136), and those with unresectable liver mCRC (METS) (n = 117). In the METS group, 63 pts had no extrahepatic disease and 54 pts had extrahepatic disease. All pts were treated with HAI plus systemic therapy. Clinicopathological data including progression free survival and overall survival (OS) were recorded. Results', ' For differences between METS and ADJ, pts with METS had enriched mutations in BRAF (12% METS vs. 3% ADJ, p = 0.006) and in SMAD4 (17.7 METS vs. 7.5% ADJ, p = 0.02). These mutations were associated with worse outcomes. BRAF mutations were associated with a lower OS (p = 0.01) in METS. All METS with no extrahepatic disease (n = 63) who had SMAD4 mutation developed hepatic progression (p = 0.02). The presence of a SMAD4 mutation was also associated with worse OS in ADJ (p < 0.001). SOX9 mutation was more common in ADJ (13%) vs. METS (6%). SRC was mutated only in ADJ and only in females. Altered genes in the ERK signaling pathway includingEGFR, KRAS, NRAS, HRAS and BRAF indicated worse OS in all subgroups receiving HAI (p = 0.0011 for the combined group, n = 253). Conclusions', ' Our study confirms the alteration spectrum previously described for liver mCRC. Novel findings include the higher prevalence of SOX9 mutation in ADJ and the exclusivity of SRC mutation in ADJ female pts, implying a positive prognostic effect. SMAD4 mutation correlated with worse OS in ADJ group and increased hepatic progression in METS group. Alteration of multiple genes in the MAPK pathway conferred a worse outcome, which may be relevant for targeted drug development.']",
        "Doc_id":"ASCO_168303-176",
        "Doc_title":" Correlation between comprehensive molecular profiling and clinical outcomes in patients with colorectal liver metastases.",
        "_version_":1606189006548107264},
      {
        "Meeting_name":" EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.",
        "Background":"['Background', ' Anti-EGFR monoclonal antibodies are used for the treatment of RAS wild type (wt) metastatic colorectal cancer. However, only a fraction of patients selected for treatment by the RAS mutation status benefit. We previously showed that EGFR gene copy number (GCN), as analyzed by immunohistochemistry (IHC)-guided in situ hybridization (ISH), predicts response to anti-EGFR therapy in KRAS exon 2 wild-type (wt) metastatic colorectal cancer. The aim of this study was to analyze the predictive role of EGFR GCN in RAS/BRAF/PIK3CA wt metastatic colorectal cancer. Methods', ' The patient material included 102 patients with KRAS exon 2 wt metastatic colorectal cancer treated with anti-EGFR antibodies. Next generation sequencing (NGS) was used for KRAS exons 2, 3 and 4, NRAS exons 2, 3 and 4, BRAF and PIK3CA gene mutation analyses from primary tumor tissue samples. EGFR GCN was analyzed by EGFR IHC guided automated silver ISH (GCN cutoff 4.0). Results', 'RAS, BRAF, and PIK3CA gene mutation analyses were successfully performed for 86.3% of the patients. Additional mutations in the RAS gene were found in 28.4% (25/88) of the KRAS exon 2 wt tumors. BRAF and PIK3CA mutations were observed in 22.7% and 15.9% of the cases, respectively. EGFR GCN was  4.0 in a majority of the RAS wt patients (40/63, 63.5%). An elevated EGFR GCN predicted a better response to anti-EGFR therapy and prolonged PFS in the RAS/BRAF/PIK3CA wt patients. In addition, most RAS wt patients with an EGFR GCN  4.0 in their primary tumors benefited of anti-EGFR therapy in terms of clinical benefit (SD, PR or CR) (Chi-Square Test, p = 0.0005), and had a longer progression free survival than those with a EGFR GCN below 4.0 (Log-Rank Test, p < 0.0001). In contrast, the response RAS/BRAF/PIK3CA wt, EGFR GCN below 4.0 patients did not differ from patients with mutant in RAS, or BRAF or PIK3CA. Conclusions', ' The study indicates that EGFR GCN serves as a predictive marker for anti-EGFR treatment efficacy in patients with RAS/BRAF/PIK3CA wtmetastatic colorectal cancer. Tumors with EGFR GCN below 4.0 appear to be as refractory to anti-EGFR treatment as tumors with mutation in any of the RAS/RAF/PIK3CA pathway genes.']",
        "Doc_id":"ASCO_165969-176",
        "Doc_title":" EGFR gene copy number to predict response to anti-EGFR treatment and survival in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.",
        "_version_":1606189000688664576},
      {
        "Meeting_name":" FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study)",
        "Background":"['Background', '  The phase III TRIBE study met its primary endpoint by demonstrating that first-line FOLFOXIRI plus bev significantly prolongs PFS, as compared to FOLFIRI plus bev (Loupakis et al, N Eng J Med 2014). At a median follow-up of 32.2 months a preliminary OS analysis indicated a borderline OS improvement with FOLFOXIRI plus bev (HR = 0.79,  p = 0.054) with a consistent effect across RAS (KRAS and NRAS codons 12, 13, 61) and BRAFV600E molecular subgroups.  Methods', '  508 pts were randomized to either FOLFIRI plus bev (Arm A, N = 256) or FOLFOXIRI plus bev (Arm B, N = 252). On available samples from RAS and BRAF wild-type (wt) pts (N = 129), also KRAS and NRAS codons 59, 117 and 146 were analysed by means of Sequenom MassArray, identifying a new all wt population (N = 93).  Results', '  At a median follow-up of 48.1 months, in the ITT population, updated median OS for Arm B vs Arm A was 29.8 vs 25.8 months (HR = 0.80, 95%CI, 0.65-0.98, p = 0.030). Estimated 5-years OS rate were', ' Arm B, 24.9% vs Arm A, 12.4%. Molecular results were informative for 357 pts (70.3%). All wt patients had longer OS as compared to RAS mutant (HR = 0.70, p = 0.006) and to BRAF mutant (HR = 0.24, p < 0.001). The benefit from FOLFOXIRI plus bev was consistent across all molecular subgroups (Table 1). All wt pts treated with FOLFOXIRI plus bev reported a median OS of 41.7 months as compared to 33.5 months in the FOLFIRI plus bev group (HR = 0.75, 95%CI, 0.45-1.24).  Conclusions', '  FOLFOXIRI plus bev significantly improves survival of metastatic colorectal cancer pts and the OS advantage increases over time. Benefit from FOLFOXIRI plus bev is independent of RAS and BRAF mutational status. All wt pts have a better outcome independently from the treatment arm. Notable results with FOLFOXIRI plus bev are achieved in all wt pts.  Clinical trial information', ' NCT00719797Arm A FOLFIRI+bev Median PFS (mos)Arm B FOLFOXIRI+bev Median PFS (mos)HR [95%CI]Arm A FOLFIRI+bev Median OS  (mos)Arm B FOLFOXIRI+bev Median OS (mos)HR [95%CI]All wt(N = 93)12.213.70.82 [0.53-1.26]33.541.70.75 [0.45-1.24]RAS mut(N = 236)9.512.00.82 [0.63-1.07]23.927.30.95 [0.71-1.27]BRAF mut(N = 28)5.57.50.56 [0.20-1.14]10.819.10.60 [0.27-1.33]']",
        "Doc_id":"ASCO_148661-156",
        "Doc_title":" FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study)",
        "_version_":1606189026018066432},
      {
        "Meeting_name":" RAS mutational status and CEA production at initial presentation in metastatic colorectal cancer.",
        "Background":"['Background', '    Serial CEA testing is recommended in the surveillance of patients with resected stage II-IV colorectal cancer. However, the sensitivity of CEA in identifying metastatic disease has not been evaluated in the settings of RAS mutant (MT) and RAS/BRAF wild-type tumors (WT). In order to evaluate the impact of RAS mutational status on CEA production, we retrospectively evaluated a single-institute metastatic colorectal cancer (mCRC) population.  Methods', '    We retrospectively reviewed, in a single center, all cases with mCRC with known RAS mutational status based on next generation sequencing (ONCO44 and ONCO48). These assays identify clinically relevant mutations in BRAF, KRAS, and NRAS. Additional eligibility criteria included the availability of CEA levels and imaging studies at first diagnosis of mCRC. Patient demographics, primary tumor location and sites of metastatic disease at 1st diagnosis were captured. CEA levels were stratified as normal or elevated based on a cut point of 5ng/ml.   Results', '    139 mCRC patients satisfied the eligibility criteria (75 RAS-MT, 59 RAS/BRAF-WT, and 5 BRAF-MT). BRAF-MT patients were excluded from the analysis due to their small sample size. Patients with RAS/BRAF-WT tumors were more likely to present with metastatic disease to the liver, but this did not reach statistical significance (p = 0.056). There was no difference in the incidence of normal CEA at presentation in RAS-MT (30%) and RAS/BRAF-WT (28%) cohorts. CEA production was dependent on the pattern of metastatic disease. Elevated CEA was associated with the presence of liver metastases versus no metastases among RAS-MT (92% vs 47% p <.0001) and RAS/BRAF-WT patients (82% vs 50% p = 0.0101). RAS status did not impact the likelihood of CEA production within the hepatic metastases and non-hepatic metastases groups.   Conclusions', ' RAS status does not appear to influence CEA production in patients with mCRC. CEA elevations are highly associated with liver metastases and are less prevalent in patients without hepatic involvement. These findings confirm the limited predictive value of CEA for non-hepatic recurrence, irrespective of RAS status.']",
        "Doc_id":"ASCO_160210-173",
        "Doc_title":" RAS mutational status and CEA production at initial presentation in metastatic colorectal cancer.",
        "_version_":1606189020811886592},
      {
        "Meeting_name":" Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay.",
        "Background":"['Background', '    The current mainstay of clinical molecular testing for advanced colorectal carcinoma (CRC) is mutation analysis for KRAS, NRAS, and BRAF to determine anti-EGFR therapy eligibility. However, the growing number and potential of targeted therapies  has led to the need for broader molecular panels to triage patients. Here, we report our experience with a next-generation sequencing (NGS) assay that enables the detection as well as molecular characterization of CRC with rare and potentially targetable receptor tyrosine kinase (RTK) alterations.  Methods', '  We use a hybrid capture-based NGS assay encompassing all exons of 341 cancer genes (MSK-IMPACT) to sequence tumor against matched normal to detect potentially actionable somatic alterations including point and indel mutations, copy number alterations, and selected structural rearrangements. CRC with hotspot mutations in KRAS/ NRAS exons 2-4 and BRAF exons 11 and 15 were excluded from further analysis as these downstream mutations often lead to primary resistance.  Results', '  Seventy four of 164 CRC had wild type RAS/RAF. Twelve cases (16%) of this subgroup harbored RTK alterations previously reported to be activating and potentially targetable. Hotspot mutations commonly seen in other tumor types were also identified, including one each of EGFR p. L858R in a patient also harboring an ERBB2 p. S310F, EGFR p. L861R, and ERBB2 p. V842I a patient with ERBB2 amplification. One each of in-frame fusions of RTKs were also detected', ' ERBB2-GRB7 in a patient with ERBB2 amplification, RET-NCOA4, and ETV6-NTRK3. Additional RTK amplifications were also observed in the absence of other oncogene alterations, including FGFR1 (n = 3), ERBB2 (n = 2), MET (n = 1) . No ALK or ROS1fusions were detected in any of the 164 CRC. Of these 12 patients with potentially targetable RTK alterations, 3 have already enrolled in matched targeted therapies.  Conclusions', '  Using a broad molecular assay to interrogate potentially actionable mutations, approximately 16% of RAS/ RAF wild type CRC harbor RTK alterations that are known to be activating and potentially responsive to inhibition.']",
        "Doc_id":"ASCO_150439-156",
        "Doc_title":" Identification of novel and potentially targetable receptor tyrosine kinase alterations in colorectal carcinoma using a 341 gene hybrid capture-based next-generation sequencing assay.",
        "_version_":1606188999000457216},
      {
        "Meeting_name":" Pan-RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4 and 6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1",
        "Background":"['KRAS, NRAS and BRAF mutations are among the most important oncogenic drivers in many major cancer types, including melanoma, lung, colorectal, and pancreatic cancer. There is currently no effective therapy for the treatment of RAS mutant cancers. LY3009120, a pan-RAF and RAF dimer inhibitor currently in phase I clinical trial, has been shown to inhibit cell proliferation of RAS- or BRAF-mutant tumor cells in vitro and xenograft tumor growth in vivo. An unbiased screen for compounds that synergize with LY3009120 in RAS/BRAF mutant cancers identified inhibitors of CDK4 among the top hits. In this study, we found that combined inhibition of RAF and CDK4 and 6 by LY3009120 and abemaciclib cooperatively reduced viability of tumor cells with KRAS, NRAS or BRAF mutation in vitro. In animal models, the LY3009120 and abemaciclib combination exhibited synergistic regression of tumor growth in multiple xenograft models with KRAS, NRAS, or BRAF mutation. Molecular mechanistic analysis revealed that pan-RAF inhibitor treatment suppressed the cyclin D1 upregulation which was mediated through CDK4 and CDK6 inhibition by abemaciclib, and the combination treatment cooperatively demonstrated more complete inhibition of RB phosphorylation. These results were further verified by CDK4 and CDK6 siRNA knockdown and another CDK4 and CDK6 selective inhibitor palbociclib. Importantly, the more complete phospho-RB inhibition and cyclin D1 suppression by LY3009120 and abemaciclib combinational treatment led to more significant cell cycle G0/G1 arrest and apoptosis of tumor cells. These preclinical findings suggest that the combinational inhibition of RAF and CDK4 and CDK6 signaling by LY3009120 and abemaciclib is synergistic and should be further studied compared to single agents in the treatment of cancer in patients with KRAS, NRAS or BRAF mutations.']",
        "Doc_id":"AACR_2016-282",
        "Doc_title":" Pan-RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4 and 6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1",
        "_version_":1606188986852704257},
      {
        "Meeting_name":" A rapid, multiplexed, and highly accurate next-generation sequencing RAS Panel for FFPE colorectal samples reporting on the absence or presence of low frequency somatic variants",
        "Background":"['Introduction', ' Next generation sequencing (NGS) is a highly sensitive method for detecting somatic mutations. Mutations in NRAS and KRAS may affect up to 50% of patients with colorectal cancer (CRC). Recent data suggest the clinical benefit of panitumumab is restricted to patients who have no tumor mutations in RAS, defined as codons 12, 13, 59, 61, 117 and 146 of KRAS and NRAS genes. An Extended RAS panel* targets these codons as a single multiplex assay. A dual strand approach distinguishes true mutations from artifacts commonly found in DNA from Formalin Fixed Paraffin Embedded (FFPE) tissue. Analytical performance of this panel was characterized.Methods', ' FFPE tissue was examined for tumor content and area. DNA was extracted from FFPE tissue, cell lines and plasmids. The DNA quality and quantity were simultaneously determined through a quantitative PCR measurement of amplifiability. TruSeq Custom Amplicon technology targeting each strand of DNA was used to construct NGS libraries. Sequencing was performed on the MiSeqDx, and the Illumina Somatic Variant Caller was used to call somatic variants.Results', ' The dual-strand amplicon approach results in high accuracy by eliminating false positives observed on one strand of DNA typical of an FFPE artifact, by requiring every variant to be detected on both strands. We evaluated performance on 500 FFPE CRC samples processed with the Extended RAS panel. Concordance against Qiagen TheraScreen and Sanger Sequencing results was evaluated. The somatic variant caller yields a specificity of 0.98 and sensitivity of 0.72 for variants in the 5%-10% range, and a specificity of 0.96 and sensitivity of 0.98, overall, where we take the alternate methods as truth. Cumulative FFPE tissue area influences performance of the RAS panel. FFPE of a range of tissue area were tested using 1, 3, 5, and 8 sections per sample. 80mm2 minimum (240mm2 recommended) cumulative tissue area using 5uM slices was optimal for performance and accuracy. DNA quantity and quality also influence test accuracy and sensitivity. A study with 40 FFPE specimens assayed over multiple operators and sequencers produced average coverage of 32,000 reads per target per sample, and over 93% alignable reads per sample. Reproducibility of mutations detected over multiple operators and instruments was 100%. The Extended RAS Panel demonstrates robust performance across many sources of variation, including FFPE DNA extraction method, DNA storage time, recommended DNA input range, qPCR/PCR thermocyclers with little to no impact on sample pass rate and agreement with Sanger sequencing. We also demonstrate detection of 56 distinct mutations in a single run.Conclusion', ' This multiplex assay achieves high accuracy for detection of somatic mutations from DNA extracted from FFPE colorectal tissue samples.*In development For Research Use Only. Not for use in diagnostic procedures.']",
        "Doc_id":"AACR_2016-3638",
        "Doc_title":" A rapid, multiplexed, and highly accurate next-generation sequencing RAS Panel for FFPE colorectal samples reporting on the absence or presence of low frequency somatic variants",
        "_version_":1606189011639992321},
      {
        "Meeting_name":" Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.",
        "Background":"['Background', '     For patients presenting with advanced and metastatic colorectal carcinoma (CRC), standard cytotoxic therapy can provide significant benefit but patients eventually develop progressive disease. We queried whether comprehensive genomic profiling (CGP) could uncover clinically relevant genomic alterations (CRGA) that could lead to targeted therapy selection.  Methods', '    DNA was extracted from 40 microns of FFPE sections from 3,117 clinically advanced CRC. CGP was performed using a hybrid-capture, adaptor ligation based next generation sequencing assay to a mean coverage depth of > 600X. The results were evaluated from each sample for all classes of genomic alterations.  Results', '    There were 1746 male (56%) and 1371 female (44%) patients with all (100%) of cases either stage III or IV at the time of sequencing. The median frequency of GA per case was 5.7. The CRGA frequency was 2.1 CRGA per case. The most frequent GA were in APC (76%), TP53 (75%) and KRAS (53%), all were higher than in TCGA (61%, 44% and 34% respectively). There was 100% concordance with the KRAS status determined by the CGP assay and standard hot-spot sequencing assays performed on the same tumor. The combined KRAS and NRAS mutation frequency was 56% and BRAF was mutated in 7%. Only 1.4% of the cases with KRAS, NRAS, or BRAF mutations harbored combination of any 2 out of the 3 genes. Potential CRGA that could lead to targeted therapy-based clinical trials included', ' PIK3CA (18%), PTEN (8%), ERBB2 (5%), SRC (4%), SMAD2 (3%), NF1 (3%), EGFR (3%), ERBB3 (2%), MET (1%) and KIT (1%). Either WNT signaling, cell cycle/apoptosis, and/or RTK/RAS signaling pathways were the altered in 83% cases. Clinical outcome case examples demonstrating efficacy of therapies targeting BRAF, ERBB2, FGFR2, and MET in CRC patients will be presented.  Conclusions', '    When CRC is evaluated by CGP, a significant number of the patients harbored CRGA which have the potential to influence and personalize therapy selection. Given the limited treatment options and poor prognosis of patients with advanced chemo-refractory CRC deep genomic profiling has the potential to identify new treatment paradigms and meet an unmet clinical need for this disease.']",
        "Doc_id":"ASCO_146935-156",
        "Doc_title":" Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.",
        "_version_":1606188978467241985},
      {
        "Meeting_name":" Aflibercept is highly active in clinically relevant, patient derived xenografts of colorectal cancer",
        "Background":"['Aflibercept (ziv-aflibercept in USA), a new fusion protein, targets vascular endothelial growth factor (VEGF)-A, VEGF-B, and placental growth factor (PlGF). Aflibercept + FOLFIRI is approved for treating metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin containing regimen. We investigated the pharmacological activity of aflibercept in CRC patient derived xenografts (PDX), most metastases-derived, and characterized PDX molecular and phenotypic properties. In 48 CRC PDX, Whole Exome Sequencing revealed', ' 85% APC, 79% TP53, 51% KRAS, 3% NRAS, 25% PIK3CA, 11% PTEN and 8% BRAF mutants. There was no significant association between angiogenic factors, tumor mutation profiles, and response to aflibercept.In tumors, protein levels of human (h) VEGF-A were significantly higher than mouse (m) VEGF-A, hPlGF, and mPlGF (Chiron et al, ESMO, 2013). Affymetrix probes detected VEGF-A and PIGF but not VEGF-B mRNA in most PDX. There was no significant association between expression of angiogenic factors and response to aflibercept. Histological sections of CRC tumors from PDX, xenografts created from cell lines, and patients tumor specimens indicated that stromal involvement in human tumors was recapitulated in PDX but not in tumors from cell lines. PlGF expression was analyzed by immunohistochemistry on colon cancer tissue arrays. A significant number of colon cancer specimens were positive for PlGF, expressed in tumor cells and stroma. Aflibercept resulted in anti-tumor activity in 47/48 CRC PDX models and complete tumor stasis in 31/48 models. Efficacy data from 5 PDX models responsive to aflibercept and CRC standard of care (SOC) drugs, all administered as monotherapies, are below. The robust activity of aflibercept in CRC PDX models that are sensitive to SOC drugs suggest that CRC patients would benefit from aflibercept treatment, independently of mutational status or expression of angiogenic factors.']",
        "Doc_id":"AACR_2014-4808",
        "Doc_title":" Aflibercept is highly active in clinically relevant, patient derived xenografts of colorectal cancer",
        "_version_":1606188994261942272},
      {
        "Meeting_name":" HDAC inhibitors and the mechanism of resistance in colorectal cancer",
        "Background":"['Although histone deacetylase inhibitors (HDACi) are considered a promising novel therapeutic approach in the light of their potent tumour-selective effects, the use of these inhibitors for treatment of colorectal cancer (CRC) have thus far demonstrated limited success as a monotherapy. What this eventually boils down to is our incomplete understanding of the molecular mechanisms, the impact of oncogenes, and thus the key pathways through which HDACi affect tumour cell growth. To shed further light on this, the involvement of oncogenic RAS - a key driver of CRC, in determining the responsiveness to HDACi has been explored. By using cell line model systems harbouring conditional oncogenic NRAS, KRAS and HRAS, we uncovered an oncogenic RAS-dependent safeguard mechanism imposed in order to evade the cytotoxic effect of HDACi and therefore apoptosis. Characteristically, cells harbouring oncogenic RAS were observed to undergo a reversible senescence-like growth arrest in G2, allowing for re-entry into cell cycle following the withdrawal of HDACi. This mechanism is implemented as a consequence of the direct targeting of RAS by HDAC inhibition, which resulted in a further amplified GTP-binding activity and subsequent signalling through the MAPK pathway. The observed outcome was an increase in the priming of MYC for ubiquitin-mediated proteasomal degradation, thereby enabling the cells to exit the cell cycle and enter the protective state of G2 arrest. This process was functionally reversed with a conditional non-degradable MYC (T58A/S62A), which in turn rendered the cells more susceptible to undergo apoptosis. Conclusively, in the context of a constitutively activating RAS mutation, the prospect of HDACi treatment was effectively improved using current MAPK-targeted therapy by preventing the observed pro-oncogenic effect of the HDACi treatment alone.']",
        "Doc_id":"AACR_2017-5170",
        "Doc_title":" HDAC inhibitors and the mechanism of resistance in colorectal cancer",
        "_version_":1606189041901895681},
      {
        "Meeting_name":" Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer.",
        "Background":"['Background', '  Anti-EGFR drug resistance is a major challenge in metastatic colorectal cancer (mCRC). The aim of this study was to elucidate molecular mechanisms of acquired resistance in mCRC patients treated with cetuximab-based therapy.  Methods', '  37 mCRC patients with acquired resistance to  cetuximab-based therapy with paired tumor samples (prior and at progression to treatment) were prospectively included. In three patients, multiple biopsies were obtained over the course of the disease. Mutations in EGFR, KRAS, NRAS, BRAF and PIK3CA genes were evaluated by next-generation pyrosequencing. Gene amplification was evaluated by FISH. Mutations were also assessed in plasma in 7 representative cases.  Results', '  Eighty-one percent of patients harbored a molecular event (comprising mutations and amplifications) in post-treatment biopsies. In one third of patients, multiple molecular events (range 2-5) coexisted in the same sample. RAS mutations were the most frequent event (40% of patients) and mostly affected exons 3 and 4, followed by mutations in PIK3CA (19%), BRAF (11%), EGFR S492R (8%) and novel mutations in EGFR ectodomain (5%). Of note, in 9 patients the mutations were already detected at diagnosis by next-generation sequencing. Multiple repeat biopsies revealed that the percentage of mutant alleles increased under drug pressure and became undetectable following drug withdrawal. Mutations were detected in plasma samples in 62% of tested cases.  Conclusions', '  We provide comprehensive evidence for the evolution of multiple mechanisms of acquired resistance to cetuximab-based therapy in mCRC. This data establishes the need of routine molecular studies at disease progression to individualize further therapeutic decisions.']",
        "Doc_id":"ASCO_133355-144",
        "Doc_title":" Evolution of heterogeneous mechanisms of acquired resistance to cetuximab-based therapy in colorectal cancer.",
        "_version_":1606189008361095169},
      {
        "Meeting_name":" Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients.",
        "Background":"['Background', '  Recently, anti-programmed death 1 (PD-1) antibody has shown promising efficacy in a phase II trial for patients with microsatellite instability-high (MSI-H) tumors, especially in those with metastatic colorectal cancer (mCRC). Currently, several clinical trials of anti-PD-1 antibody for patients with MSI-H mCRC are ongoing. However, little is known about the frequencies and clinicopathological features of MSI-H mCRC in Japanese patients.  Methods', '  Patients with histologically confirmed adenocarcinoma of mCRC were eligible for this observational study. MSI status was analyzed in tumors using the MSI Analysis System (Promega) composed of 5 mononucleotide markers. KRAS, NRAS, BRAF and PIK3CA mutations were also evaluated using the multiplex kit.  Results', '   A total of 232 patients were enrolled until August 31, 2015, of which MSI-H was detected in 5 patients (2.1%). Among five patients with MSI-H mCRC, median age was 45 years (28-75), four had tumors on right-sided colon, five had moderately differentiated adenocarcinoma, one had poorly differentiated adenocarcinoma, and three had stage IV disease at presentation. Overall survival for patients with MSI-H mCRC from the start of first-line systemic chemotherapy ranged from 8.1 to 62.0 month. All five patients with MSI-H mCRC had RAS wild-type tumors and two had BRAF V600E mutation. One patient with MSI-H mCRC was enrolled in a phase II trial of anti-PD-1 antibody.  Conclusions', '   MSI-H mCRC is rare in Japanese patients. A large scale nationwide cancer genome screening project together with MSI status is required to evaluate more detailed clinicopathological features and facilitate the enrollment of patients with MSI-H mCRC for clinical trials with anti-PD-1 antibody.']",
        "Doc_id":"ASCO_159353-173",
        "Doc_title":" Clinicopathological features of microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC) in Japanese patients.",
        "_version_":1606189006875262976},
      {
        "Meeting_name":" Not all RAS mutations created equal",
        "Background":"['Background', ' Mutations (mts) in RAS predict lack of response to anti-EGFR therapy in colorectal cancer. Outside the typical RAS mts (KRAS/NRAS Codons 12, 13, 59, 61, 117, 146) cited in guidelines and anti-EGFR labeling, clinical impact of other atypical RAS mts is uncertain. Methods', ' Available literature and databases were surveyed to identify 80 KRAS/NRAS mts. We used the NovellusDx Functional Annotation for Cancer Treatment (FACT) to transfect these RAS mts (repeated a mean of 5.5 times/mt) in a cell-based assay that quantifies nuclear ERK localization as a measure of MAPK pathway activation, and normalized to wild type (WT) transfection. In 963 metastatic colorectal cancer patients (pts) with BRAF WT/KRAS mutant tumors, overall survival (OS) was evaluated by level of RAS signaling activity. Results', ' Of the surveyed mutations,96% (45/47) of typical mts and 39% (13/33) of atypical mts increased MAPK pathway activation above WT (range', ' 107%-211% of WT activity). Within the typical RAS mts, mts in NRAS or exon 3, 4 of KRAS had higher activity than mts in exon 2 (codons 12/13) of KRAS, reaffirming the biologic relevance of expanded RAS testing (median activity of 130% vs 178%, P < 0.001). The median activity of atypical RAS mts was lower than typical RAS mts (110% vs 159%, P < 0.001). Several notable exceptions in atypical RAS mts with high activity levels were KRAS V14I, Q22K, D33E, N116S, and F156L (all > 165% of WT activity). Conversely, within the typical RAS mts in the guidelines, KRAS G13C and K117R were not shown to increase activity significantly above WT. Pts with any RAS mt with MAPK activity above the median of typical mts had a worse OS compared to pts below the median in univariate (HR 1.45, 95% CI 1.04-2.32, P = 0.033) and multivariate models (HR 1.96, 95% CI 1.13-3.42, P = 0.017) that controlled for age, gender, sidedness, and synchronous vs metachronous presentation. Conclusions', ' Functional characterization confirmed activity of RAS mts in the current guidelines, but also suggested that a subset of atypical RAS mutations have similar levels of activation of the MAPK pathway. Within the subset of pts with RAS mts, those mts resulting in high MAPK activity are associated with notably shorter OS.']",
        "Doc_id":"ASCO_184704-199",
        "Doc_title":" Not all RAS mutations created equal",
        "_version_":1606188976531570688},
      {
        "Meeting_name":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "Background":"['Background', '  In the management of metastatic colorectal cancer (mCRC), all RAS (KRAS, NRAS) and BRAF V600E mutation status guides therapeutic options and identify a unique cohort of patients (pts) with a more aggressive clinical course. We hypothesizedthat relapsed/refractory CRC pts develop unique mutational signatures that guide standard and targeted therapy but also predict for therapeutic response, identify novel driver mutations and highlight key signaling pathways for clinical decision making.  Methods', ' Relapsed/refractory mCRC pts (N=31) were molecularly profiled by NGS Caris Molecular Intelligence (IHC, FISH/CISH, NGS) and/or Foundation One (NGS, copy number). Samples were annotated by histology, primary and/or metastatic site, biopsy location, gene mutation, domain, topology, and mutation count. Web-based bioinformatics tools (Enrichr/IntAct) were utilized to analyze mutational profiles, identifying pathway-networks.    Results', '  Pts included progressed on fluoropyrimidines, oxaliplatin, irinotecan, bevacizumab, cetuximab or panitumumab. Most common histology was adenocarcinoma followed by squamous cell carcinoma (colon N=28; rectal N=3). TP53 was the most common mutation followed by APC, KRAS, PIK3CA, BRAF, SMAD4, SPTA1, FAT1, PDGFRA, ATM, ROS1, ALK, CDKN2A, FBXW7, TGFBR2, NOTCH1 and HER3. Pts had on average >5 unique gene mutations. High mutational burden was not predictive for PD-1 (5 pts) or PD-L1 (1 pt) positivity. The most common activated signaling pathways were', ' ERRB2/HER2, FGFR, p38 activation through BRAF-MEK cascade via RIT and RIN, ARMS-mediatedactivation of MAPK cascade, and VEGFR2.     Conclusions', ' Dominant oncogene mutations do not always equate with oncogenic dependence, therefore understanding the pathologic interactome in each patient is important to both identification of clinically relevant targets and choosing the next best therapy. Mutational signatures derived from corresponding pathway-networks represent a meaningful tool to 1). Evaluate functional investigation in the laboratory, 2). Predict response to drug therapy, and 3). Guide rational drug combinations in relapsed/refractory mCRC pts entering targeted and immune checkpoint trials.']",
        "Doc_id":"ASCO_157504-173",
        "Doc_title":" Novel mutational and pathway signatures in relapsed/refractory colorectal cancer patients.",
        "_version_":1606189028578689024},
      {
        "Meeting_name":" Molecular profiling of patients (pts) with advanced colorectal cancer (CRC)",
        "Background":"['Background', '  In routine clinical practice the prevalence of somatic mutations other than KRAS G12/13, PIK3CA, and BRAF in colorectal cancer (CRC) has not been well described. This study reports molecular profiling of pts with advanced CRC in clinical setting.  Methods', '  Patients (pts) with advanced CRC are enrolled in an ongoing institution-wide screening program. Molecular profiling is performed on formalin-fixed and paraffin-embedded (FFPE) archival tissues using a customized Sequenom panel (23 genes, 279 mutations) or the Illumina MiSeq TruSeq Cancer Panel (48 genes, 212 amplicons, 500x coverage) in our Clinical Laboratory Improvement Amendments-certified laboratory. PTEN is determined by immunohistochemistry (IHC), with H score <1 defined as negative. Statistical analysis was performed with chi-square tests.  Results', '  From March 2012 to October 2013, 190 pts were enrolled. At least one mutation was found in 55% (82/153) and 89% (33/37) of pts using Sequenom or MiSeq platforms respectively (p<0.01). Of all 190 pts, KRAS G12/13 mutation was identified in 35%, and non-G12/13 KRAS, BRAF, or NRAS mutations were present in 5% , 6%, and 4% respectively. Other mutations found included PIK3CA (13%, 24/190), CTNNB1, ERBB2, FGFR3, and EGFR (1% each). MiSeq detected additional mutations including KRAS A146 or L19F (4/37), SMAD4 (4/37), FRXW7 (3/37), APC (15/37), TP53 (26/37), ERBB4 (1/37), PTEN (1/37), and IDH1 (1/37). Co-mutation with KRAS was found in 63% of pts with PIK3CA mutation and 80% of pts with APC mutation. Of 85 pts with known PTEN IHC status, 19% were negative. A higher average number of mutations was observed in right- versus left-sided CRC (p<0.01).  Mutations with known clinical significance (RAS and BRAF) were collectively more prevalent in right colon (p<0.01).  Conclusions', '  Targeted next-generation DNA sequencing identifies more genomic alterations than SNP genotyping. Current strategy of anti-epidermal growth factor receptor therapy in KRAS G12/13 wild type pts might not benefit >15% of pts due to presence of other RAS/BRAF mutations. Clinically relevant genomic alterations are more likely to be detected in right colon.']",
        "Doc_id":"ASCO_129859-144",
        "Doc_title":" Molecular profiling of patients (pts) with advanced colorectal cancer (CRC)",
        "_version_":1606188971872747520},
      {
        "Meeting_name":" A reversible DNA methylation signature precedes sporadic mutations in the colorectal adenoma-dysplasia-cancer development",
        "Background":"['Background and aims', ' New generation sequencing and array technologies now allow the systematic investigation and comparison of genetic or epigenetic alterations in AD-CRC. The colorectal adenoma-dysplasia-cancer (AD-CRC) development is characterised by sporadic (<45% frequency) mutations in a limited number of genes. Recent epigenetic investigations showed that methylation of selected genes occurs in high frequency (>95%) in early stages of cancers already.Aims', ' Evaluation of the role of epigenetic and genetic alterations in the AD-CRC development using new generation sequencing and DNA methylation arrays.Materials and methods', ' DNA was isolated from fresh frozen biopsy specimens (20 normal; 33 adenomas; 17 CRCs). First, a multiplex PCR panel was designed to amplify mutation hot spots of 12 selected genes (APC, BRAF, CTNNB1, EGFR, FBXW7, KRAS, MSH6, NRAS, PIK3CA, SMAD2, SMAD4, TP53). Further DNA methylation analysis of 94 genes was performed on Human Colon Cancer EpiTect Methyl II Signature PCR Array (Qiagen) from the same DNA specimen. After RNA isolation whole genome expression analysis was performed with HGU133plus2 microarrays (Affymetrix) from 49 normal, 49 adenoma and 49 CRC specimens and on HT-29 cells with and without 5-aza-deoxycytidin treatment. Immunohistochemistry confirmation of expression changes on protein level was performed using tissue microarrays.Results', ' Mutations were found in 76% of adenomas and 78% of the cancer cases. The average number of mutations found in mutated samples was 1; 1,8; 1,9 and 2,3 in low grade adenomas, high grade adenomas, carcinomas and serrated adenomas, respectively. The APC suppressor gene was mutated in adenomas more frequently than in carcinomas (36% vs. 24%). The most frequently mutated genes were APC, TP53 and KRAS with 36%, 18% and 26% frequencies in adenomas and 24%, 47% and 45% frequencies in carcinomas.DNA methylation was found in 100% of the investigated colorectal adenoma and cancer specimens. Eight genes were found to be methylated in all of the cases. This gen set included SFRP1, MAL, SLIT2, SST, VIM; another set of genes (DKK1, SLI3, TMEFF2) was found to be hypermethylated in adenomas and cancers in >75% of the cases. In adenomas 56 genes, in dysplasias 40 in cancer 37 genes were methylated (>50% of the cases). The effect of methylation could be confirmed by decreased mRNA and protein expression. Demethylation treatment successfully restored the expression profile of the top methylated genes.Conclusion', ' Methylation of gene sets occurred in early premalignant stages followed by somatic mutations in increasing number through the AD-CRC development. Demethylation treatment could reverse the systematic, robust methylation alterations. Epigenetic alterations precede the somatic mutations of the AD-CRC and show higher significance in CRC development than genetic.']",
        "Doc_id":"AACR_2015-3826",
        "Doc_title":" A reversible DNA methylation signature precedes sporadic mutations in the colorectal adenoma-dysplasia-cancer development",
        "_version_":1606189027733536768},
      {
        "Meeting_name":" Analysis of correlation between oncogene mutation and response to chemotherapy in all RAS wild type metastatic colorectal cancer, using next-generation sequencing technology.",
        "Background":"['Background', '  Targeted therapies of monoclonal antibodies have changed the treatment of metastatic colorectal cancer (mCRC). A target therapy with chemotherapy regimen for mCRC was decided by KRAS mutation status (KRAS exon2 [codon12, codon13]).  Currently, there are many reports suggesting that in addition to analysis of KRAS mutation status, the evaluation of EGFR gene copy number, levels of EGFR ligands, BRAF, NRAS, PIK3CA mutations could be helpful to have a more accurate selection of patients who may have a benefit from anti-EGFR targeted drugs.  Methods', '  Mutation status of 50 oncogenes were analysed in 35 mCRC patients with all RAS wild type, using next-generation sequencing technology. The response for chemotherapy was classified response group (R group) and non-response group (N group) by RECIST. The relation between mutation status of 50 oncogenes and the response for chemotherapy was assessed. Results', '  There were 25 oncogene mutations in the 50 genes. Driver mutation associated with oncogenic mutation deeply were 5 oncogenes, which were PIK3CA, AKT1, BRAF, PDGFRA and TP53. Only BRAF mutation was significantly associated with poor chemo response in the 5 oncogenes. A case which had two driver mutations was only in the N group. One of the two driver mutations was tumor suppressor gene, TP53.  Conclusions', '  BRAF mutation and the number of driver mutations are key predictors of chemosensitivity in the mCRC cases with all RAS wild type.']",
        "Doc_id":"ASCO_139910-158",
        "Doc_title":" Analysis of correlation between oncogene mutation and response to chemotherapy in all RAS wild type metastatic colorectal cancer, using next-generation sequencing technology.",
        "_version_":1606188992053641216},
      {
        "Meeting_name":" Personalized therapy for metastatic colorectal cancer in Colombia (ONCOLGroup).",
        "Background":"['Background', '  Targeted therapies have improved the survival of patients with metastatic colorectal cancer (mCRC). Data about expression of EGFR, KRAS, NRAS, and BRAF mutation status, and PI3K/PTEN expression improved patient selection for targeted treatments.  Methods', '  This study included 202 patients with mCRC who were treated at the Fundacin Santa Fe de Bogot (FSFB) from March 2009 to March 2013. The overall response rate (ORR), clinical benefit (CB), progression free survival (PFS) and overall survival (OS) were estimated. The OS was analysed according to KRAS, BRAF and PI3K mutational profile.  Results', '  Median age was 58,5-yo (+/- 9.7); 88% on included pts had ECOG 0-1 and dominant metastatic sites were the liver (53.5%), regional lymph nodes (15.3%), lungs (9.4%) and the peritoneum (9.9%). All patients received first line chemotherapy plus some monoclonal antibody (78% involving bevacizumab). ORR was 32.3% and CB reached 76% in the 152 evaluable patients. First line PFS was 7.6-mo (95%CI 4.9-9.2), higher for combinations including bevacizumab compared to cetuximab (7.9 vs. 4.5-mo; p=0.012). The median time for the maintenance following first line treatment (PS1) was 5.9-mo (95%C 3.2-14.2). Median OS was 36 months (95%CI 29.7-42.9), time extended in patients treated with some monoclonal antibody compared to those only receiving conventional chemotherapy (30.5 vs. 25 months; p=0.007) and in KRAS-Wt population (40 vs. 26-mo for KRAS mutants; p=0.028). OS was also higher amongst those receiving second (27.7 months vs. 10.3-mo; p=0.0001) and third line interventions (23 vs.9.7-mo; p=0.06). 32.7% of the tumours harboured a KRAS mutation, 10.9% harboured a PIK3CA mutation, and 6.4% harboured a BRAF mutation. OS for BRAF-Wt population was 30-mo (95%CI 20.1-41.0), whilst those carrying the BRAF mutation lived for 13-mo (95%CI 9.2-17.0; p=0.09).  Conclusions', '  These results agreed with those previously described in the literature. Routine genotyping and its correlation with diverse outcomes in mCRC in Colombia are possible and necessary to improved patient selection for targeted treatments.']",
        "Doc_id":"ASCO_132997-144",
        "Doc_title":" Personalized therapy for metastatic colorectal cancer in Colombia (ONCOLGroup).",
        "_version_":1606189033322446848},
      {
        "Meeting_name":" A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients.",
        "Background":"['Background', '  Panitumumab (P) has shown activity in terms of response and survival in patients (pts) with all RAS wild-type (WT) metastatic colorectal cancer (mCRC). The activity and toxicity of oxaliplatin (O)-capecitabine (C) (capox) with P have been questioned by previous studies.  Methods', \"  Pts with exon 2 KRAS WT mCRC received first-line chemotherapy with the combination of O 130 mg/m2, C 2000 mg/m2 and P 9 mg/Kg, repeated every 3 weeks for at least 6 cycles or until disease progression (PD) or intolerable toxicity. The primary endpoint was objective response rate (ORR). According to Simon's 2-stage optimal design, assuming the expected ORR to be at least 60% and the minimum acceptable ORR 45%, 77 pts were required at the final step.  Results\", '  78 pts were enrolled. Median age was 65.5 years, males 58%, females 42%, ECOG performance status 0 (80%), 1 (19%) and 2 (1%). 44 pts (54%) completed 6 cycles. Most frequent reasons of discontinuation were PD (11 pts), toxicity (7 pts), pt refusal (7 pts) and doctors decision (4 pts). Relative dose intensities were 99.8% for P, 96.6% for O and 81.8% for C. Grade 3-4 toxicities were anemia (4%), leukopenia (1%), neutropenia (3%), thrombocytopenia (4%), skin toxicity (19%), diarrhea (10%), neuropathy (5%), hypokalemia/hypomagnesemia (5%), hand-foot syndrome (4%) and mucositis (3%). Two toxic deaths from cardiac arrest occurred (3%), the first in a pt with grade 4 neutropenia and the other in a pt with grade 3 diarrhea. ORR was 56% (complete 8%, partial 49%), stable disease 18%, PD 8%, non-evaluable pts 2.5% and early discontinuation 14%. After a median follow-up of 30 months, median PFS was 8.1 (95% CI 6.8-9.4) and median OS 20.2 (95% CI 15.4-25.8). Among 61 pts evaluated for mutations, 8 (13%) had an exon 3-4 KRAS nutation, 2 (3%) NRAS, 4 (7%) BRAF, 4 (7%) PIK3CA and 2 (3%) AKT1 nutations. Patients with KRAS, NRAS or BRAF mutations compared with all RAS/BRAF WT patients did not differ in terms of ORR (50% vs. 55%, respectively), PFS (7.7 vs 8.1, respectively) and OS (20.2 vs 19.2, respectively).  Conclusions', '  First-line capox-P did not appear to exhibit improved safety and activity in pts with KRAS WT mCRC. (NCT', ' 01215539) Clinical trial information', ' NCT01215539']",
        "Doc_id":"ASCO_147086-156",
        "Doc_title":" A single-arm, multicenter, phase II study of panitumumab in combination with capecitabine/oxaliplatin in first line, wild-type KRAS metastatic colorectal cancer patients.",
        "_version_":1606189007575711744},
      {
        "Meeting_name":" Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.",
        "Background":"['Background', ' RO5126766 is a potent RAF and MEK inhibitor with activity in xenografts models of RAS and RAF-mutated cancers. We present data from the RAS/RAF-mutated advanced solid tumor cohort and the initial results for the multiple myeloma (MM) cohort. Methods', ' Patients with KRAS, NRAS or BRAF-mutant tumours were treated with RO5127566 using a novel schedule', '4mg twice weekly in 4-week cycles. For MM patients, it was given 3 weeks out of 4 and co-administration of weekly dexamethasone was authorised. Response assessment was completed using RECIST 1.1 criteria for solid tumours and the International Myeloma Working Group (IMWG) criteria were used for MM. Results', ' A total of 20 patients with solid tumours (10 NSCLC, 5 gynaecological cancers and 5 miscellaneous cancers) and 1 MM patients were evaluable. Among the 10 KRAS-mutant NSCLC patients, tumour regression was seen in 6/10 (60 %), of which 3/10 (30 %) were partial responses. Two of these patients had maintained response for over 1 year and one patient is still on study after 30 cycles. Of the gynaecological cancers, 3/5 patients (60%) achieved a partial response (KRAS-mutant endometrial and ovarian cancer and BRAF-mutant ovarian). Of these patients, 1 of the KRAS mutants had received 2 previous lines of MEK inhibitors and the BRAF mutant had previously received a BRAF inhibitor. In the miscellaneous group, 4 patients with colorectal cancer (2 BRAF and 2 NRAS) and 1 patient with NRAS-mutant melanoma were treated and none responded. Two patients with MM have been treated so far (1 KRAS, 1 KRAS+NRAS). The one evaluable patient has had an IMWG partial response (PR) after 1 cycle (FLC- from 324 mg/L to 161mg/L, ratio 0.03 to 0.08) without concomittant dexamethasone. This patient was previously treated with an immunomodulatory drug, a proteasome inhibitor and two ASCTs. Conclusions', ' RO5126766 has shown exciting preliminary activity across a wide range of RAS- and RAF-mutated malignancies, with significant response rates in lung and gynaecological cancers. To our knowledge, the PR seen in our MM patient represents one of the first responses to a single-agent RAF/MEK inhibitor in multiple myeloma in a trial context. Clinical trial information', ' NCT02407509']",
        "Doc_id":"ASCO_185646-199",
        "Doc_title":" Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.",
        "_version_":1606189016046108672},
      {
        "Meeting_name":" RAS mutation prevalence among patients with metastatic colorectal cancer",
        "Background":"['Background', '   Guidelines for prescribing anti-EGFR therapy for metastatic colorectal cancer (mCRC) require prior testing to confirm RAS (exons 2, 3, 4 of KRAS and NRAS) wild-type status in Europe and the USA. There is limited published evidence reporting the prevalence of RAS mutations in patients with mCRC in a real-world setting. The aim of this study was to use data from a range of real-world sources to obtain RAS mutation prevalence estimates for different geographic regions.  Methods', '   Aggregated RAS mutation prevalence data were collected from 13 sources, including individual pathology centers (n = 7), mCRC registries (n = 3), and Amgen-sponsored studies (n = 3). Data sources included in this study originated in Europe (n = 10), the Middle East (n = 2), and South America (n = 1). A meta-analysis of all collected data was carried out to investigate the effect of heterogeneity amongst the data sources and obtain pooled RAS prevalence estimates for each, using a mixed regression model.  Results', '   Aggregate data from 4322 patients with mCRC were included in the pooled meta-analysis. The overall RAS mutation prevalence across all data sources was estimated to be 43.5% (95% CI', ' 41.545.5%). RAS mutation prevalence varied between data sources, ranging from low estimates of 33.7% (95% CI', ' 28.439.3%) for a Middle Eastern pathology dataset, and 34.6% (95% CI', ' 27.742.1%) for a Middle Eastern mCRC registry, to the highest estimates of 53.6% (95% CI', ' 43.263.8%) and 54.1% (95% CI', ' 51.756.5%) in two European pathology centers, in the Czech Republic and Poland, respectively. Conclusions', '   This is one of the first studies to carry out a large pooled analysis of RAS mutation prevalence, based on real-world data. There was a high degree of heterogeneity between the sources included, possibly due to the types of data source, patient selection criteria, geographic location, or differences in laboratory testing methods. The estimated RAS mutation prevalence reported here is lower than that in a recent pooled analysis of past clinical trials, which reported an overall prevalence of 55.5% (95% CI', ' 53.957.9%) (Peeters M, et al. Eur J Cancer 2015;51', '170413). Further investigations are required to explain the disparity in these findings.']",
        "Doc_id":"ASCO_160011-173",
        "Doc_title":" RAS mutation prevalence among patients with metastatic colorectal cancer",
        "_version_":1606189017856999424},
      {
        "Meeting_name":" A novel ERK inhibitor is active in models of acquired resistance to BRAF and MEK inhibitors.",
        "Background":"['The high frequency of activating BRAFV600E mutations in melanoma (40-70%), thyroid (50%) and colorectal cancer (10%), or KRAS/NRAS mutations in melanoma (20%), pancreatic (90%), colorectal (50%) and non-small cell lung cancer (30%), provides strong rationale for targeting the MAPK pathway as a therapeutic strategy 1-6. Vemurafenib (PLX4032) and dabrafenib (GSK2118436), selective BRAF inhibitors, and trametinib (GSK1120212), an allosteric MEK inhibitor, have shown robust clinical efficacy in melanoma patients 7-10. However, the majority of responses are transient and cellular resistance is often associated with pathway reactivation involving the downstream extracellular-signal-regulated kinases 1 and 2 (ERK1/2) (reviewed in 11). We hypothesized that pathway blockade at ERK, the last signaling node prior to MAPK transcriptional programming, would not only be efficacious in MAPK-activated tumors but would also have utility in BRAF or MEK inhibitor resistant settings. We therefore sought to identify small molecule inhibitors of ERK. This report describes the identification and characterization of SCH772984, a potent and selective ATP competitive inhibitor of ERK1/2 which displays behaviors of both type I and type II kinase inhibitors. SCH772984 has nanomolar cellular potency on tumor cells with mutations in BRAF, NRAS, or KRAS and induces tumor regressions in xenograft models at tolerated doses. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistant models as well as in the context of BRAF/MEK combination resistance. Together these data support the clinical development of ERK inhibitors, not only in patients with MAPK activated tumors, but also in patients who have developed acquired resistance to BRAF or MEK inhibitors or resistance to the recently described combination of these agents.']",
        "Doc_id":"AACR_2013-2343",
        "Doc_title":" A novel ERK inhibitor is active in models of acquired resistance to BRAF and MEK inhibitors.",
        "_version_":1606189010178277376},
      {
        "Meeting_name":" Modeling the rise of intratumoral heterogeneity in growing, static, and regressing human colorectal polyps",
        "Background":"[\"Benign adenomatous colon polyps are thought to be transformed into cancers through the stepwise accumulation of mutations. However, not all polyps progress. A significant number remain static in size, regress, or resolve completely. The mechanisms underlying these differential fates are unknown, and currently there are no biological characteristics that can reliably predict which polyps will grow or progress into invasive cancer. To determine the mutational landscape, targeted next generation sequencing was performed on a unique collection of small (6-9mm) colorectal polyps with known growth rates based on interval imaging with CT colonography. To determine spatial location of identified mutations within a polyp, micro-dissection was performed followed by quantitative PCR to validate low frequency mutations. The mutational landscape of small polyps is varied both within and among individual polyps. Polyps carried 0-3 pathogenic mutations with the most frequent being in APC (67%, 32/48), KRAS/NRAS (17%, 8/48), BRAF (17%, 8/48), FBXW7 (10%, 5/48), and TP53 (8%, 4/48). Additionally, 13% (6/48) contained driver mutations at varied mutant allele frequencies, indicating the presence of subclonal populations. In silico modeling of tumor growth was used to determine the likely size at which additional driver mutations arose in order to observe those varied frequencies. This model of colon tumor growth was adapted so that mutations occur with a given probability of 105, which may change the fitness positively or negatively, and the lineage from these mutant subpopulations was tracked during tumor growth. In silico polyps were sectioned and mutant allele frequency was recorded and compared to the frequencies observed from the targeted sequencing of human polyps. Contrary to the slow step-wise accumulation of mutations theory, these data indicate small colonic polyps can have multiple pathogenic mutations in crucial driver genes that arise early in a tumor's existence. Understanding the molecular pathway of tumorigenesis and clonal evolution in polyps that are at risk for progressing to invasive cancers will allow us to begin to better predict which polyps may be more likely to progress into adenocarcinomas and which patients are predisposed to developing advanced disease.\"]",
        "Doc_id":"AACR_2016-151",
        "Doc_title":" Modeling the rise of intratumoral heterogeneity in growing, static, and regressing human colorectal polyps",
        "_version_":1606189033976758272},
      {
        "Meeting_name":" Genomic testing to enhance treatment choices and clinical trial accrual in metastatic colorectal cancer",
        "Background":"['Background', '  Tumor genome sequencing is being used widely in clinical settings but its value to individual patients has not been well-studied. A prospective cohort study of outpatient genomic testing to identify prevalence of actionable alterations and their impact on management decisions was conducted.  Methods', '  Eligibility requirements included pathologic diagnosis of select solid tumor malignancies without a known curative option, age 18 years, and an ECOG PS of 0-2. Data for the colorectal cancer (CRC) subgroup are presented here. Tumor samples were sequenced for up to 315 candidate genes using FoundationOne (Cambridge, MA). Results were discussed at the Cleveland Clinic Genomics Tumor Board that made therapeutic recommendations to treating physicians.  Results', '  From Aug 2013 to Aug 2014, samples from 45 patients with CRC were analyzed. Median age was 60 years; 23 (51%) were female; 38 (84%) were white. Median time from consent to result was 25 (range, 7-75) days. One (2%) sample had inadequate tissue. A median of 5 (range, 2-19) mutations were detected per sample; APC (89%), TP53 (73%) and KRAS (66%) were most common. A therapy targeting an actionable alteration was recommended in 22 (51%) patients; 88% of these recommendations were for clinical trials. To date, 6 (33%) of 18 patients who switched management after test results received genomics-driven therapies (Table). Previously unknown RAS (KRAS Q61H, NRAS) mutations were detected in an additional 3 patients, influencing EGFR antibody use decisions. The commonest reason for non-receipt of therapy based on the test result was non-availability of clinical trials.  Conclusions', '  Routine tumor genome profiling in CRC patients is feasible and influenced treatment decisions in a third of patients. A genomics tumor board for the interpretation of rapidly evolving information, and improved access to clinical trials of targeted agents are critical to the success of precision oncology. TargetTherapyNClinical TrialsFLT3Dovitinib2PTCH1SMO inhibitor1Off-label usePIK3R1Everolimus1FLT3Sunitinib1HER2Trastuzumab1Non-genomics-based-Standard systemic therapy6-Standard local therapy4-Hospice2']",
        "Doc_id":"ASCO_140479-158",
        "Doc_title":" Genomic testing to enhance treatment choices and clinical trial accrual in metastatic colorectal cancer",
        "_version_":1606188988145598464}]
  }}
